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INTRODUCTION 
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Chapter 1 
 
Non-small-cell lung cancer (NSCLC) is a prominent cause of cancer death in many 
Western countries.1 Of the 8000 new cases of lung cancer diagnosed yearly in the 
Netherlands, 80% has NSCLC.2 Only 25% of these patients are candidates for a 
curative treatment option.3 Surgery is the primary choice of treatment for these 
patients. For those who cannot or will not undergo surgery, radiotherapy is an 
alternative.4 For the majority of patients only palliative treatment options are possible.  
Despite the various treatment options, many of these patients will eventually suffer a 
recurrence with severe symptoms from local tumour growth before demise.5 It is 
therefore a challenge to search for new perspectives in palliative cancer care. 
 
The clinical studies described in this thesis focus on the following options: 
1. Feasibility of repeat radiotherapy as part of palliative care,  
2. New treatment combinations to gain better results in palliative care and life 
expectancy, finally resulting in a more radical approach. 
3. Optimalization of palliative irradiation schemes for those patients who only 
can be treated with radiotherapy. 
 
Chapter 2 
 
A common problem in the late 1980’s were complaints of a recurrent tumor in 
patients, treated with radiotherapy before. In these days in only 12% of patients 
complete tumor regression could be obtained with radiotherapy as a single modality 
treatment, even after doses of 60 Gy.6 Therefore, a local tumour recurrence rate of 50 
– 65% in patients treated with external beam radiotherapy was seen.5 In these patients, 
with symptoms as a result of renewed tumour progression, data on repeat radiotherapy 
were scarce.7,8 The number of cases in these studies was limited and the radiotherapy 
schemes used varied. Chemotherapy was no alternative9, as effective 
chemotherapeutic agents only became available in more recent years.10  
Radiation oncologists were reluctant to retreat these patients with external beam 
irradiation, afraid to exceed the tolerance treshhold dose of normal tissues such as 
lung parenchyma11, the spinal cord12-14 and the esophagus.15 The limits in tolerance 
dose because of normal tissues, were not known for repeat radiotherapy. To reduce 
the possibility of complications, the dose to normal tissues had to be limited. 
Therefore, techniques were used to limit the retreated volume to the site of tumour 
recurrence only. Endoscopic techniques, as brachytherapy, laser ablation, or 
photodynamic therapy, each have their own limitations, but have in common that they 
are only suitable for patients with centrally located tumors with no extension beyond 
the trachea or bronchus.16-19 Repeat external beam radiotherapy has the advantage, 
that it can also cover the tumour burden around trachea and bronchus and in the 
mediastinum, but the disadvantage that a larger volume is irradiated. As life 
expectancy is limited, the duration of the retreatment is preferably as short as possible. 
The effectiveness and safety of hypofractionation was shown in palliative settings for 
primary treatment19, and at the time had to be proven for repeat radiotherapy. In 
repeat radiotherapy data of palliative response rates were available7,8 but the duration 
of such response was not known.  
All this prompted us to initiate in 1991 a prospective study of hypofractionated 
radiotherapy for patients with recurrent intrathoracic NSCLC after prior curative 
external beam treatment. Response was measured as the maximum relief of 
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symptoms. We focused on response rates with regard to the different symptoms and 
toxicity, but also on the duration of the palliative effect. The study was discontinued 
in 1999 when chemotherapy became an alternative and subsequently accrual 
declined.20  However, we demonstrated that a reasonable palliative effect could be 
obtained with two fractions of 8 Gy. 
 
Chapter 3 
 
In this - and the following two chapters, we describe the results of EORTC study 
08941 which was initiated in 1994. In this study loco-regional control and survival 
were compared for induction chemotherapy followed by either radiotherapy or 
surgery. Patients had histological or cytological proven unilateral mediastinal 
lymphnode metastasis of a non-resectable NSCLC stage IIIA(N2). All were treated 
with induction chemotherapy. Only patients with a tumour response were randomized 
between external beam irradiation and surgery. Up-front, they had to be fit enough to 
undergo pneumonectomy. 
This study was initiated because of a couple of changes in the treatment of lung 
cancer in the previous years. 
Firstly, chemotherapy regimens showed to be beneficial in reducing tumor burden 
locally and at distance.20 Chemotherapy as sensitizer to radiotherapy showed a better 
local control and a decrease in distant metastases, both resulting in a better survival.21  
Secondly, as in the early 1990’s, a curative resection was seldom performed in case of 
ipsilateral mediastinal lymphnode metastasis (stage IIIA N2), the treatment consisted 
of radiotherapy or a wait and see policy, considering the treatment had to be only 
palliative.22 The treatment goal in this category of patients is to postpone or relieve 
tumor related symptoms as long as possible. Gradually however doses up to 60 Gy in 
6 weeks were used and 2-year survival rates of 17% were reported.23 Although this 
survival rate is less than is achieved with curative surgical or radiation treatments4, it 
still implies a chance of cure. Because of these two developments it was considered 
that maybe combined modality may be better, and that radiotherapy only would no 
longer be acceptable.Consequently, treatment intention for this particular group of 
patients was redefined in 1997 from palliative to radical22 and finally in 2002 in 
curative.24 
As surgery still was the primary treatment option in curative settings, the study 
evaluated surgery as an alternative for radical radiotherapy after a response to 
induction chemotherapy. Surgery was expected to offer a better chance of loco-
regional control and survival than radiotherapy.25-27 A hypothesis which was not 
confirmed, based on the results of our study. 
 
Chapter 4 
 
The choice of chemotherapeutic regimens was also open for debate. The response 
rates of the chemotherapy regimens used in those days was 30%.28 The search for 
more effective regimens continued. New chemotherapeutic agents became available, 
such as Gemcitabine. In EORTC study 08955 the objective was to better define the 
efficacy/feasibility of Gemcitabine/cisplatin (GC) as induction chemotherapy within 
the ongoing EORTC study 08941. The results of this EORTC study such were that 
good, that this combination became one of the new standard regimens.  
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Chapter 5 
 
Quality assurance is an important issue in the EORTC. 29 In 1987 the EORTC 
Radiotherapy Group introduced a series of procedures to document systematic errors, 
e.g. by dummy runs, made in single institutions. This dummy run gives also 
information about accuracy of the design and the application of phase III study 
protocols. In 1991 Koning30 recommended immediate monitoring of treatment 
parameters and uniform assessment of patient data in clinical trials. However, at the 
start in 1994 of the EORTC study 08941 these quality measures on radiotherapy 
treatment were not yet implemented. Questions about the quality of radiotherapy data 
came up halfway the trial31, as not all investigators adhered to prescribed treatment 
schemes. At site visits, the radiotherapy treatment fields and set up appeared to be 
correct, but compliance to the protocol was subject to improvement. 
Therefore, in May 1999 the protocol was amended detailing the radiotherapy 
prescriptions.32 The radiotherapy prescriptions were tightened and updated as follows: 
planning-CT became standard for the whole treatment procedure, time frames and 
dose specifications were formulated more precisely, questionnaires revised, and 
participants instructed. The target volumes were redefined in accordance with the 
specifications of the ICRU 50 report.33 The radiotherapy data before and after the 
amendment are presented. This amendment resulted in an improvent of the quality of 
and the compliance to the radiotherapy and an enhancement of the reliability of the 
final results of the study. 
 
Chapter 6 
 
In this and the next chapter the clinical and socio-economic results of the prospective 
National Study on the effect of irradiation with different treatment schemes in Non-
Small-Cell Lung Cancer (NSCLC) (OG98/009) are presented.  
There remains a group of patients not fit enough to undergo either chemotherapy or 
combined treatment, but still with a need to be palliated. Radiotherapy has been 
shown to be an effective palliative treatment, but the radiation schedule is still 
controversial.34 Due to the contradictory reports in the literature, radiation oncologists 
in the Netherlands were unable to reach a consensus on the palliative schedule for 
patients with poor prognosis NSCLC. Because of subgroup analysis results within the 
MRC study19, we expected for patients with poor prognostic factors an equal outcome 
for two Dutch treatment schemes with regard to palliation and survival: 10 x 3 Gy at 4 
– 5 fractions a week, and 2 x 8 Gy at day 1 and 8. Because of the relative shortage of 
radiotherapy facilities, 2 x 8 Gy for palliation would be preferred. 
Specifically, seven tumor related symptoms were scored and response measured over 
52 weeks. The sum of these scores is calculated over time. We argue this total 
symptom score gives a better view of the overall palliative effect than represented by 
each separate symptom. It covers not only diminishing symptoms, not responding 
symptoms, but also intensification of symptoms, because of toxicity. The fluctuation 
in time of the total symptom scores was compared between both treatment arms, 
representing the duration of the palliative effect. The 10 x 3-Gy scheme resulted not 
only in a more protracted duration of palliation, but also in a small survival gain. 
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Chapter 7 
 
Not only therapeutic, but also socio-economic reasons could affect the treatment 
choice. Therefore, a cost-effectiveness assessment for both treatment arms was 
performed. A pragmatic model was constructed to estimate lifelong costs and quality 
adjusted life years. Patients were followed for up to one year, with symptom palliation 
as primary outcome measure. Utility was measured using the EuroQol classification 
system.35 Societal costs were assessed during the initial 12 weeks, using cost 
questionnaires used in 3 of the 11 participating centers. Despite the higher costs, 
partly because of the increased survival for the 10 x 3-Gy scheme,  the cost-utility 
ratio is still acceptable according the Dutch standards.36 Based on this conclusion and 
the better palliative effect, the  10 x 3-Gy scheme has to be the standard. 
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Summary 
 
Purpose: To evaluate prospectively efficacy, toxicity, and duration of the palliative 
effect of retreatment with external beam radiotherapy in symptomatic patients with 
recurrent non-small-cell lung cancer. 
Patients and Methods: Twenty-eight symptomatic patients with local recurrence of 
non-small-cell lung cancer underwent repeated treatment after previous radiotherapy 
(equivalent dose, 46 – 60 Gy). Reirradiation consisted of two fractions of 8 Gy on 
days 1 and 8 with 2 opposed beams using 6-18-MV photon beams at the site of 
pulmonary recurrence. The physician scored symptom resolution. 
Results: Relief of hemoptysis and superior vena cava syndrome could be obtained in 
all assessable cases (100%). Treatment was less effective for coughing (67%) and 
dyspnea (35%). The overall median duration of this palliative effect was 4 months. 
Palliation in almost all patients lasted more than one-half of their remaining life span. 
The Karnofsky performance score improved in 45% of assessable cases. One patient 
had Grade 2 esophagitis. Complications consisted of tumor-related fatal hemoptysis in 
5 patients (17%) and 1 death from bronchoesophageal fistula (4%). 
Conclusion: External beam hypofractionated reirradiation can be effective as a 
palliative treatment for local complaints in non-small-cell lung cancer. The 
complication rate of reirradiation was acceptably low. 
 
Key words: Non-Small-Cell Lung Cancer, Repeated RT, Radiotherapy, Palliation. 
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Introduction 
 
Non-small-cell lung cancer (NSCLC) is a prominent cause of cancer death in many 
Western countries, including The Netherlands.1,2 Surgery is the first option for the 
curative treatment of patients with NSCLC. However, many patients are no longer 
candidates for this type of treatment at the time of primary diagnosis. For patients who 
are medically inoperable or who have recurrent or unresectable NSCLC, radiotherapy 
(RT) is an alternative to surgery. More recently, a combined modality approach with 
chemoradiotherapy or chemotherapy has been advocated as an alternative. However, 
many patients are also unable to undergo chemotherapy or combined treatment.3 
Therefore, a substantial number of patients are still treated with primary RT either 
with radical (high dose) or palliative (low dose) intent. However, even after radical 
irradiation for NSCLC, a complete response is only obtained in a few patients.4 Local 
tumor recurrence occurs in 50 – 65 % of the patients. In 25-30% this recurrence will 
be localized.  These patients will eventually have severe symptoms from local tumor 
regrowth before final demise.5 Whether repeated RT of these patients is possible and 
useful is uncertain and published data are scarce. Repeated RT with brachytherapy, 
laser ablation, or photodynamic therapy may be considered for some patients but will 
not be suitable for all. For all these treatment modalities, the tumor burden should be 
low and the tumor extension beyond the trachea or bronchus should be limited.6,7 
Laser treatment can be as effective as brachytherapy, but the combination of laser 
ablation and brachytherapy can yield a two- to threefold prolongation of the palliation 
duration compared with laser therapy alone.8 Palliation in recurrent NSCLC is 
achieved in 67% of the patients treated with brachytherapy alone.9 Retreatment with 
external beam RT (EBRT) might be another option but the dose might be greater than 
the tolerance of the normal tissues such as lung parenchyma and spinal cord.10-14 
 
We prospectively studied 28 patients who underwent repeated RT for proven 
recurrent locoregional NSCLC with special attention to the efficacy on relief of 
symptoms and the toxicity of such a treatment. We anticipated that about 50-60 
patients would be suitable for reirradiation in the period of the study. However, the 
strict entry criteria, a slow accrual at the start, and a decreasing accrual at the end of 
the study owing to an increasing popularity of chemotherapy, resulted in a relatively 
small number of patients. Still, this number exceeds those of similar studies treated 
with a uniform schedule.10-14 
 
 
Methods and materials 
 
Between August 1991 and April 1999, 28 patients with recurrent NSCLC were 
entered in this prospective study in which the value of retreatment with EBRT was 
tested. The patient characteristics are summarized in Table 1.  
All patients gave written informed consent before entry into the study. Patients were 
eligible for the study if the following criteria were met. 
Recurrent NSCLC had been proven by either positive histologic and/or cytologic 
findings. Also patients with visible recurrent tumor at bronchoscopy and/or evident 
tumor progression at chest-CT-scan were accepted. 
  19
Abbreviations: KPS = Karnofsky performance score; NSCLC = Non-small-cell lung cancer; 
RT = radiotherapy; EBRT = external beam RT. Data in parentheses are RT regimens. 
 
 
Recurrence was histologically confirmed in 19 patients. In 5 patients, tumor 
recurrence was clinically evident at bronchoscopy. In another 4 patients, obvious 
progression of tumor growth was seen on consecutive chest CT scans. All patients 
underwent a chest X-ray and/or chest CT to visualize tumor regrowth at their initial 
site to establish the diagnosis of recurrent disease. Additionally, patients had had 
superior vena cava syndrome (SVCS), dyspnea, hemoptysis, cough, or a combination 
of these. An overview of all diagnostic procedures and complaints is presented in 
table 2. 
 
Abbreviation: n= number of patients; SVCS = superior vena cava syndrome. 
 
 
Table 1. Patient characteristics 
Gender (n) 
   Male 
   Female 
 
27  
  1 
Age (y) 
   Median 
   Range 
 
68 
52 – 83 
KPS 
   Median 
   Range 
 
80 
40 - 90 
Histologic type 
   NSCLC 
Initial RT (n) 
   RT for recurrence after surgery (n) 
   Adjuvant RT after surgery (n) 
   RT as primary treatment (n) 
Repeated EBRT (n) 
 
28 
28  
      2  (55.2 Gy in 24fx 6 wk) 
      1  (46.0 Gy in 20 fx in 4 wk) 
    25  (36-60 Gy in12-30 fx in 3-6 wk) 
28  (2 x 8 Gy, Days 1 and 8) 
Interval to re-RT (mo) 
   Median 
   Range 
 
17  
6 – 72 
Table 2. Complaints and diagnostic procedures 
 Diagnostic procedure 
Complaint n  Bronchoscopy Biopsy Chest X-ray Chest CT 
SVCS 5  3 2 5 5 
Hemoptysis 13  12 9 10 5 
Dyspnea 19  17 16 19 16 
Coughing 8  7 6 6 6 
 24 19 24 19 
 20  
All patients had been treated with EBRT in the past. Three patients had undergone a 
surgical resection as first-line treatment consisting of a lobectomy in two and 
bilobectomy in one patient. One of these patients subsequently underwent RT to the 
mediastinum to a dose of 46 Gy in 20 fractions during 4 weeks immediately 
postoperatively. The other 2 patients underwent RT to a dose of 55.2 Gy in 24 
fractions during 6 weeks at 23 and 35 months after surgery because of a first 
recurrence. All other patients underwent primary RT to the tumor with a 10–20-mm 
margin and a field extending to the adjacent mediastinum. The total dose to the 
primary tumor varied from 36 to 60 Gy given in four to five fractions weekly in 2–3 
Gy fractions. The dose to the mediastinum was 46 Gy, applied using the same 
fractionation scheme. One of these patients was treated three times for a local 
recurrence: first with brachytherapy, 8 months later with repeated EBRT, and another 
8 months later with laser vaporization. All patients had been treated with 10- or 18-
MV energy photon beams. The minimal interval from the initial RT course to the 
repeated EBRT had to be 6 months (median interval 17 months). 
Most patients had received radical RT as first treatment, during which the generally 
accepted spinal cord tolerance dose of 50 Gy had already been reached (15). 
Although, on basis of recent animal studies, the spinal cord can recover from injury 
(16), the lack of such data at the time of this study precluded repeated RT of the cord 
after previous RT up to 50 Gy. No special limitations were given according to the 
volume of lung parenchyma, esophagus, or heart to be reirradiated. At repeated RT, 
we tried to spare the contralateral lung as much as possible and took care with the 
volume of the total lung that was reirradiated to reduce the possible risk of radiation 
pneumonitis. Because the life expectancy for this population was limited, no special 
attention was paid to cardiac dose. Field sizes varied from 6 x 7 to 14 x 15 cm (mean 
surface area 104 cm2 and median field size 9.5 x 11 cm). Repeated RT was delivered 
at the site of the recurrence using two opposing oblique fields to avoid the spinal cord. 
Two fractions of 8.00 Gy were given on Days 1 and 8 with 6–18-MV photon beams. 
Chemotherapy during repeated RT was not allowed. No restrictions were made 
concerning concurrent medications, including steroids. 
Patients were followed according to the protocol for response, side effects, and 
survival from start of repeated RT at 6 and 12 weeks and every 3 months thereafter 
until death. At each follow-up visit, the relief of complaints, Karnofsky performance 
score (KPS), toxicity score according to the World Health Organization toxicity scale 
and complications were evaluated. To score the symptom response, we created our 
own scoring system because no validated system was available (17). This system 
takes into account the general subjective perception of symptom relief by the patient. 
The physician scored relief of complaints according to patient’s statement for each 
symptom as vanished (complete resolution of the symptom), as diminished (any 
improvement without complete resolution), as stabilized (no change), or progressive 
(deterioration). The best response at any time was reported. We also performed 
physical examination and chest X-ray followed by bronchoscopy and/or chest CT in 
case of abnormal clinical findings or progression of complaints. If a patient died at 
home, the date of death was checked with the general practitioner. Nevertheless, the 
cause of death remained unknown for 3 patients. The date of death, however, was 
retrieved for all, including the patient withdrawn from follow-up 4 months after 
treatment. The evaluation of symptoms could be assessed for 25 patients. 
We defined the symptom response period as the number of months between the start 
of repeated RT and assessment of progression of the specific symptom or at the time 
of death. The median and range of the duration of symptom response were calculated. 
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The proportion of patients with symptom relief is presented, and 95% confidence 
intervals (Cis) were computed on the basis of the exact binominal distribution. 
Overall survival was measured in days from the start of repeated RT to the date of 
death, and the overall survival curve was estimated using the Kaplan-Meier method 
(18). 
 
 
Results 
 
Table 3 shows the palliative effect of the retreatment. The symptom response was 
computed up to progression of the symptom considered in each line of Table 3. 
 
Abbreviations: V = vanished (complete resolution of the symptom); D = diminished (any 
improvement without complete resolution); S = stabilized (no change); P = progressive 
(deterioration); SVCS = superior vena cava syndrome; KPS = Karnofsky performance score. 
Numbers in parentheses are the range. 
 
 
Thirteen patients had only one symptom, 14 had two symptoms, and 1 had three 
symptoms at presentation. The relief of symptoms could not be scored in 3 patients 
because 1 patient was lost to follow-up, and 2 died before a response could be 
measured. Overall, 71% of the patients (95% CI, 51–87%) had partial or complete 
symptom relief of one or more of their symptoms. All assessable patients with SVCS 
showed improvement. Dyspnea was relieved in 6 (35%) of 17 assessable patients 
(95% CI, 14–62%) and stabilized in 10. In all 13 patients with hemoptysis, it 
disappeared or diminished. Coughing was relieved in 4 (67%) of 6 patients (95% CI, 
22–96%) and stabilized in 1 patient.  Among the 20 patients for whom change in KPS 
was known, symptom relief resulted in an improvement of the KPS in 9 (45%; 
95%CI, 23–69%). In 8 patients, the KPS was stable. In 3 patients, the KPS 
deteriorated. The complete vanishing of symptoms was only seen in patients who had 
one symptom before repeated RT. The overall median duration of symptom relief was 
4 months (range, 1-19 months).  
As is shown in figure 1, the palliative effect lasted in most patients until the last 
month of their life. However, those who lived >6 months had recurrent complaints 
during their remaining lifespan. 
 
 
Table 3. Overview of symptom response after reirradiation 
 Symptom response (n) 
Symptom 
 
Not 
assessable 
(n) V D S P 
 
Persistent 
palliation 
(n) 
 
Median 
response 
duration (mo) 
SVCS 1 3 1   2 4   (2 –12) 
Hemoptysis  12 1   8 5   (1 –14) 
Dyspnea 2 4 2 10 1 6 4   (1 –19) 
Cough 2  4 1 1 0 5   (2 –10) 
KPS 8 9 8 3   
  (improved) (stabilized) (deteriorated)   
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Figure 1.  Relation between duration of symptom control and life span 
 
Esophagitis toxicity grade 3-4 was not seen. One patient, who had undergone 
brachytherapy for his first recurrence 8 months earlier, had Grade 2 esophagitis 
according to the World Health Organization toxicity scale. Radiation pneumonitis 
occurred in 1 patient. Treatment-related death occurred in 1 patient who died of a 
bronchoesophageal fistula following laser treatment 2 months after repeated RT.  
The overall survival is shown in Fig. 2. The median survival was 5.6 months (95 % 
CI, 4.4–8.8). Only 3 patients were still alive after 1 year. At the time of analysis, all 
patients had died.  The interval between the primary treatment and repeated RT 
exceeded the survival time after repeated RT in all patients treated. None of the 
patients with an interval of <10 months survived >5 months. All patients surviving >1 
year had a tumor-free interval of  >1 year. 
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Figure 2. Overall survival 
The cause of death could not be determined in 2 patients who died shortly (2 and 4 
months) after retreatment, nor in the patient who withdrew from follow-up after 4 
months. One patient probably died as a result of the retreatment. This patient was 
treated for hemoptysis with a field size of 8 x 9 cm. Two months later, because of 
renewed complaints of hemoptysis, laser treatment was given. A bronchoesophageal 
fistula occurred with pulmonary infection and subsequent demise. In the remaining 24 
patients, local or distant metastasis occurred. Of the 20 patients with local tumor 
progression, 16 died as a result and 4 died of cachexia. Of the 4 patients without local 
tumor regrowth, 2 died of cachexia and 2 of cardiac failure. Five of the 13 patients 
referred for hemoptysis died after retreatment, after a period of symptom relief, owing 
to fatal hemoptysis from recurrent tumor growth (3, 5, 6, 11 and 11 months after 
repeated RT). The field size in these patients varied from 8 x 8 to 11 x 13 cm. 
 
Discussion 
 
 
The issue how to palliate patients with local tumor regrowth after previous radical RT 
is controversial. Only 2–3 % of the patients are amenable to additional radical 
treatment by reoperation or radical repeated RT. Repeated RT after previous radical 
RT has hazards, and only limited data are available regarding its effectiveness.10-14,19 
 
The radiation dose reported to palliate symptoms by repeated EBRT varies from 6 to 
60 Gy.10-14 Symptom improvement is reported to occur in 48–75% of patients.10-14 We 
reirradiated 28 patients to palliate symptoms of tumor regrowth with two 8-Gy 
fractions. In 71% of our patients, this treatment resulted in symptom relief. This 
schedule was most effective in palliating hemoptysis and SVCS (90–100%), but was 
less effective in palliating dyspnea and coughing (45%). The 2 x 8-Gy schedule has 
the advantage of causing little discomfort to the patient and being less dependent on 
the availability of radiation equipment and time, and the results seem equal to those 
obtained with more intensive schedules.12 The median survival of 5.6 months in our 
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group is comparable with the median survival time in retrospective repeated RT 
studies (range, 3 – 5.4 months).10-14 
 
The lack of specific criteria to define symptom response and palliation makes it 
difficult, or even impossible, to interpret and compare results across various studies.17 
A recent study has validated the Edmonton Symptom Assessment Scale; however, it 
pertains to symptoms at 2 days and for pain only.20 Because we used a general 
subjective scoring of symptom response, the influence of co-medication could not be 
fully excluded. However, it is likely that the repeated RT mostly contributed to this 
symptom relief and its duration, because these patients were referred for repeated RT 
owing to insufficient symptom relief with best supportive care. 
 
The duration of palliation in relation to the remaining survival time is the most 
important factor in measuring the effectiveness of the retreatment. In none of the 
mentioned studies about repeated RT were details given about the duration of 
palliation. In 22 of our 25 patients, the percentage of their remaining life span during 
which palliation could be achieved was ≥ 50%. Most patients were palliated until a 
few weeks before they died. Symptom relief resulted in an improved or stabilized 
KPS in almost all assessable patients. These results are comparable with the findings 
of Bleehen et al 21 after primary palliative RT for NSCLC. Renewed progression of 
tumor growth after repeated RT finally resulted in the death of most patients, mostly 
within a few months.  The observation of a relation between the interval of primary 
treatment and retreatment to overall survival time can be helpful in estimating the 
prognosis of the patients sent for retreatment. 
 
Death from massive hemoptysis is particularly distressing for patients and families. 
Nevertheless, repeated RT could not prevent this in 5 of 13 patients with hemoptysis. 
In 4 of these patients, renewed tumor progression was proven by bronchoscopy. The 
field sizes were comparable to those of the rest of the study population. Because none 
of the patients without hemoptysis at the time of repeated RT died of fatal hemoptysis, 
we consider these events primarily tumor related and not treatment related. 
 
The acute toxicity of this schedule was acceptable. Acute esophagitis was very mild 
and persisted only for a few weeks. 
 
The period between repeated RT and laser therapy could be of importance in reducing 
the risk of bronchoesophageal fistula.22 One patient who underwent laser treatment 8 
months after repeated RT did not develop bronchoesophageal fistula. In contrast, the 
interval between laser treatment and repeated RT was only 2 months in the patient 
who did develop a fatal bronchoesophageal fistula. 
 
Data on the risk of radiation pneumonitis after repeated RT are scarce because the 
relation to dose and field sizes is rarely stated. Our treatment fields encompassed only 
the recurrent tumor burden to prevent unnecessary complications because of the high 
fractionation dose. The overall incidence in the literature of repeated RT varies from 
0% to 60% (22 of a total of 138 patients) (10-14). Of these, Okamoto et al14 reported 
Grade 2 and 3 radiation pneumonitis in 19 of 34 patients who received either 
palliative or radical treatment. No relation to dose or treatment volume was given. 
Montebello et al12 had 1 patient with radiation pneumonitis after 51 Gy in 17 fractions 
during 28 days through 169 cm2 AP-PA fields. Gressen et al13 reported 1 of 23 
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patients with fatal radiation pneumonitis after 30 Gy with concurrent and post-
repeated RT chemotherapy. That we saw only 1 patient with radiation pneumonitis in 
our group after a field size of 8x9 cm suggests that 2 x 8 Gy is safe in this respect. 
 
 
Conclusions 
 
Repeated EBRT with 2 x 8 Gy can be very effective as palliative treatment for 
localized complaints due to tumor regrowth, especially for hemoptysis and SVCS. 
The complication rate was acceptably low.  Despite a short median duration of the 
palliative effect, most patients were palliated during a substantial part of their 
survival. The palliation lasted in almost all patients > 50% of their remaining lifespan. 
Repeated RT, therefore, was an effective and safe treatment in the case of an isolated 
recurrent intrathoracic tumor with symptoms. 
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Abstract 
 
Background: Induction chemotherapy before surgical resection increases survival 
compared with surgical resection alone in patients with stage IIIA non–small-cell lung 
cancer (NSCLC). We hypothesized that following a response to induction 
chemotherapy, surgical resection was superior to thoracic radiotherapy as 
locoregional therapy.  
Methods: Patients with histologic or cytologic proven stage IIIA-N2 NSCLC were 
given three cycles of platinum-based induction chemotherapy. Responding patients 
were subsequently randomly assigned to surgical resection or radiotherapy. Survival 
curves were estimated using Kaplan-Meier analyses.   
Results: Induction chemotherapy resulted in a response rate of 61% (95% confidence 
interval=57 to 65%) among the 579 eligible patients. A total of 167 patients were 
allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who 
underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 
42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after 
surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the 
surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the 
radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and 
pulmonary toxicities occurred in 4% and 7%; one patient died of radiation 
pneumonitis. Median and 5-year overall survival for patients randomly assigned to 
resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, 
respectively (hazard ratio =1.06, 95% confidence interval=0.84 to 1.35). Rates of 
progression-free survival were also similar in both groups.  
Conclusion: In selected patients with pathologically proven stage IIIA-N2 NSCLC 
and a response to induction chemotherapy, surgical resection did not improve overall 
or progression-free survival compared with radiotherapy. In view of its low morbidity 
and mortality, radiotherapy is to be considered the preferred locoregional treatment 
for these patients.  
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An estimated 1.2 million new cases of lung cancer occur yearly worldwide, resulting 
in annual fatalities of 183,000 in Europe and 160,000 in the United States (1). Eighty 
percent of all lung cancers are non–small-cell lung cancer (NSCLC), and 
approximately 15% of patients with NSCLC are diagnosed with stage IIIA-N2 disease 
(2). This subgroup is heterogeneous, with lymph nodes that are only microscopically 
invaded to those that are radiologically visible with bulky ipsilateral mediastinal 
lymph node involvement (3). Surgical resection in selected patients results in 5-year 
survival rates of 7–24% (4). Preoperative chemotherapy has been shown to increase 5-
year survival to 17–36% (5-7). The combination of platinum-based chemotherapy and 
thoracic radiotherapy yielded a 5-year survival rate of 15% in a meta-analysis (8), and 
this combination has since been considered standard treatment for patients with 
unresectable stage IIIA disease. In a prospective study (9), concurrent 
chemoradiotherapy resulted in a 5-year survival rate of 20%.  
Based on the results of these previous studies, we hypothesized that surgery may be 
superior to radiotherapy following induction chemotherapy.  Therefore we performed 
a large multicenter prospective randomized trial to compare surgery with radiotherapy 
in patients with stage IIIA-N2 NSCLC who showed a response to induction 
chemotherapy. 
 
Patients and Methods 
 
Eligible patients had to have cytologic or histologic proof of unresectable stage IIIA-
N2  NSCLC (2). Staging included physical examination, a computed tomography 
(CT) scan of the thorax, and ultrasound or CT scan of the upper abdomen. Guidelines 
for unresectability were as follows: 1) any N2 involvement by a non-squamous 
carcinoma; 2) in case of squamous cell carcinoma, any N2 nodal involvement 
exceeding level 4R for a right-sided tumor and level 5 and 6 for a left-sided tumor. N2 
found only at thoracotomy after a negative staging mediastinoscopy was not 
necessarily considered unresectable. Tumors and/or any involved mediastinal lymph 
node(s) had to be unidimensionally measurable on CT scan. Patients had to be older 
than 18 years, have a World Health Organization (WHO) performance status of 0–2, 
show no evidence of pulmonary fibrosis, and be considered fit for the combined 
modality treatment by their local multidisciplinary team. Patients with pre-existing 
neurotoxicity, with infections, who had had prior therapy for NSCLC, or had 
concurrent or prior malignancy were excluded. Patients had to give written informed 
consent for participation. 
Induction chemotherapy consisted of three cycles of cisplatin, at a dose of at least 80 
mg/m² per cycle, or carboplatin, at a target area under the curve (AUC) of at least 5 
per cycle, combined with at least one other chemotherapy drug. Three phase 2 trials 
investigating the activity of novel drug combinations (10-12) were nested within the 
present study.  
Response was evaluated with CT scan after at least two cycles of induction 
chemotherapy and scored according to WHO criteria (13), but confirmation was not 
required. Eligibility was reassessed before random assignment. Only patients showing 
a response (complete, partial, or minor) to induction chemotherapy were eligible for 
random assignment to either surgery or radiotherapy after stratification for type of 
response, histologic subtype, and institution (14). Locoregional therapy (i.e., surgery 
or radiotherapy) had to start within 6 weeks of random assignment. The standards, 
definitions, and criteria of radiotherapy and surgery have been reported previously 
(15, 16). A compliance score was defined based on the following radiotherapy 
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prescription requirements: 1) an interval from the last day of induction chemotherapy 
until the start of radiotherapy of less than 10 weeks, 2) the use of three-dimensional 
planning, 3) the use of lung tissue correction, 4) a dosage administered to the primary 
tumor and involved mediastinum of 60–62.5 Gray (Gy) and to the uninvolved 
mediastinum of 40–46 Gy, 5) a fractionation size of 1.95 to 2.05 Gy, 6) a number of 
fractions of  30 to 32, and 7) a total treatment duration of 40 to 46 days (17). 
Mediastinal downstaging was defined as the absence of tumor on pathologic 
examination of the resected mediastinal lymph nodes. A resection was considered 
complete if, following review of the surgery and pathology report by one of the 
authors (PVS), both surgical margins and the highest mediastinal lymph node were 
found to be free of tumor. Postoperative radiotherapy consisting of 56 Gy in once-
daily fractions of 2 Gy was recommended in cases of incomplete resection and had to 
start between the 4th and 10th postoperative week.  
Pulmonary function was measured at least once before and after surgery or 
radiotherapy. The management of treatment related toxicities and complications was 
left to the local investigator. Surgical complications were recorded descriptively. 
Radiotherapy toxicity was scored according to the National Cancer Institute of 
Canada Clinical Trials Group Expanded Common Toxicity Criteria (18). Patients 
underwent follow-up visits every 3 months for 2 years and every 6 months thereafter, 
which included clinical evaluation, a chest-X-ray, and additional investigations when 
clinically indicated.  
 
Statistical analysis and trial conduct 
 
The primary endpoint of the trial was overall survival measured from the day of 
random assignment and analyzed on all randomly assigned patients according to the 
intention-to-treat principle. Secondary endpoints were progression-free survival and 
safety. Progression-free survival was defined as time to progression or death, 
whichever came first, and both progression and death were considered as events. 
Assuming a 15% 5-year survival with radiotherapy, a two-sided type 1 error of 5%, 
and a power of 80%, 292 events were necessary to detect an increase to 25% in the 5-
year survival with surgery. Assuming 8 years of accrual and 2 further years of follow-
up, 358 patients had to be randomly assigned. At an historically assumed 1:1 
randomization rate of 56%, 640 patients had to be accrued. The trial was closed after 
randomization of slightly fewer patients (332) than initially foreseen, after 
statistician’s advice that this early closure would not interfere with its power, because 
the observed number of deaths for the primary endpoint (279) was close to that 
required at the time of the analysis. The posterior power as computed with EAST 
v4.1, (Cytel Software Corporation, Cambridge, MA, USA) was approximately 75%.  
Randomization was performed by a central computer–generated random allocation 
sequence at the European Organisation for Research and Treatment of Cancer 
(EORTC) Data Center. Both arms were compared using a two-sided log rank test, and 
survival curves were estimated using the Kaplan-Meier technique. The statistical 
significance level was set at 0.05, and all comparisons were two-sided. Uni- and 
multivariable analyses of prognostic factors using the Cox proportional hazards model 
were conducted on all randomly assigned patients and per treatment arm. 
Proportionality was checked visually based on the Kaplan-Meier survival curves. 
Because there was no suggestion of nonproportional hazards, a formal test was not 
applied. 
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Two interim analyses on all outcomes of the study were conducted after 80 and 146 
deaths. Stopping rules for efficacy were specified a priori in the protocol, considering 
an alpha-spending function with O'Brien and Fleming boundary. The results of these 
interim analyses were declared to the members of the Independent Data Monitoring 
Committee only, who recommended continuing the trial. Following an audit of 
radiotherapy quality control and according to recommendations given during the first 
Independent Data Monitoring Committee review, the protocol was amended in 1999 
as follows: 1) Radiotherapy prescription needed to be better detailed and adhered to 
(14, 17); 2) only the following induction chemotherapy regimens were allowed: 
cisplatin-docetaxel, cisplatin-gemcitabine, carboplatin-paclitaxel, cisplatin-vindesin 
(with or without ifosfamide), carboplatin-etoposide and cisplatin-ifosfamide-
mitomycin; 3) uniform definitions of unresectability and complete resection were 
introduced and the available data reviewed accordingly; 4) a formal process of 
reporting serious adverse events and late treatment-related side effects was 
implemented. The study protocol and all amendments were approved by the Protocol 
Review Committee of the EORTC and the Ethical Committees of all participating 
institutions. This study was registered at www.clinicaltrials.gov with number 
NCT00002623. 
 
Results 
 
A total of 582 patients were registered from December 1, 1994, to December 1, 2002, 
from 41 institutions of the EORTC-Lung Cancer Group. The study was prematurely 
closed due to lower than planned accrual at a slightly lower (n= 332) than the required 
number of randomly assigned patients. This study was analyzed in December 2005 
after a median follow-up of approximately 6 years, and no losses to follow-up for 
overall survival occurred in the randomized patients. The CONSORT diagram is 
shown in Fig. 1. Patient, tumor, and induction chemotherapy characteristics of the 579 
eligible and the 332 randomly assigned patients are provided in Table 1. 
Induction chemotherapy consisted mainly of a platinum/gemcitabine (40%) or a 
platinum/taxane combination (21%) (19). Eighty-seven percent of patients received 
three cycles of induction chemotherapy; nine patients never started induction 
chemotherapy. An overall response rate of 61% (95% confidence interval [CI] = 57 to 
65%) was observed. Thirty-eight responding patients were not randomly assigned 
because of refusal (n=14), inoperability (n=15), unresectability (n=5), toxicity of 
induction chemotherapy (n=2), or for unknown causes (n=2). Retrospective analysis 
by response type in the 332 randomly assigned patients showed that 316 had an 
objective response, 12 had stable disease, and four progressed on induction 
chemotherapy. Of the 16 non-responding patients above, six were allocated to surgery 
and 10 to radiotherapy. The patient and tumor characteristics of the randomly 
assigned patients and the distribution of the observed responses to induction 
chemotherapy were well balanced. 
One hundred fifty-four (93%) of the 165 patients in the radiotherapy arm were 
irradiated (Table 2). The results of the radiotherapy quality assurance have been 
published (17). The overall compliance to the radiotherapy prescribed was 55%. The 
median overall treatment time from start of induction chemotherapy to the end of 
radiotherapy was 145 days (range=91–194). Acute grade 3–4 esophageal and 
pulmonary toxicities were observed in one (<1%) and five patients (4%), respectively. 
Late pulmonary and esophageal fibrosis occurred in 11 (7%) and 1 (<1%) patients, 
respectively, and one patient died of radiation pneumonitis. 
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Fig. 1.  Trial design and CONSORT diagram.  This flow chart describes the different 
populations included in the study analysis: registered (n=582), eligible (n=579), randomized 
(n=332). Patients were allocated and actually treated as per protocol with either surgery or 
radiotherapy. 
 
One hundred fifty-four (92%) of the 167 patients in the surgery arm underwent 
surgery (Table 3). The results of the operated patients have been reported previously 
(15). Briefly, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a 
pathologic downstaging, and 5% a pathologic complete response; 4% died within 30 
days following surgery. Resection was performed after a median of 49 days 
(range=22–86) after the last cycle of induction chemotherapy. Postoperative 
radiotherapy was administered to 62 (40%) patients, among whom two cases of grade 
3 acute esophagitis and one case of grade 4 acute pneumonitis was observed.  
 
 
Median overall survival, estimated from the time of registration in all 579 eligible 
patients, was 15.4 months (95% CI= 14 2 to 17.3). The results of overall and 
progression-free survival, estimated from the day of randomization, were similar in 
the 332 patients allocated to both treatment arms (Table 4). Median survival time and  
No. of patients registered: 582 
3 patients excluded because of lack of informed consent 
No. of patients randomized: 332 (57%) 
Stratified for type of response, histological subtype and institution 
No. allocated to Surgery: 167 No. allocated to Radiotherapy:  165 
No. not irradiated: 11 (7%) 
     - operated : 3 
     - unfit for Radiotherapy : 8 
No. not operated: 13 (8%) 
    - irradiated : 5 
    - unfit for Surgery : 8 
Surgery: 154 (92%) Radiotherapy: 154 (93%) 
No. of included patients: 579 
No. of patients off study: 247(43%) 
- progressive or stable disease or death: 175 
- toxicity or refusal: 37 
- other: 35 
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Fig. 2 Overall survival rates estimated from time of randomization using Kaplan-Meier 
analyses. P value (tw-sided) was calculated using the log rank test. 0=number of deaths; 
N=number of patients. Hazard ratio=1.06, 95% confidence interval=0.84 to 1.35; P=.596.  
 
 
 
 
Fig. 3  Progression-free survival rates estimated from time of randomization using Kaplan-
Meier analyses. P value (two-sided) was calculated using the log rank test. 0=number of 
deaths; N=number of patients. Hazard ratio=1.06, 95% confidence interval=0.85 to 1.33; P= 
.605. 
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5-year overall survival percentages were 17.5 months and 14% in the radiotherapy 
arm and 16.4 months and 15.7% in the surgery arm, respectively. Kaplan-Meier 
analyses showed that overall survival (Fig. 2) and progression-free survival (Fig. 3) 
were similar among patients in both arms. Site of first relapse was more often 
locoregional in the radiotherapy arm and more often distant in the surgery arm (Table 
4). Of all the baseline characteristics and stratification factors of the randomly 
assigned patients that were included in the multivariable analyses, only histologic 
subtype was prognostic, with a higher risk of death for patients with non-squamous 
histologies. 
 
After adjusting for histologic subtype, the treatment comparison was till not 
statistically significant. In the radiotherapy arm, none of the patient or treatment 
characteristics –including randomization before or after the protocol amendment- was 
prognostic. In the surgery arm, extent and type of resection were prognostic factors 
(for lobectomy versus pneumonectomy, hazard ratio [HR] = 0.59, 95% CI=0.40 to 
0.87 and for complete resection versus non-radical resection, HR= 0.46, 95% CI=0.32 
to 0.67). Unplanned exploratory subgroup analyses were performed in the 154 
surgery-arm patients (Table 5). Patients who underwent a (bi-) lobectomy, had a 
complete resection, had pathologically proven mediastinal clearance had a statistically 
significantly better outcome than patients who underwent a pneumonectomy, had 
incomplete resection, or had no mediastinal clearance. Patients who received 
postoperative radiotherapy had similar overall survival outcomes as patients who did 
not.  Multivariable analysis of survival showed that extent and completeness of 
resection, mediastinal clearance and postoperative radiotherapy were all statistically 
significant factors.  However, due to their small number of patients these results 
should be considered with caution.  
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Table 1. Characteristics of patients, tumors, and induction chemotherapy* 
*This table describes the characteristics of the patients, their tumors, and their 
response to the induction chemotherapy in the whole group of eligible patients and in 
both randomized subgroups, regardless whether they actually received the allocated 
treatment. All percentages are rounded. VATS = Video Assisted Thoracic Surgery; 
cT= clinical Tumor stage. NA = not available. 
†At registration. 
‡Including transbronchial and transthoracic fine needle aspiration or core biopsy. 
Population Randomly assigned patients 
Variable 
All registered 
patients 
(n=579) 
Radiotherapy 
arm (n=165) 
Surgery arm 
(n=167) 
Sex, n (%) 
Male  
Female  
 
427 (74) 
152 (26) 
 
127 (77) 
38 (23) 
 
119 (71) 
48 (29) 
Age, median (range)† 61 (29–78) 62 (33–76) 61 (29–78) 
Caucasian ethnicity, n % 552 (95) 160 (97) 162 (97) 
Histologic subtype, n (%) 
Squamous carcinoma 
Adenocarcinoma 
Large cell carcinoma 
Other 
 
NA 
NA 
NA 
 
66 (40) 
46 (28) 
46 (28) 
7 (4) 
 
65 (39) 
57 (34) 
41 (25) 
4 (2) 
Proof of N2 by, n (%) 
Histology 
Cytology 
Clinically only 
Type of biopsy, n (%) 
Mediastinoscopy 
VATS 
Thoracotomy 
Needle procedure‡ 
 
528 (91) 
41 (7) 
10 (2) 
 
478 (83) 
6 (1) 
34 (6) 
56 (10) 
 
152 (92) 
8 (5) 
5 (3) 
 
135 (82) 
1 (1) 
13 (8) 
13 (8) 
 
155 (93) 
11 (7) 
1 (1) 
 
141 (84) 
4 (2) 
8 (5) 
14 (8) 
cT at registration, n (%) 
cT1 
cT2 
cT3 
cT4 
other/unspecified 
 
67 (12) 
396 (68) 
100 (17) 
13 (2) 
3 (1) 
 
21 (13) 
119 (72) 
25 (15) 
0 
1 
 
20 (12) 
120 (73) 
25 (16) 
1 
0 
Patients receiving three cycles of 
induction chemotherapy, N (%) 
503 (87) 165 (100) 166 (99) 
Median interval between registration 
and random assignment, days (range) 
NA 71 (0–113) 73 (0–117) 
Response on induction chemotherapy,  
N (%) 
Complete response 
Partial and minor response 
Stable disease 
Disease progression 
 
 
22 (4) 
332 (57) 
105 (18) 
80 (14) 
 
 
8 (5) 
147 (89) 
8 (5) 
2 (1) 
 
 
12 (7) 
149 (89) 
4 (2) 
2 (1) 
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Table 2. Characteristics of locoregional treatment in the thoracic radiotherapy arm (N 
= 154)* 
Protocol prescription No. of patients treated 
according to prescription (%) 
No. of fractions given = 30–32 131 (85) 
Fraction size = 1.95–2.05 Gy 134 (87) 
Duration = 40–46 days  123 (80) 
Interval between 
Day 1 of last cycle induction 
chemotherapy and day 1 of radiotherapy 
within 10 weeks 
Day 1 of last cycle induction 
chemotherapy and random assignment 
within 4 weeks 
Random assignment and day 1 of 
radiotherapy within 6 weeks 
 
133 (86) 
 
 
93 (60) 
 
 
136 (82) 
Planning CT scan 
performed 
with lung correction 
 
141 (92) 
138 (90) 
Dose and location of radiation  
primary tumor (60–62.5 Gy) 
mediastinum 
involved (60–62.5 Gy) 
uninvolved (40–46 Gy) 
 
129 (84) 
 
115 (75) 
134 (87) 
*These figures relate to all patients who were allocated to the radiotherapy arm and 
were actually irradiated. CT= computed tomography; Gy=Gray. 
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Table 3. Characteristics of locoregional treatment in the surgical resection arm (N = 
154)* 
 
Characteristic No. of patients with this characteristic 
(%) 
Extent of resection 
 Pneumonectomy 
right-sided 
left-sided 
(Bi-)lobectomy 
Exploratory thoracotomy 
Other (remediastinoscopy) 
 
72 (47) 
38 (25) 
33 (22) 
59 (38) 
22 (14) 
1 (<1) 
Type of resection  
Complete 
Pathologically complete 
 
77 (50) 
8 (5) 
Downstaging 
ypN0 
ypN1 
ypN2 
ypN3 
missing 
 
39 (25) 
25 (16) 
86 (56) 
1 (1) 
3 (2) 
Operative mortality within 30 days
overall 
after pneumonectomy 
after right-sided pneumonectomy 
after left-sided pneumonectomy 
after lobectomy 
after exploratory thoracotomy 
 
6 (4) 
5 (7) 
2 (5) 
3 (9) 
0 (0) 
1 (5) 
PORT 
dosage (Gy), median (range) 
no. of fractions, median (range) 
62 (40) 
50 (0–60) 
25 (8–30) 
*These figures relate to all patients who were allocated to the surgery arm and were 
actually operated on. Mortality rates are expressed as number of deceased within 30 
days/ number with the specific type of resection. Gy=Gray; PORT=postoperative 
radiotherapy; ypN=pathologic N after induction therapy. 
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Table 4. Outcome after random assignment* 
Outcome Radiotherapy arm 
(N= 165) 
Surgery arm 
(N= 167) 
P† 
Median follow-up, months 73 67  
No. deceased (%) 141 (86) 138 (83)  
Overall survival (95% CI) 
Median, months 
2 year, % 
5 year, % 
Hazard ratio (95% CI) 
 
17.5 (15.8 to 23.2) 
41 (33 to 47.9) 
14 (9 to 20) 
1 (referent) 
 
16.4 (13.3 to 19.0) 
35 (28 to 42) 
15.7 (10 to 22) 
1.06 (0.84 to 1.35) 
 
 
 
 
.6 
Progression 
No. progressing (%) 
Site of first relapse  
Locoregional  
Distant 
Both 
 
130 (79) 
 
71 (55)‡ 
50 (39)‡ 
9 (7)‡ 
 
115 (69) 
 
37 (32)‡ 
70 (61)‡ 
8 (7)‡ 
 
Progression-free survival  
(95% CI) 
Median, months 
2 year, % 
Hazard ratio (95% CI) 
 
 
11.3 (8.9 to 12.7) 
24 (18 to 31) 
1 (referent) 
 
 
9 (7.6 to 11.2) 
27 (20 to 33) 
1.06 (0.85 to 1.33) 
 
 
 
 
.6 
*These figures relate to all randomly assigned patients on intention-to-treat basis.  
CI=confidence interval. †P values were calculated using a two-sided log rank test. 
‡Percentage of the patients  progressing in either arm.  
 
 
Table 5. Exploratory analyses in 154 patients in the resection surgery arm* 
Subgroup N Median OS, 
months 
(95%CI) 
5-year OS, 
% 
P, 
Univariate 
analysis 
 
P, 
Multivariate 
analysis 
Extent of 
resection 
(bi-)lobectomy 
pneumonecto
my 
 
 
58 
72 
 
 
25.4 (17.7 to 48.9) 
13.4 (11.1 to 19.5) 
 
 
27 
12 
.009 .03 
Mediastinal 
status 
ypN0–1 
ypN2 
 
 
64 
86 
 
 
22.7 (17.6 to 42.7) 
14.9 (11.2 to 18.5) 
 
 
29 
7 
<.001 .04 
Type of resection 
complete 
incomplete 
 
77 
76 
 
24.1 (16.7 to 42.4) 
12.1 (9.5 to 17.1) 
 
27 
7 
 
<.001 
 
.01 
No PORT 
PORT 
92 
62 
14.1 (11.2 to 19.9) 
18.0 (15.0 to 25.9) 
19 
13 
.6 .004 
*OS=overall survival; PORT= postoperative radiotherapy; CI = confidence interval; 
ypN = pathologic N after induction therapy.  P values were calculated using a two-
sided log rank test. 
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Discussion 
  
This large randomized multicenter study demonstrated that surgery did not improve 
survival after a radiologic response to induction chemotherapy in patients with 
unresectable stage IIIA-N2 NSCLC as compared with radiotherapy. These results are 
important because several centers routinely use induction chemotherapy followed by 
surgery to treat patients with this stage of disease based on small randomized studies 
that showed that surgery alone is inferior to perioperative chemotherapy and surgery 
in stage IIIA patients (5-7). The results of this study are robust in terms of numbers 
and mature in terms of follow-up and are similar to those observed in trials with a 
similar hypothesis but with a different design (20, 21) The North American Intergroup 
Trialists recently reported a median survival rate of 23.6 months and 22.2 months for 
induction chemoradiotherapy with or without resection, respectively.. 
The best treatment option for patients with stage IIIA-N2 has been debated. Part of the 
debate is caused by the heterogeneity of presentation at diagnosis, varying from 
intracapsular involvement of a single lymph node, in which surgery is indicated, to 
bulky mediastinal invasion, in which radiotherapy has been standard treatment until 
approximately a decade ago. A strength of our study is its requirement of pathologic 
proof of mediastinal involvement and the randomiz assignment of responders only. 
Although the definition of non-resectable tumor was left to the judgement of the local 
surgeon, clear guidelines were provided, and surgery and pathology reports were 
reviewed centrally.  
The limitations of this study rely mainly on evolving staging and treatment standards 
in the course of its accrual. We strongly feel that these do not influence the 
conclusions. One possible limitation is stage migration; this, will affect patient 
selection but is equally distributed over both arms by the process of randomization. 
Another is that changes in treatment standards occurred in both arms.  However, their 
net magnitude on the outcome is likely to be limited.   
The complete resection rate in this series can be considered low in comparison with 
others (20, 21), but it should be interpreted with the definition that became the later 
standard (22).  The feasibility of a sequential trimodality approach in patients with 
N2-disease, which was proven by mediastinoscopy, was explored in CALGB trial 
8935 (23)   In that trial, 74 patients were initially treated by two cycles of induction 
chemotherapy consisting of cisplatin and vinblastine.  In patients with response or 
stable disease, surgical resection was performed followed by sequential adjuvant 
chemoradiotherapy. Sixty-three patients in CALGB 8935 underwent an exploratory 
thoracotomy with 46 (75%) having resectable lesions.  Applying the same criteria for 
complete resection as in our study, 23 patients or 36.5% of those undergoing 
thoracotomy had a complete resection. In only 10 patients was the disease 
pathologically downstaged, and there were no pathologic complete responses.  
Operative mortality was 3.2%, and 7-year overall  survival was 10% (24).  Thus, in 
CALGB 8935 the complete resection rate was less than 40% after two cycles of 
induction chemotherapy, with only a small fraction of patients having a pathologic 
downstaging. In the present study applying the same criteria, three cycles of induction 
chemotherapy yielded a higher resectability rate. 
The survival of the not–completely resected patients in the present study is worse than 
that of patients in the radiotherapy arm. This difference may be explained by the fact 
that there is within the radiotherapy-arm a subgroup of patients with pathologically 
complete response and a subgroup of patients with mediastinal downstaging.  Several 
series have shown that pathologic complete resection and mediastinal downstaging 
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are stronger predictive factors than complete resection (25, 26).  The number of 
patients in these two subgroups was not determined but is estimated to be similar to 
that of the corresponding subgroups in the surgery arm by the process of 
randomization after induction therapy. 
The observed high rate of pneumonectomies in this trial was likely the result of the 
prevailing opinion among the surgical community during its initial years—i.e., in 
patients with N2 disease the whole lung had to be removed. Later, lobectomy with 
systematic nodal dissection was regarded by most surgeons to be adequate treatment, 
provided that a complete resection was performed (15, 27). In subgroup analysis, we 
observed a statistically significantly better outcome after (bi-)lobectomy than after 
pneumonectomy, and this difference has also been observed in the North American 
Intergroup Trial (21). Pneumonectomy as such is also a known independent negative 
prognostic factor (28, 29), due in part to the higher stage of the disease in patients 
who require this extensive operation and also to an increased operative mortality 
associated with this procedure, especially for right-sided tumors. Surgical expertise 
and hospital volume are determinants of outcome and complication rate of lung 
cancer surgery (30). However, we observed a low post-operative mortality rate in our 
study, even among patients who underwent right-sided pneumonectomy. Patient 
selection may have contributed to this observation (247 patients were excluded for 
surgery or radiation therapy due to inadequate response). Furthermore, post-operative 
mortality is markedly high after chemoradiation (21), suggesting a possible 
detrimental effect of this induction combination.  
Surgery is highly unlikely to be beneficial when persistent mediastinal involvement is 
present after induction treatment, as shown in this study and by others (25, 26). 
Whether these patients should be offered further radical radiotherapy is debatable, 
because their disease will relapse mainly as distant metastases. Hence, the assessment 
of mediastinal clearance becomes very important. Fluoro-desoxy-glucose positron 
emission tomography scan, endoscopic ultrasound, and remediastinoscopy all claim a 
higher accuracy than CT-scan in restaging after induction therapy, and the techniques 
may complement each other (31). Whether only patients with mediastinal clearance 
should be offered surgery remains uncertain. Only an adequately powered trial, in 
which patients with proven mediastinal clearance are randomly assigned between 
surgery and radiotherapy, can truly address this question (32). The EORTC-LCG is 
considering such a study (van Meerbeeck, personal communication). 
The induction treatment used in this study was platinum-based chemotherapy. 
Although several different regimens were used, nearly all randomly assigned patients 
received three cycles, and major responses were achieved in more than 50% of them, 
similar to the results obtained in other series of induction chemotherapy (33-34). The 
rate of pathologic complete remission is lower with induction chemotherapy alone 
when compared with chemoradiotherapy (9, 35). Although pathologically complete 
response has predictive importance in other tumor types, it is still unknown whether 
response has relevance for long term survival in NSCLC. Furthermore, although 
chemoradiation per se does not increase the pneumonectomy rate, it is associated with 
higher rates of Adult Respiratory Distress Syndrome, bronchopleural fistula, and 
empyema (15). In a multicenter trial among IIIA-N2 NSCLC patients in Germany 
(36), the addition of twice-daily chemoradiation to induction chemotherapy, followed 
by resection, had no impact on outcome compared with induction chemotherapy and 
resection only but contributed to a statistically significantly higher rate of grade 3/4 
esophagitis. In the US Intergroup Trial (21) the rate of severe post-operative 
complications and operative mortality was higher than in our study. A Swiss co-
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operative group study (26) reported a pathologic remission rate of 19% using cisplatin 
and docetaxel induction chemotherapy and observed a low operative morbidity and 
mortality and high survival rates, suggesting that third-generation induction 
chemotherapy might be superior to second-generation concurrent chemoradiotherapy. 
However, we could not reproduce the high response rate of this combination in a 
multicenter nested phase 2 trial performed within our trial (12). It is to be expected 
that improvements in radiotherapy timing, planning, and fractionation, together with 
the use of better tolerated chemotherapy agents or targeted agents, will result in better 
compliance and reduce the complication rate of concurrent chemoradiation (37). The 
role of the intensity of the induction treatment is the subject of an ongoing 
randomized US trial (38). 
During the 8 years that this trial was ongoing, radiotherapy standards underwent 
substantial improvements. This change in practice was addressed by a formal 
protocol-specified amendment to the prescription requirements. The tumor volume 
irradiated encompassed the pre-chemotherapy tumor areas with a margin that can be 
considered as optimal. Geographic misses have been reported to occur in 
reconstructing pre-chemotherapy target volumes in 26% of patients (39). This can 
result in a lower locoregional control, but few data from randomized trials on treating 
pre- or post-chemotherapy target volumes exist (40). Of more concern may be the 
interval between induction chemotherapy and the start of radiotherapy. Although 86% 
of patients in the radiotherapy arm started their radiotherapy within the prescribed 70 
days of their last induction chemotherapy cycle, it has been shown that 41% of tumors 
progress when a mean interval of 80 days between induction chemotherapy and 
radiotherapy (41). Although only five patients were not treated after randomization 
because of clinical deterioration or tumor progression, this delay could be responsible 
for the high observed local relapse rate in the radiotherapy arm. Similar considerations 
apply with regard to the overall treatment time. The use of concurrent 
chemoradiotherapy has been reported to  result in lower overall treatment times and is 
associated with better short-term survival results at the risk of higher toxicity (42). 
Our observed median overall treatment time of 145 days in the radiotherapy arm 
could be alone responsible for the observed difference in survival with the concurrent 
chemoradiotherapy arm of the Intergroup Trial (21) but other explanations are 
possible. Survival in the Intergroup Trial was counted from time of randomization, 
and thus a median of 2.5 months has to be added to compare survival times in this 
trial with those of studies with upfront randomization (20, 21, 36). Furthermore, most 
studies also combined induction treatment with postoperative chemotherapy (5-7, 9, 
20, 21), and the latter has recently been associated with improved outcome, which 
may also bias the comparison (43). 
In conclusion, our study demonstrates that surgery does not improve survival 
compared with chest radiotherapy in patients with unresectable stage IIIA-N2 lung 
cancer after response to induction chemotherapy. In view of its low morbidity and 
mortality, radiotherapy is to be considered the preferred locoregional treatment for 
these patients. Properly designed studies to investigate whether surgery has a role in 
patients with confirmed mediastinal clearance are needed.  
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rounded %) to the 332 randomized patients: 
Free University Medical Center, Amsterdam, NL (E Smit, G Giaccone, J van Mourik, 
P. Postmus): 11; Erasmus MC, Rotterdam NL, (T Splinter, A Maat, S Senan, M de 
Jonge, J van Meerbeeck): 9; St. Antonius Ziekenhuis Nieuwegein NL (F. Schramel): 
8; ARTI Arnhem, NL (G Kramer, H Smit, S Gans): 6; Radboud University MC, 
Nijmegen NL (J Festen, V Tjan Heijnen, J. Termeer): 6; Jeroen Bosch Ziekenhuis, ‘s 
Hertogenbosch NL (B. Biesma): 6; Netherland Cancer Institute, Amsterdam NL (N 
van Zandwijk, P Baas, J. Belderbos): 5; LUMC Leiden, NL (L. Willems): 5; UZ 
Gasthuisberg, Leuven B (J. Vansteenkiste, P. de Leyn): 4; UMCU, Utrecht NL (N. 
Schlösser, SY Elsharouni): 4; UZA Edegem B (P Van Schil, J van Meerbeeck): 3; 
Isala, Zwolle NL (J Stigt): 3; AZ Middelheim Antwerp B (D. Galdermans, K. Goor, 
P. De Roover): 2; OLV Gasthuis, Amsterdam NL (B. Kwa): 2; AZ St.Jan Brugge, B ( 
D. Van Renterghem): 2; Klinicni Center Golnik SL (A. Debeljak): 2; UCL Mont 
Godinne, Yvoir B (L. Delaunois): 2; Royal Marsden Hospital Sutton UK (I Smith, M. 
O’Brien, P. Goldstraw): 2; Ospedale SL Gonzaga, Torino, I (G. Scagliotti): 1; Spaarne 
Ziekenhuis, Haarlem, NL (H. van Breukelen): 1.; National Cancer Institute, Genoa, I 
(A. Ardizzoni ): 1; Slotervaartziekenhuis, Amsterdam NL (P. van Spiegel): 1; Maria 
Sklodowska-Curie MCC, Warsaw PL (M. Krzakowski): 1; Lievensberg Ziekenhuis, 
Bergen op Zoom NL (H. Liem); Franciscusziekenhuis, Roosendaal NL (A. van 
Boxem) ; UZGent B (P. Pinson, G. Joos); Weston Park Hospital, Sheffield UK (M. 
Hatton); Royal Infirmary, Leicester UK, (K. O’Byrne); Policlino Monteluce, Perugia I 
(S. Darwish); Clinique Ste. Elisabeth, Namur B (A. Baudoux); AZ Zusters 
Barmhartigheid Ronse B (J. Verschuere); CHR-St.Jozeph, Mons B (JP d’Odemont); 
Istituto Nazionale, Napoli I (C. Gridelli); Elkerliek Ziekenhuis, Helmond NL (P. van 
Valenberg); Ziekenhuis De Heel Zaandam, NL (A. van Bochove); Leyenburg 
Ziekenhuis, Den Haag NL (E. Lammers); Hopital de Jolimont, Haine- St. Paul, B (M. 
Beauduin); Twee Steden, Tilburg NL (H. Goey); Western General Hospital, 
Edinburgh UK (A. Price); AZ Hoge Beuken, Antwerpen B (W. Moorkens); Stedelijk 
Ziekenhuis, Roeselare B (W. Verbeke): all <1. 
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Summary 
 
Purpose: Our objective was to better define the activity/feasibility of 
gemcitabine/cisplatin (GC) as induction chemotherapy in patients with stage IIIA N2 
non–small-cell lung cancer (NSCLC) followed by surgery or radiotherapy within a 
large, ongoing comparative study (EORTC 08941).  
Patients and Methods: Forty-seven chemotherapy-naive patients with NSCLC, 
median age of 58 years, stage IIIA N2 disease, World Health Organization 
performance status of 0 or 1, and the ability to tolerate a pneumonectomy received 
gemcitabine 1,000 mg/m2 on days 1, 8, and 15 and cisplatin 100 mg/m2 on day 2, 
every 4 weeks. Patients received induction chemotherapy (three cycles) before re-
evaluation and randomization to surgery or radiotherapy.  
Results: Grade 3/4 thrombocytopenia, the main hematologic toxicity, occurred in 60% 
of patients but was not associated with bleeding. Full-dose gemcitabine was given in 
48% of the courses. Severe nonhematologic toxicity was uncommon. Two patients 
with preexisting, autoimmune pulmonary fibrosis had deterioration of pulmonary 
function after radiotherapy. Thirty-three (70.2%; 95% confidence interval, 55.1% to 
82.7%) of the 47 eligible patients had objective responses (three complete responses 
and 30 partial responses). Mediastinal nodes were tumor-free after induction therapy 
in 53% of cases. Resections were considered complete in 71% of the patients who 
underwent thoracotomy after induction therapy. Median survival for all recruited 
patients (N = 53) was 18.9 months, with an estimated 1-year survival rate of 69%.  
Conclusion: In patients with N2 stage IIIA NSCLC, GC is a highly active and well-
tolerated induction regimen. GC should be explored in combination with surgery or 
radiotherapy in stage I and II patients.  
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Introduction 
 
The rationale for using induction chemotherapy in locally advanced non–small-cell 
lung cancer (NSCLC) is based on the considerations that chemotherapy may prevent 
the growth of systemic disease and, at the same time, shrink the locoregional 
macroscopic disease, which may then be adequately treated with surgery, 
radiotherapy, or both.1 Several groups have shown that this approach is feasible in 
patients with stage III disease, who usually have better response rates than patients 
with stage IV disease.2,3 Moreover, three small randomized trials comparing surgery 
alone with a combined program of induction therapy followed by surgery have shown 
prolonged survival in the combined-modality arms.4-6 In many centers, induction 
therapy followed by surgery and/or radiotherapy has thus become standard therapy for 
selected groups of patients with stage III disease.7  
Gemcitabine (2',2'-difluorodeoxycytidine), an analog of deoxycytidine with 
established activity in NSCLC, is an anticancer drug with novel properties and 
mechanism of action.8 The combination of gemcitabine and cisplatin (GC) has been 
shown to be synergistic in preclinical studies.9,10 In patients with advanced NSCLC, 
this combination produced objective response rates of more than 50%.11,12 In three 
randomized studies in the same category of patients, GC was more active than 
cisplatin alone13 and produced a higher response rate as well as a longer response 
duration and time to progressive disease than the etoposide-cisplatin combination.14 In 
addition, GC produced a higher response rate than the three-drug combination of 
mitomycin, ifosfamide, and cisplatin.15  
The early suggestions of increased efficacy of the GC combination prompted the 
European Organization for the Research and Treatment of Cancer (EORTC) Lung 
Cancer Cooperative Group to initiate a phase II trial to better define the toxicity and 
activity of this combination as an induction regimen for patients with stage IIIA 
NSCLC. This trial was the first of a series of phase II studies using new chemotherapy 
combinations within the setting of one large, ongoing randomized trial in patients with 
stage IIIA N2 disease (EORTC 08941) comparing surgery with radiotherapy after 
induction chemotherapy.  
 
 
Patients and Methods 
 
Patient Selection 
 
Eligibility criteria for study entry included the following: stage IIIA NSCLC with 
biopsy proof of positive N2 nodes, World Health Organization (WHO) performance 
status score of 0 to 1, and an adequate baseline organ function defined as a WBC 
count of at least 3,000/µL, liver and renal function within normal limits, and 
spirometric values allowing pneumonectomy. Patients who had previous 
chemotherapy, radiotherapy, or presence of active infection were excluded from the 
study. All patients gave written informed consent, and the study was approved by the 
EORTC Protocol Review Committee (PRC) and by the ethics committees of the 
participating centers.  
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Treatment Plan 
 
Gemcitabine 1,000 mg/m2 was administered as a 30-minute intravenous infusion on 
days 1, 8, and 15 of a 28-day treatment cycle. On day 2, cisplatin 100 mg/m2 was 
infused over 30 minutes after intravenous hyperhydration with 1,500 mL saline (plus 
potassium chloride) and administration of standard antiemetics. The doses of 
gemcitabine and/or cisplatin were adjusted to the outcomes of blood counts and blood 
chemistry immediately before the infusion(s), and toxicity was recorded during 
treatment. Full doses of chemotherapy were given if WBC and platelet counts on the 
day of treatment were 3 x 109/L and 100 x 109/L, respectively. Chemotherapy was 
administered at 75% of the planned dose in the event of grade 2 hematologic toxicity 
and at 50% of the planned dose in the presence of grade 2 neurotoxicity or a creatinine 
clearance rate less than 60 mL/min. Dose reductions were handled the same way for 
both agents. Doses were withheld if myelotoxicity or neurotoxicity exceeded grade 2 
or if creatinine clearance dropped below 40 mL/min. Three cycles of chemotherapy 
were administered unless progressive disease or intolerable toxicity was recorded.  
 
Patient Evaluation 
 
A complete history, physical examination, complete blood cell count with differential, 
serum biochemistry, urinalysis, spirometry, bronchoscopy, computed tomography 
(CT) scan of the chest and upper abdomen, and ECG were obtained at baseline. 
Patients were monitored throughout treatment by recording history, toxic events, and 
complete blood cell counts with differential (weekly); serum chemistry determinations 
were repeated just before the start of each chemotherapy cycle. Tumor response was 
evaluated by CT scan after three cycles of treatment. CT examinations were reviewed 
by an independent radiologist, the study chairman, and the responsible physician. A 
complete response (CR) was defined as the complete disappearance of all 
abnormalities on the CT scan. A partial response (PR) was defined as a reduction of 
more than 50% in the sum of the products of two perpendicular diameters of the 
primary tumor and hilar and mediastinal nodes (if enlarged). Stable disease was 
defined as a less than 50% reduction or a less than 25% increase in the sum of the 
products of two perpendicular diameters per site. Response rate calculations were 
based on all eligible patients (N = 47). Almost all patients with responsive disease 
gave consent to be randomized to thoracic surgery or radical radiotherapy (ongoing 
trial EORTC 08941). Repeated mediastinoscopy/tomy and spirometry were not 
included in the postchemotherapy evaluation. The combined-modality approach of this 
study did not allow the formal 4-week confirmation of response to chemotherapy 
alone according to WHO criteria. Overall, survival was measured from the date of 
registration to the date of death or last follow-up examination and was estimated using 
the Kaplan-Meier method.16  
 
Results 
  
Patient Characteristics 
 
From March 1996 to August 1997, 53 patients were enrolled onto the study. Six 
patients were ineligible: three patients had stage IIIB disease and another three 
patients had started protocol treatment before registration.  
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Table 1. Patient characteristics 
Characteristic   No. of patients  % 
Total recruited 53 NA 
Total eligible 47 NA 
Sex   
Male 33 70 
Female 14 30 
Age, years   
Median 58  
Range 44-78  
TNM stage   
T1N2M0 3 6 
T2N2M0 40 85 
T3N2M0 4 9 
Histology   
 Squamous cell 20 43 
 Adenocarcinoma 10 21 
 Undifferentiated 15 32 
 Large-cell 2 4 
WHO performance status   
0 28 60 
1 19 40 
Abbreviations: NA, not applicable; TNM, tumor-node-metastasis system. 
 
Characteristics of the 47 eligible patients (listed in Table 1) included a median age of 
58 years (range, 44 to 78years), WHO performance status of 0 in 60% of the patients, 
and squamous cell carcinoma as the predominant histologic subtype (43%). All 
patients had N2 disease. In one case, the N2 involvement was found by thoracotomy 
(open-close): one of the mediastinal nodes appeared less than 1 cm on the CT scan and 
was found to be adherent to the superior caval vein; thus no primary surgery was 
attempted. In all other cases, mediastinal lymph node involvement was confirmed by 
mediastinoscopy/tomy (42 cases) or needle biopsy/aspiration cytology (four cases). In 
32 of the 47 patients, baseline CT scans provided an estimate of the largest diameter 
of the N2 nodes. This diameter was less than 10 mm in one case, between 10 and 20 
mm in 10 cases, between 20 and 30 mm in 11 cases, and more than 30 mm in 10 
cases. Among the 15 remaining patients in whom CT did not allow an exact 
measurement, there were at least five patients with mediastinal lymph node 
enlargement on plain-chest roentgenograms.  
 
Hematologic Toxicity 
 
During 127 treatment cycles with GC, grade 3/4 neutropenia was observed in 38.3% 
of the patients. Only one patient (2.1%) had febrile neutropenia. Grade 3/4 anemia 
was seen in 14.9% of the patients. Thrombocytopenia was the predominant 
hematologic toxicity: grade 3/4 thrombocytopenia was seen in 46% of the treatment 
cycles (59.6% of the patients; Table 2); however, thrombocytopenia was not 
associated with an increased number of bleeding events, and no platelet transfusions 
were administered. Overall, hematologic toxicity frequently caused dose omission 
(34%) or reduction (23%) of the gemcitabine doses on day 15. 
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Table 2. Hematologic Toxicity (N = 47) 
 nadir* 
 grade 0 grade 1 grade 2 grade 3 grade 4 
 No. of 
pts 
% No. of 
pts 
% No. of 
pts 
% No. of 
pts 
% No. of 
pts 
% 
Leukocytes 7 14.9 10 21.3 16 34.0 14 29.8 –  
Neutrophils 16 34.0 2 4.3 11 23.4 8 17.0 10 21.3 
Thrombocytes 2 4.3 4 8.5 13 27.7 11 23.4 17 36.2 
Hemoglobin –  13 27.7 27 57.5 6 12.8 1 2.2 
Abbreviations: pts = patients. *National Cancer Institute common toxicity criteria. 
 
 
Nonhematologic Toxicity 
 
Nonhematologic adverse events were typical of conventional cisplatin-based 
combinations used in patients with NSCLC (Table 3). Nausea and vomiting occurred 
frequently but reached grade 3 in only a minority of patients (14.8% and 10.6%, 
respectively). Grade 3/4 neurotoxicity mainly involved ototoxicity (four patients). 
Sensory neuropathy never exceeded grade 1.  
 
Table 3. Number of patients with nonhematologic toxicities (N = 47) 
 Grade* 
 0 1 2 3 4 3/4 (%) 
Nausea 10 13 17 7 — 14.8 
Vomiting 14 10 18 5 — 10.6 
Headache 36 4 1 0 0 0 
Sensory 
neuropathy 
37 9 0 0 0 0 
Other 
neurotoxicity† 
23 8 8 3 2 10.6 
Alopecia 19 8 14 5 — 10.6 
Lethargy 12 16 16 3 — 6.4 
Creatinine 35 9 1 — 1 2.1 
Febrile 
neutropenia 
46 — — 1 — 2.1 
Infection 37 — 3 1 — 2.1 
Diarrhea 38 6 2 1 — 2.1 
Hemorrhage 29 11 1 1 — 2.1 
Weight loss 38 4 1 1 — 2.1 
Shortness of 
breath  
36 1 — 1 — 2.1 
* National Cancer Institute common toxicity criteria.  
† Other neurotoxicity excludes constipation, headache, and sensory neurotoxicity. 
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Flu-like symptoms were occasionally seen, and alopecia (grade 2 or more) was noted 
in 40% of patients. In two patients with known seropositive rheumatoid arthritis and 
pulmonary fibrosis, pulmonary dysfunction deteriorated after radiotherapy. One 
patient died 1 month after the radiotherapy. The autopsy confirmed a complete 
remission but also revealed the presence of organizing diffuse alveolar damage in 
addition to pulmonary fibrosis. The other patient died 7 months after radiotherapy with 
signs of pulmonary dysfunction in addition to recurrent disease that was diagnosed 5 
months earlier. 
 
Dose-Intensity 
 
Cisplatin was administered within the 90% to 110% range of the intended dose in 92% 
of the courses. As a result of omissions and dose reductions, only 48% of the courses 
were at the intended dose of gemcitabine, which translated into 259 infusions at the 
intended dose, 66 infusions at reduced dose, and 55 omitted infusions. 
Thrombocytopenia on day 15 was the main reason for dose reductions or withholding 
of gemcitabine. Because of a miscalculation of body-surface area, one patient received 
more than 110% of the intended doses of cisplatin and gemcitabine during cycle 2.  
 
Response to Induction Therapy and Additional Treatment 
 
The CT scans of responding patients were reviewed and all were independently 
confirmed, with the exception of one patient for whom CT scans could not be 
obtained. A summary of treatment and responses is presented in Fig 1.  
Of the 38 patients who received the planned induction therapy of three cycles of GC, 
33 patients responded (three CRs and 30 PRs), for an overall response rate of 70.2%  
(95% confidence interval, 55.1% to 82.7%). In addition, there were three patients with 
no change (minor response in two) and two with progressive disease. Among the nine 
patients who did not receive the planned induction therapy of GC, seven discontinued 
GC therapy because of toxicity (ototoxicity in three cases). Three of these seven 
patients achieved PR with other gemcitabine combinations and were subsequently 
randomized to additional treatment with surgery or radiotherapy per EORTC 08941. 
Thus a total of 35 patients were randomized to additional surgery (n = 17) or 
radiotherapy (n = 18) per EORTC 08941. In the group of patients who underwent 
thoracotomy, minor (n = 1), partial (n = 15), and complete (n = 1) clinical responses 
were confirmed. The surgeon decided to perform an open-close thoracotomy in one 
case and resection in 16 cases. Resections were judged to be complete in 71% of the 
patients. After induction therapy, the mediastinal nodes of 53% of the cases were 
tumor-free.  
Twelve patients were not randomized to additional surgery or radiotherapy. Reasons 
for nonrandomization included cerebral infarction for one patient, lack of response for 
five patients (one was later corrected to PR by review panel) for patients who received 
three cycles of GC, toxicity for two patients who received two cycles of GC, and 
toxicity, progression, and second primary tumor in two, one, and one patient(s), 
respectively, who received one cycle of GC. 
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Fig 1. Summary of treatment and response. 
Abbreviations: NC, no change; MR, minor response. aPatients not randomized to radiotherapy 
or surgery (n = 12). bOne patient was judged to have stable disease by the attending 
physician, but the review panel documented a PR. 
 
 
After induction treatment, one patient received laser therapy (second primary tumor) 
and nine received radiotherapy. Two  
patients, who stopped protocol treatment with GC, continued with other chemotherapy 
combinations followed by surgery.  
 
Survival 
 
At the time of this analysis, after a median follow-up period of 19 months, 29 of the 
53 patients have died. In 27 cases, the deaths were related to the malignant diagnosis. 
One patient died from a cardiovascular cause. In another case, a (viral) infection was 
noted as the cause of death. The median duration of survival was 18.9 months, and the 
estimated 1-year survival rate was 69% (95% confidence interval, 56% to 82%). The 
survival curve is depicted in Fig 2. 
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Fig 2. Duration of survival. 
 
 
Discussion 
 
In the last 10 to 15 years, many phase II trials have investigated multimodality 
treatment strategies that included induction chemotherapy and surgical resection in 
patients with stage III NSCLC. The substantial variability in the design of these trials 
makes interpretation of the results difficult. However, it has been well recognized that 
patients with stage III NSCLC are consistently more sensitive to preoperative 
chemotherapy than patients with stage IV disease.17 Therefore, the EORTC Lung 
Cancer Cooperative Group decided to further study new chemotherapy combinations 
within the framework of a comparative study in patients with NSCLC IIIA N2, 
evaluating the role of surgery and radiotherapy after induction therapy.  
GC was selected as the first combination tested. Preclinical data led this research 
group to adopt the GC schedule developed by Crinò et al,11 in which gemcitabine is 
given on days 1, 8, and 15 and cisplatin on day 2. This regimen allows incorporation 
of gemcitabine in the DNA before cisplatin is given, which in experimental studies 
seems to favor synergistic interaction.9,10 In this context, it is worth mentioning that 
reanalysis of clinical (phase II) studies also suggested better efficacy of cisplatin when 
given after gemcitabine.18,19  
When comparing the toxicities of different GC schedules, the administration of 
cisplatin on day 2 has been associated with more pronounced thrombocytopenia than 
that observed with cisplatin administration on day 15. The results of this study, in 
which almost 60% of patients had grade 3/4 thrombocytopenia, are in line with this 
observation. Fortunately, this thrombocytopenia was not associated with an increase in 
bleeding events.  
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Nonhematologic toxicities were typical for a cisplatin-containing combination. The 
worsening of pulmonary function that occurred after radiotherapy in two patients with 
preexisting pulmonary fibrosis reinforces the fact that radiation pneumonitis is seen 
more often after combined-modality treatment. Gemcitabine is a potent radiosensitizer 
that has been associated with severe radiation pneumonitis when given at full dose 
concurrently with radiotherapy.20,21 On the other hand, the data showing the feasibility 
of combining gemcitabine at lower doses with concurrent radiotherapy in patients 
with stage III NSCLC22 indicate that the preexisting fibrotic pulmonary lesions must 
have contributed to the pulmonary dysfunction observed. Patients with preexistent 
fibrotic pulmonary disorders must, therefore, be excluded from the combination of GC 
and radiotherapy until the interactions with pulmonary fibrosis are better understood. 
Overall, the clinical results of this study confirm previous observations that the GC 
combination has acceptable toxicity.  
The high response rate produced by three courses of GC is accounted for by the 
inclusion of all eligible patients and the exclusion of responding patients completing 
fewer than three courses of GC. The response rate of 70.2% is far greater than the 
percentages demonstrated in previous phase II and III studies in patients with 
advanced or metastatic NSCLC. This difference is likely related at least in part to the 
increased sensitivity to chemotherapy of patients with stage III disease who have a 
good performance status. On the other hand, this response rate, which is among the 
highest for preoperative chemotherapy, occurred despite significant tumor bulk; in 
fact, the large majority of patients had significant N2 enlargement on CT and a 
relatively low exposure to gemcitabine. It may be theorized, therefore, that a day 2 
cisplatin schedule clearly exhibits synergism, resulting in greater activity and 
increased hematologic toxicity.  
In the past, it has been difficult to prove the superiority of one chemotherapy regimen 
against NSCLC over another. Taking into account the activity of the GC combination 
as induction treatment in this trial, there is a good reason to consider GC for induction 
therapy in patients with earlier-stage disease. A preliminary report also indicates that 
this group of patients may benefit from induction chemotherapy.3 Of the 17 patients 
randomized to the surgical arm after induction therapy, 94% were operable; in 71% of 
these cases, the resection was considered complete. Especially important is the fact 
that mediastinal lymph nodes were rendered tumor-free in 53% of cases. This figure is 
somewhat higher than that obtained in the Memorial Sloan-Kettering Cancer Center 
experience, but exactly the same as that reported after the trimodality approach 
(concurrent chemotherapy and irradiation followed by surgery) used by the Southwest 
Oncology Group (SWOG). Nodal downstaging is of particular interest, as it was the 
only significant prognostic factor in a multivariate analysis of this SWOG (8805) 
trial.23 Other data in this SWOG study, including a 46% major pathologic response 
rate in patients with stable disease, suggested that chemotherapy given concurrently 
with radiotherapy may be more effective than chemotherapy alone. Interestingly, the 
percentage of patients who underwent complete resection in this study was identical 
(71%) to that of the SWOG study, and median survival was similar (18.9 months in 
EORTC 08955 v 15 months in SWOG 8805). The question of whether radiotherapy is 
necessary in the induction regimen24 remains important, and it is expected that the 
outcomes of this study will encourage investigations optimizing the addition of 
radiotherapy to GC.22  
Concerning the GC schedule, the present experience indicates that slight 
modifications may be advisable. While keeping dose-intensity largely unchanged, the 
schedule can be limited to 3 weeks by giving gemcitabine (1,250 mg/m2) on days 1 
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and 8 only and cisplatin (75 mg/m2) on day 2. An almost identical schedule has 
already been shown to be feasible.14  
In conclusion, our data show that GC with cisplatin on day 2 is highly active in 
patients with stage IIIA N2 NSCLC. The combination of GC with surgery and 
radiotherapy was feasible, and the present results encourage the exploration of this 
combination in patients with resectable, early-stage disease. 
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Summary 
 
Purpose: To investigate the improvement of quality of radiotherapy and compliance 
to the protocol amendment of EORTC study 08941.  
Patients and Methods: The radiotherapy-specific data were analyzed of 154 patients 
with stage IIIA-N2 Non-Small-Cell Lung Cancer who were actually irradiated after 
response to 3 cycles of platinum-based induction chemotherapy. The parameters of 
quality assessed in 93 patients before and in 61 after protocol amendment included: 
time interval between last chemotherapy course and start of thoracic radiotherapy, the 
use of a 3-D planning CT, dose and fractionation scheme to the primary tumour, the 
involved – and uninvolved mediastinum, duration of radiotherapy and toxicity. 
Results: A significant improvement of all quality parameters was noted, except for 
the overall treatment time, which decreased slightly. 
Conclusions: Protocol amendment resulted in an improvement of quality and 
compliance of parameters, at the cost of some increase in overall treatment time. The 
latter reflects logistic problems rather than poor compliance. 
 
Keywords: Non-Small Cell Lung Cancer, Quality Assurance, Radiotherapy 
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Introduction 
 
Three meta-analyses show that the addition of cisplatin containing combination 
induction chemotherapy followed by radiotherapy results in an absolute survival gain 
of 4% at 2 years in stage III non-small-cell lung cancer.1-3 
In 1994 the European Organisation for Research and Treatment of Cancer (EORTC) 
Lung Cancer Group launched a randomised trial (08941) in patients with irresectable 
stage IIIA N2 NSCLC to address the question which locoregional treatment was 
superior following a response to systemic induction with platinum-based combination 
chemotherapy: surgical resection or thoracic radiotherapy.4 
Quality assurance is an important issue in the EORTC.5 In 1987 the EORTC 
Radiotherapy Group introduced a series of procedures to document systematic errors, 
dummy runs, made in single institutions. This dummy run gives also information 
about accuracy of the design and the application of phase III study protocols. In 1991 
Koning 6 recommended immediate monitoring of treatment parameters and uniform 
assessment of patient data in clinical trials. However, at the start in 1994 of the 
present randomised study these quality controls on radiotherapy treatment were not 
yet implemented. Questions about the quality of radiotherapy data came up halfway 
the trial, as not all investigators adhered to prescribed treatment schemes. At site 
visits, the radiotherapy treatment fields and set up appeared to be correct, but 
compliance to the protocol was subject of improvement. 
In May 1999, the protocol was amended with  detailing and tighthening of the 
radiotherapy prescriptions. The aim was to improve the quality of and the compliance 
to the radiotherapy and to enhance the reliability of the final results of the study. This 
report focuses on the radiotherapy quality data before and after this protocol 
amendment.  
 
 
 
Patients and methods 
 
In EORTC 08941, patients with proven stage IIIA-N2 NSCLC were treated with 3 
cycles of platinum-based induction chemotherapy; responding patients were then 
randomised between thoracic radiotherapy or surgical resection.7 
The EORTC Protocol Review Committee (PRC) and the local ethical committees 
approved the protocol and its amendment. All patients had to give informed consent 
prior to randomisation according to local practice. 
In the surgery arm, 165 patients were included and 40% was referred for post-
operative radiotherapy because of presumed irradical resection according to the preset 
definition. These postoperative radiotherapy data are not the subject of this paper. 
 
Protocol Amendment for improving Radiotherapy Quality 
 
In the protocol amendment of May 1999, most of the guidelines for writing protocols 
published in 1995 by the EORTC Radiotherapy Group8 were implemented. The 
protocol was revised with the target volumes redefined according the specifications of 
the ICRU 50 report.9 The radiotherapy prescriptions were tightened and updated as 
follows: planning-CT scan became standard for the whole treatment, timeframes and 
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dose specifications were formulated more precisely, case report forms revised, and 
radiotherapists instructed (Table 1). 
 
 
Table 1: Protocol prescriptions before and after the amendment 
Before the amendment After the amendment 
1. CT-based treatment planning 
mandatory for boost only 
1. 3-D planning CT mandatory from start 
of treatment 
2. No time intervals stated for ICT-Rand 
and Rand-RT 
2. Time intervals prescribed (see Table 3) 
3. Involved fields: 60 – 62.5 Gy in 30 
fractions 
3 Involved fields: 60 Gy in 30 fractions  
5x per week 
4. Uninvolved regions: 40 – 45 Gy in 20 
– 23 fractions 
4 Uninvolved regions 40 – 46 Gy in  
20 – 23 fractions 5x per week 
5. Fraction size at least 1.80 Gy 5 Fraction size 2.00 Gy 
6. Tumor margins ≥ 2 cm for involved 
areas, the margins of the uninvolved 
areas were not specified 
6 GTV 1 (prechemo involved areas) with 
≥ 1 cm margin; GTV 2 (uninvolved 
areas) without margins 
  7. Implementation of ICRU 50 guidelines 
Abbreviations: ICT = induction chemotherapy; Rand = randomisation; RT = thoracic 
radiotherapy; GTV = gross tumour volume. 
 
The primary protocol requirements were specified as follows: The primary tumour 
and areas of radiological nodal involvement had to be treated with at least 2 cm 
margin to a dose of 60-62.5Gy using daily fractions of 2 Gy. The lymphatic drainage 
areas of the uninvolved mediastinum on CT scan of the thorax should have received a 
dose of 40-45 Gy in daily fractions of 2 Gy. The total radiation dose should have been 
60 Gy with lung tissue correction (0.3 or CT-based), given in 30 daily fractions of 2 
Gy for 5 treatments per week. The fractionation dose should have been calculated for 
the target volume and should not have been less than 1.8 Gy. The overall radiotherapy 
treatment time should not have exceeded 7 weeks. Megavoltage equipment with 
photon energies of at least 4 MV was required. For fixed Source Skin Distance (SSD) 
techniques a treatment distance of 100 cm had to be used. In addition to dose 
distribution in the central axis plane, central dose at upper and lower limits of target 
volume should have been calculated and wedged filters used as compensators if 
greater than 10% inhomogeneity resulted from varying tissue thickness. CT –based 
treatment planning was mandatory for the boost technique only. Treatment could be 
started with conventional APPA opposed treatment fields. Simulator films and 
treatment plans with specified target volume and dose distributions had to be available 
for review. 
In the amendment, volumes of interest and organs at risk were more precisely 
described according ICRU 50 specifications.9 CT-based 3D- planning with lung tissue 
correction became mandatory for the whole radiation treatment. Dose inhomogeneity 
was accepted between +/- 10 %. Dose prescriptions were described more precisely 
and alternative treatment schemes were no longer allowed. 
Minor deviations from the prescribed dose, were defined as tumour dose between 55 – 
66 Gy, dose to the involved mediastinum between 55 – 66 Gy, and fraction dose 
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between 1.8 - 2.20 Gy. Major protocol deviations were defined as a fraction size of 
>2.20 Gy and/or fraction number <28. 
 
Data collection on delivered radiotherapy 
 
The data on the quality of the delivered radiotherapy were retrospectively collected 
for the period before the introduction of the amendment and prospectively for the 
period after the amendment. Site visits to participating institutes were performed in 
1998 and 1999 by 2 experienced radiation-oncologists of the EORTC Lung Cancer 
Group. Data checked on site were: field sizes, margins, treatment techniques, and 
dose delivery. 
Toxicity was scored using the National Cancer Institute of Canada Clinical Trials 
Group Expanded Common Toxicity Criteria.10 Acute toxicity was scored for white 
blood cell counts, platelets, upper gastro-intestinal, pharynx and oesophagus, and lung 
toxicity. Only grade 3 – 4 toxicities will be discussed in this analysis. 
The case report forms were revised according the new prescriptions. All investigators, 
and specifically the radiotherapists, were instructed of the changes in protocol 
guidelines initiated in May 1999. Further, intensification of the data control at the 
EORTC Data Centre was performed.  
 
Endpoints and statistics 
 
To study the impact of this amendment, we defined a measure of compliance based on 
1. interval scored from the last day of induction chemotherapy (ICT) till the start of 
thoracic radiotherapy (≤10 weeks), 2. the use of 3-D planning, 3. the use of lung tissue 
corrections, 4. the dosages administered to the primary tumour (60 – 62.5 Gy), the 
involved – (60 – 62.5 Gy) and uninvolved (40 – 46 Gy) mediastinum, 5. the 
fractionation size (1.95 – 2.05) and numbers (30 – 32), and 6. the duration of the 
radiotherapy treatment (40 – 46 days). We also report data on the interval between last 
day of ICT and randomisation, and from randomisation until start of thoracic 
radiotherapy, as well as toxicity data. Indeed, a reduction in toxicity rate was expected 
as standard dose prescriptions had to be followed and hypofractionated treatment 
schemes were not any longer allowed. Descriptive statistics are presented for these 
variables. All analyses are to be considered as exploratory and unplanned in the 
protocol. 
 
 
Results 
 
Patient inclusion 
 
EORTC study 08941accrued  578 patients between December 1994 and December 
2002; of these 332 were randomised.7 Among the 165 patients randomised to the 
radiotherapy arm, 154 patients started their allocated protocol treatment and are the 
subject of this analysis. Of these, 93 patients were randomised before and 61 after 
May 1999, period at which the protocol amendment was implemented. A summary of 
the characteristics of the patients allocated to and actually treated with radiotherapy is 
given in table 2. Distribution of gender, T status and histological subtypes are similar 
between both randomisation periods. 
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Analysis of portal films and planning data during the site visits revealed no major 
deviations in target volumes and margins from protocol prescriptions. 
 
Table 2: 
Baseline characteristics at registration of patients 
randomised to the radiotherapy arm 
 Randomisation period 
 Before amendment 
(N = 93) 
After amendment 
( N = 61) 
Variable N (%) N (%) 
Sex 
Male 
Female 
 
71 
22 
 
(76) 
(24) 
 
47 
14 
 
(77) 
(23) 
cT 
T1 
T2 
T3 
Tx 
 
10 
68 
14 
1 
 
(11) 
(73) 
(15) 
(1) 
 
10 
42 
9 
0 
 
(16) 
(69) 
(15) 
(0) 
Histological subtype 
Squamous cell 
Non-squamous cell 
 
38 
55 
 
 
(41) 
(59) 
 
25 
36 
 
(41) 
(59) 
Randomised in The Netherlands 
Yes 
No 
 
66 
27 
 
(71) 
(29) 
 
53 
8 
 
(87) 
(13) 
 
 
Compliance to radiotherapy protocol prescription 
 
Table 3 shows data on compliance to protocol prescriptions for both periods. 
Response evaluation after the last chemotherapy course was done within the required 
time period of 4 weeks or less in 53% of patients before and 72% after the amendment 
respectively. The number of patients starting thoracic radiotherapy within the required 
10 weeks or less after the last induction chemotherapy course, however, decreased 
from 91% before to 79% after the amendment. The median interval increased from 50 
(range 17 – 113) to 53 (range 20-84) days.  There is a trend towards longer time 
interval after randomisation till thoracic irradiation for patients in The Netherlands 
than for those patients treated outside The Netherlands (Table 3). Before protocol 
amendment 11% respectively 4% of the patients was not treated within 6 weeks after 
randomisation. After protocol amendment this number increased to 29% respectively 
12% of the patients. 
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Abbreviations: ICT = induction chemotherapy; Rand = randomisation; RT = thoracic 
radiotherapy 
* includes all items except interval ICT-Rand and Rand-RT 
 
 
Planning-CT was in the initial protocol mandatory for the boost dose only, and after 
protocol amendment mandatory from start of the treatment. 
All patients were treated with various photon beams of 6-18 MV. The compliance for 
dose delivery to the primary tumour, the involved and the uninvolved mediastinum,  
improved from 75 to 97%, 66 to 89% and 86 to 89% respectively. 
In general the compliance to the protocol improved from 48% (45/93 patients) to 66% 
(40/61 patients).  For all 154 patients, 85 (55%) fulfilled all protocol prescriptions. 
Minor deviations from the prescribed dose, were observed in 140 patients (91%), 127 
(83%), and 139 patients (90%) patients respectively. Major deviations were observed 
in 16 patients (10%), 14 before and 2 after protocol amendment (see Table 4). 
In 2/16 patients (12%) treatment scheme was changed because distant metastasis 
occurred during radiotherapy treatment. 
 
Toxicity of radiotherapy 
 
The Biological Effective Dose (BED) for tumour and late toxicity is given (Table 4) 
for the aberrant treatment schemes.  
 
Table 3: Overview of compliance to protocol prescription 
Before amendment After amendment  
 N=93 N=61 
 Protocol prescription Number (%) pts 
Interval  
 
ICT-RT  ≤10 wks 
ICT-Rand ≤ 4 wks 
Rand-RT ≤ 6 wks 
- in The Netherlands 
- outside The Netherlands 
85 (91) 
49 (53) 
85 (91) 
59 (89) 
26 (96) 
48 (79) 
44 (72) 
49 (80) 
40 (71) 
  7 (88) 
Planning-
CT  
Performed 
With lung correction 
82 (88) 
80 (86) 
59 (97) 
58 (95) 
Dose (Gy): 
 
Tumour (60 – 62.5) 
Mediastinum 
- Involved (60 – 62.5)  
- Uninvolved (40 – 46)  
70 (75) 
 
61 (66) 
80 (86) 
58 (97) 
 
54 (89) 
54 (89) 
Fraction- 
numbers 
 
30 – 32 
 
72 (77) 
 
59 (97) 
Fraction 
size (Gy) 
1.95 – 2.05 75 (81) 59 (97) 
Duration  40 – 46 (days) 67 (72) 56 (92) 
Compliance to protocol* 45 (48)  40 (66) 
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Table 4: Overview of major protocol deviations used in individual patients: 
before protocol amendment 
Duration 
(days) 
Dose 
primary (Gy) 
Fraction 
numbers 
Fraction dose BED 
tumour 
BED  for late toxicity 
23* 35.0 16 2.18 * * 
40 56.0 24 2.33 69.0 121 
34 55 22 2.50 62.5 124 
43 48.0 18 2.66 60.8 112 
22 48.0 16 3.00 62.4 120 
22 45.0 15 3.00 58.5 112 
22 45.0 15 3.00 58.5 112 
22 45.0 15 3.00 52.2 112 
21 45.0 15 3.00 58.5 112 
22 45.0 15 3.00 58.5 112 
22 45.0 15 3.00 58.5 112 
22 45.0 15 3.00 58.5 112 
15 40.0 8 5.00 72 200 
16 40.0 8 5.00 72 200 
After protocol amendment 
31* 45.0 20 2.25 * * 
39 56.0 23 2.43 69.6 124 
Prescribed dose 
40 60.0 30 2.00 72 120 
Formula for reference treatment: BEDref  = Dose ref  [1 + fraction dose ref /(α/β)] 
α/β for tumour = 10, and for late toxicity α/β = 2  
* Patients stopped because of distant metastasis 
 
Only 5 (5%) patients before the amendment and 2 (3%) patients after the protocol 
amendment had toxicity grade 3-4 in any of these variables (Table 5). Two patients 
with pre-existent lungfibrosis died because of a radiation pneumonitis after induction 
chemotherapy with gemcitabine/cisplatin. 
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Table 5:  Acute toxicity in thoracic radiotherapy after induction chemotherapy 
 Randomisation period 
Variable Before protocol amendment 
(N = 93) 
After protocol amendment 
(N = 61) 
WBC (109/l) 
   ≥ 4 
  2 - <4 
  <2 
unknown/missing 
 
69 
8 
0 
16 
 
(74) 
(9) 
 
(17) 
 
46 
4 
0 
11 
 
(75) 
(7) 
 
(18) 
Platelets (109/l) 
  ≥ 100 
  50 - <100 
  <50 
 unknown/missing 
 
39 
1 
1 
52 
 
(42) 
(1) 
(1) 
(56) 
 
48 
1 
0 
12 
 
(79) 
(2) 
(0) 
(20) 
Upper GI toxicity 
  Degree 0 
  Degree 1-2 
  Degree 3-4 
 
59 
34 
0 
 
(63) 
(37) 
 
 
42 
19 
0 
 
(69) 
(31) 
 
Pharynx and Oesophagus 
toxicity 
  Degree 0 
  Degree 1-2 
  Degree 3-4 
 
 
19 
74 
0 
 
 
(20) 
(80) 
 
 
15 
45 
1 
 
 
(25) 
(74) 
(2) 
Lung toxicity 
  Degree 0 
  Degree 1-2 
  Degree 3-4 
  Missing 
 
46 
42 
4 
1 
 
(50) 
(45) 
(4) 
(1) 
 
26 
34 
1 
0 
 
(43) 
(56) 
(2) 
 
Other acute toxicity 
  No 
  Yes 
 
80 
13 
 
(86) 
(14) 
 
49 
12 
 
(80) 
(20) 
Abbreviations: WBC = white blood count 
 
 
Discussion 
 
In 1999, quality control of EORTC 08941 showed limited protocol compliance 
mainly due to the use of hypofractionated treatment schemes. That was the reason for 
a protocol amendment with more strict prescriptions on the radiotherapy delivery. We 
observed that due to this amendment overall treatment parameters as dose, 
fractionation, and overall treatment time improved substantially. The stricter 
regulations in the amendment resulted in a gain in overall compliance to the protocol 
of 17%.  
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Unexpectedly, we also observed that despite the more strict protocol prescription, the 
proportion of patients starting with radiotherapy within 10 weeks of the last cycle of 
chemotherapy actually declined from 91% to 79%. This was mainly due to an 
increased delay between randomisation and start of radiotherapy and not due to a 
further delay between chemotherapy and randomisation. Apparently, chest physicians 
and medical oncologists became now also aware of the importance to improve their 
time schedule. The use of a planning-CT, which became mandatory for the whole 
treatment course, was probably the main reason the number of patients started with 
thoracic radiotherapy within 10 weeks after finishing chemotherapy decreased. 
Planning-CT is a more time-consuming technique than conventional simulation.11 
Furthermore, the shortage of radiation equipment12 could be responsible for 
lengthening of the time interval, as a large majority (77%) of the patients in this study 
were treated in the Netherlands (Table 2 and 3). However, we consider the gain in 
quality control with the introduction of a planning-CT for the whole treatment to be 
more important on the main outcomes of this trial than the increase of 3 days of the 
median time before and after the amendment. 
The Planning Target Volume (PTV) prescribed by the protocol amendment, had a 
margin of ≥1 cm around the pre-chemotherapy tumour areas and pathological hilar or 
mediastinal nodes (Gross Tumour Volume or GTV). All patients in this study had at 
least a response at randomisation. 
Shih et al13 showed for fast CT-scan at shallow free breathing that internal margins 
(expansion margins) of 13 mm are required to approximate the composite GTV in 
95% of cases. Van Sörnsen de Koste et al14 showed that margins of 15 mm around 
GTV in immobile tumours using conventional planning-CT are adequate, but in 
mobile tumours the coverage is still inadequate in 11% of the cases. Lagerwaard et 
al15 recently showed in reconstructing pre-chemotherapy target volumes clinicians 
may fail to treat the actual pre-chemotherapy tumour volume in 26% of the cases. 
This can result in lower local control, but no data exist of randomised trials in treating 
pre- or post-chemotherapy target volumes. Therefore, we consider the margin of ≥1 
cm around prechemotherapy tumour areas and mediastinal nodes used in the present 
protocol as adequate. The majority of patients were planned using a 3-D planning-CT 
during this study, reaching 99% after protocol amendment. Thus, based on the 
abovementioned findings and the pre-amendment site visits, we believe that no major 
concerns exist about the quality of and the compliance to treatment planning volumes. 
Before protocol amendment, a major protocol violation in the administered tumour 
dose was present in 15% of patients with doses to primary tumour of less than 55 Gy 
or in excess of 66 Gy. These findings were worse than found in an earlier study 
wherein incorrectly given radiation doses were reported in only 7% of the cases.6 
Although the protocol already recommended fraction doses of 1.8 - 2.0 Gy at 
initiation of the study, capacity problems in several hospitals led to the introduction of 
hypofractionated treatment schemes. After amendment of the protocol, it was stressed 
that dose prescriptions had to be strictly followed. This resulted in a substantial 
improvement of the protocol compliance.  
A reduction in overall treatment time to 20-24 days using hypofractionated schemes 
on loco-regional control is evident. Lester16 treated stage I-III NSCLC patients to 50-
55 Gy in 15-20 fractions over 3-4 weeks. This resulted in a favourable outcome 
compared to standard radical radiotherapy data. Cheung17 used 48 Gy in 12 once-daily 
fractions for early stage non-small-cell lung cancer patients with a recurrence free 
survival after 2 years of 40%. The CHART study18 showed a reduction of overall 
treatment time to 12 consecutive days with a hyperfractionated treatment scheme of 
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thirty-six fractions of 1.5 Gy given three times per day, resulting in a gain in two-year 
survival of 9%, compared to 30 fractions of 2 Gy to a total dose of 60 Gy in 6 weeks.  
On the other hand, hypofractionation can increase the risk of late toxicity. Abratt et 
al19 showed that the biological effect of radiation on tumours is increased as overall 
treatment time is shortened, but this is not true for late-reacting normal tissue. 
However, for patients with stage III tumours treated with combined modality more 
conservative hypofractionation regimens are warranted. The BED for late toxicity in 
only 2 hypofractionation schemes (BED 200) is much higher than in the standard 
treatment scheme (BED 120).20 Therefore, no differences in toxicity over both periods 
were to be expected. 
The two patients, who died after induction chemotherapy followed by radiotherapy, 
were both treated according to the initial protocol prescriptions, but suffered from 
interstitial lung fibrosis.21 Maas et al22 showed the combination of 
gemcitabine/cisplatin as part of  combined modality treatment, especially 
radiotherapy, resulted in an decline of pulmonary function and could be responsable 
for an increase of toxicity. However, van Zandwijk et al21 showed the combination of 
gemcitabine/cisplatin is safe as induction treatment. Therefore, patients with 
interstitial lung fibrosis were hence excluded from further inclusion in 08941. 
This trial was running over a period of more than 8 years. During this period, 
radiotherapy techniques changed to the actual standards.  The progress in simulation 
techniques urged for standard 3-D planning techniques. The improvement of protocol 
compliance after the amendment supports the earlier recommendation of immediate 
monitoring of treatment parameters and uniform assessment of patient data in clinical 
trials. For future trials we would recommend to use routine checks on the quality of 
(any) delivered treatment as this would provide the possibility of corrections in the 
protocol shortly after start of a study and guarantee compliance. 
 
 
Conclusion 
 
After protocol amendment, a substantial improvement of protocol compliance was 
observed, despite some increase in overall treatment time. The latter is thought to 
reflect logistic problems rather than poor compliance. The use of hypofractionated 
treatment schemes is of some concern with respect to the outcome of the trial. Our 
data support the use of strict radiotherapy specifications, dummy runs, and quality 
control from the start of a large study and frequent quality assessments during it. 
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Summary 
 
Purpose: A national multicenter randomized study compared the efficacy of  2 x 8 Gy 
versus our standard 10 x 3 Gy in patients with inoperable stage IIIA/B (with Eastern 
Cooperative Oncology Group score of 3 to 4 and/or substantial weight loss) and stage 
IV non-small-cell lung cancer. 
Patients and Methods: Between January 1999 and June 2002, 297 patients were 
eligible and randomized to receive either 10 x 3 Gy or 2 x 8 Gy by external-beam 
irradiation. The primary endpoint was a patient-assessed score of treatment effect on 
seven thoracic symptoms using an adapted Rotterdam Symptom Checklist. Study 
sample size was determined based upon an average total symptom score difference of 
more than one point over the initial 39 weeks post-treatment. The  time course of 
symptom scores were also evaluated, and other secondary endpoints were toxicity and 
survival. 
Results: Both treatment arms were equally effective, as the average total symptom 
score over the initial 39 weeks did not differ. However, the pattern in time of these 
scores differed significantly (P <0.001). Palliation in the 10 x 3-Gy arm was more 
prolonged (until week 22) with less worsening symptoms than in 2 x 8-Gy.  
Survival in the 10 x 3-Gy arm was significantly (P = .03) better than in the 2 x 8-Gy 
arm with 1-year survival of 19.6% (95%CI, 14.1 to 27.3%) versus 10.9% (95%CI, 6.9 
to 17.3%). 
Conclusion: The 10 x 3-Gy radiotherapy schedule is preferred over the 2 x 8-Gy 
schedule for palliative treatment, as it improves survival and results in a longer 
duration of the palliative response. 
 
Keywords: Randomized trial, non-small-cell lung cancer, irradiation, palliative 
treatment, hypofractionation 
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Introduction 
 
The treatment of non-small-cell lung cancer (NSCLC) is still a challenge for the 
oncologist. In the past decade, combined-modality treatment in stage III disease and 
chemotherapy for stage IV disease improved the survival and quality of life in 
NSCLC patients.1 Unfortunately, many patients are unfit to undergo these intensive 
treatments.2 Patients who undergo palliative chemotherapy may eventually require 
treatment for locoregional complaints. 
Symptoms such as hemoptysis, chest pain, dysphagia, and dyspnea in NSCLC can all 
be effectively palliated using different radiation treatment schemes.3  The 
effectiveness of these palliative schemes varies for each symptom, but is most 
effective for hemoptysis and chest pain in patients with Eastern Cooperative 
Oncology Group (ECOG) score of 2 to 3.4 The optimal dose for palliation remains 
controversial.5 In the first Medical Research Council (MRC) trial reported in 1991, no 
differences in palliative effect or in survival were seen between 13 x 3 Gy and 2 x 8.5 
Gy.6  In a second MRC study (1992)7 for poor prognostic patients only, no differences 
in palliation or survival were seen between 10 Gy single dose and 2 x 8.5 Gy. 
However in a study by Bezjak et al 8 a difference in survival between 20 Gy in five 
fractions and a 10-Gy single dose was demonstrated in favor of the multifractionation 
treatment. In a subgroup-analysis, however, this survival advantage was not seen in 
patients with an ECOG score ≥ 2. Later data suggested a survival advantage of 13 x 3 
Gy over 2 x 8.5 Gy in patients with good performance status.9. For patients in a poor 
general condition it still has to be proven whether 2 x 8.5 Gy is equally effective as 10 
x 3 Gy. 
Due to the contradictory literature, radiation oncologists in the Netherlands were 
unable to reach a consensus on the palliative schedule for patients with poor- 
prognosis NSCLC. The present study was designed for patients with stage IV NSCLC 
(ECOG 0 to 1) in whom chemotherapy options were exhausted. Patients with ECOG 
2, stage IV disease were also eligible, as chemotherapy for this group of patients was 
not general practice at the start of this study.10 We focused on patients with poor 
general condition and/or significant weight loss with stage III or stage IV NSCLC, 
comparing 10 x 3 Gy with 2 x 8 Gy. Because of the results of the MRC studies 
mentioned here, we expected both treatment arms to have an equal outcome for 
palliation as for survival.6 
 
Patients and Methods 
 
Patient population 
 
Patient characteristics are presented in table 1. The diagnosis NSCLC had to be 
cytologically or histologically confirmed. Tumor stage was IIIA to IV in combination 
with performance status 3 to 4 and/or a weight loss of more than 5% in 3 months or 
greater than 10% in 6 months before diagnosis. Patients with stage IV, ECOG stage 0 
to 2 disease could also be included if, in the opinion of the treating pulmonologist, no 
further chemotherapeutic options were left after prior chemotherapy, or a substantial 
weight loss and/or comorbidity prevented the use of chemotherapy. 
Patients had to have a minimum patient-assessed total symptom score of 8, indicating 
at least some burden on at least one of the complaints caused by the tumor itself (Fig 
1). Furthermore, the patient should be physically and mentally fit enough to 
participate in this study. Patients having superior vena cava syndrome (SVCS) at 
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presentation, prior radiotherapy to the chest, and/or other malignant diseases in the 
past or concurrent chemotherapy were excluded. 
 
Study Endpoints and Data Collection 
 
Primary endpoint of this study were palliation of thoracic symptoms measured over 
26 questionnaires (39 weeks) after random assignment. Secondary endpoints were 
toxicity and survival. Patients were also asked to provide information about quality of 
life and costs.  These data will be published separately in a cost-utility analysis. 
Thoracic symptoms were measured using a total symptom score that measured the 
extent to which patients were bothered by seven tumor-related symptoms (Fig 1).  
Existing validated questionnaires were considered either too burdensome11 or not 
specific enough for our patient population.11,12 Based on symptoms previously 
observed in irradiated patients with NSCLC,13 we instead adapted the Rotterdam 
Symptom Checklist.11 We maintained the symptoms lack of appetite and dyspnea, and 
added chest pain, coughing, hemoptysis and hoarseness. In a different format, patients 
also reported their level of dysphagia.14 Using four-point Likert scales for each 
symptom, the total symptom score could range from 7 (not bothered at all on any 
symptom) to 28 (bothered very much on all symptoms). Palliation was defined as an 
average total score below the baseline score. 
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Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group. 
Table 1: Baseline patient characteristics 
 10 x 3 Gy 2 x 8 Gy 
 No. of 
patients 
  
% 
No. of 
patients 
  
% 
No. of patients 148   149   
Sex, No.       
 Male  
Female 
118 
30 
  119 
30 
  
Age, years       
 Median 
SD 
68.9 
8.7 
  69.3 
10.5 
  
Time since diagnosis, years    
 Median 
Range 
 
0.08 
0.01-7.31 
  
0.08 
0.00-8.28 
 
Baseline symptom score    
 Median  
SD 
12.71 
2.42 
  
12.88 
2.52 
  
Tumor stage, No. of patients   
 IIIA  
IIIB 
IV 
16 
56 
76 
  
24 
59 
66 
  
Tumor type, No. of patients   
 Sqamous cell carcinoma 
Adenocarcinoma  
Large cell carcinoma 
Other 
64 
37 
39 
8 
  
60 
27 
53 
9 
  
Diagnosis by, No. of patients   
 Histology 
Cytology 
114 
34 
  
114 
35 
  
Treatment indication, No. of patients   
 Primary lesion 
Recurrent lesion (no prior 
irradiation) 
142 
6 
  
147 
2 
  
Prior chemotherapy 18   20   
Other treatment at start irradiation: 
Pain medication 
Other medications 
Antibiotics 
Not specified 
Supplemental oxygen 
80 
54 
50 
5 
49 
9 
 98 
67 
60 
5 
58 
8 
 
Substantial weight loss (%) 104  70.2 109  73.1 
ECOG score  
 0  
1 
2 
3 
4 
9 
45 
60 
33 
1 
 6.1 
30.5 
40.6 
22.3 
0.1 
5 
48 
44 
51 
1 
 3.4 
32.2 
29.5 
34.2 
0.1 
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In addition, information about acute toxicity as nausea, vomiting, and radiation 
esophagitis-induced dysphagia was collected, using the National Cancer Institute of 
Canada Clinical Trials Group Expanded Common Toxicity Criteria.15 
 
Figure 1. Thoracic symptom checklist (originally in Dutch). 
 
 
The data collection schedule for follow-up is presented in Table 2. All symptoms 
were entirely patient-based scored. A maximum of 33 questionnaires would be sent in 
case follow-up would be sent in case follow-up could be completed. On average, 17.4 
sets (53%) per patient were received because a substantial number of patients did not 
survive long enough or stayed fit enough to fill in all the questionnaires over 52 
weeks. Of the 4,369 questionnaires sent by the data manager to the individual patient, 
4,306 were returned.  
The first questionnaire was completed prior to random assignment, the last 
questionnaire in the 52nd week after random assignment. 
Follow-up after 52 weeks was continued by the data manager, who made three-
monthly inquiries to establish the survival. 
To what extent during the past week have you been bothered by complaints that may 
arise from    your disease? 
Please put a cross by the answer that is most applicable to you. 
 
Example: Have you been bothered, during the past week, by: 
 
 
 Not at all A little Quite a bit Very much 
Fatigue     
 
 
Have you been bothered, during the past week, by: 
 
 Not at all A little Quite a bit Very much 
Lack of appetite 
Shortness of breath 
Pain in the chest 
Coughing 
Coughing up blood 
Hoarseness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Problems with swallowing: food won't go down 
      able to eat solid food; food goes down easily 
      only able to eat semi-solid food; food goes down with plenty of liquid 
      only able to eat liquid food  
      not able to eat liquid food 
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* Only once 2 months after the start of the treatment.  
†  Only together with questionnaires 2 to 9. 
‡ Only together with questionnaires 2, 4, 6, 8, 10 and 12. 
 
 
Statistical analysis 
 
The study was designed as an equivalence study. We assumed as null hypothesis that 
the response score of the 2 x 8 Gy to be at least 10% lower compared to our standard 
10 x 3 Gy.  We expected a response rate of 65% with the standard treatment.  We 
compared the average total symptom score for all present symptoms during 39 weeks. 
With this design, 134 patients per treatment arm were needed to obtain, at a 5% 
significance level, a power of .90 of correctly concluding equivalent effectiveness. 
Expecting an ineligibility and withdrawal of patients of 10% a total number of 300 
patients were needed. 
A response was defined as a reduction in the total symptom score by more than one 
point compared to the baseline.  Progression was defined as an increase of the total 
symptom score by more than one point, if re-treatment was given, or in case the 
patient did not return the questionnaire. A difference in palliative effect between the 
two schedules was defined as a difference of at least one point in the average total 
symptom score for at least one of the symptoms. Data are presented over the initial 39 
weeks, as too few patients remained alive to allow for meaningful analysis. 
Table 2: overview of data collection 
Measurements 
Before Randomization 
 Follow-up measurements 
After Randomization 
 
 
Doctor 
 
Data 
Manager 
 
Patient 
 
2 Months After Start 
and Every 2 months 
Thereafter for a 
Maximum of 12 
months 
(data manager) 
Weekly and After 3 
Months every 2 Weeks 
for a maximum of 52 
weeks 
(patient) 
Date of randomization X      
Performance status X      
Weight loss X      
TNM - classification X X     
Histology X      
Medication X X     
 Follow-Up assessment after randomization 
 Quality of Life   X   X 
 Tumor related 
thoracic symptom 
score 
X  X   X 
 Toxicity      X† 
 Radiotherapy 
delivered according to 
protocol 
    X *  
 Date of histology  X     
 Retreatment with 
radiotherapy 
    X  
 Patients follow up/ 
survival  
    X  
 Costs      X‡ 
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A secondary analysis was performed in which average total symptom score was 
corrected for the initial total symptom score at the start of the treatment and time of 
follow-up during this period. The latter was performed as initially higher total 
symptom score could result in a higher chance of a declining total symptom score and 
would suggest a better outcome. Also, differences in the course of the total symptom 
score between each treatment arm over the first 39 weeks were analyzed using the 
random effects model using the natural splines function in S-PLUS 6.2 professional 
edition.16 
A secondary analysis was performed in which average total symptom score was 
corrected for the initial total symptom score at the start of the treatment and time of  
follow-up during this period. The latter was performed as initially higher total 
symptom score could result in a higher chance of a declining total symptom score and 
would suggest a better outcome. Also, differences in the course of the total symptom 
score between each treatment arm over the first 39 weeks were analyzed using the 
random effects model using the natural splines function in S-PLUS 6.2 professional 
edition.16 
The overall survival of both treatments was described using the Kaplan-Meier 
survival curves.17 The log-rank test was used to compare overall survival between 
both treatments.  
Fisher’s exact test was used to compare the rates of toxicity between both groups. All 
reported P values are two-sided, and significance level was set at .05. 
All data were evaluated according to the intention-to-treat principle. 
 
 
Radiation treatment 
 
Patients were randomized, without stratification, either to the multiple fractionation 
scheme of 10 x 3 Gy, four to five times per week, or the hypofractionated scheme of 2 
x 8 Gy, given on day 1 and day 8. Irradiation was given using two opposing anterior-
posterior fields with 6- to 18-MV photon beams. The treatment portals encompassed 
the tumor, with a margin of 1 ½ - 2 cm including adjacent pathological lymph nodes. 
No limitations were set for the target volume. Dose calculation was not corrected for 
tissue inhomogeneities. 
Comedication, including corticosteroids and analgetics, and supplemental oxygen 
were allowed and documented. 
 
Ethical issues 
 
The study fulfilled all criteria as prescribed by the Dutch Law on Medical Research. 
Approval of the protocol by the Central Medical Committee of Ethics was obtained 
and each participating radiotherapy center had also a separate approval by their Local 
Medical Committee of Ethics. Random assignment took place after receiving 
informed consent of the patient. 
 
 
Results 
 
From the January 1, 1999, to May 31, 2002, 303 patients from 13 radiotherapy centers 
were randomized. Six patients were not eligible because of stage III disease with 
WHO performance scores 0 to 1 and no weight loss. Of the 297 patients who were 
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eligible, 148 patients received 10 x 3 Gy and 149 patients received 2 x 8 Gy.  All 
patients’ survival and toxicity data were available and analyzed. 
 
Baseline patient characteristics were well balanced between the two groups (Table 1). 
No major differences were seen between the two treatment groups for age, histology, 
stage, and prior chemotherapy. Requirements for comedications and supplemental 
oxygen were well balanced between the 2 treatment arms. Most patients had a poor 
general condition, as 213 patients (71.7%) had substantial weight loss at 
randomization. Also, 190 patients  (63.9%) presented with an ECOG score of 2 or 
more. Only a slight, but statistically not significant (P = .145), imbalance in ECOG 2 
and 3 in favor of the 10 x 3-Gy arm was recorded.  
 
 
 
Table 3: Overview of the Patient-Assessed Symptom Score at Start per Treatment Arm 
 Symptom Score Patients 
with 
Symptom 
Score >1 1. not at all 2. a little 3. quite a bit 4. very much
 
 
 
Symptom/ 
Treatment arm 
N % N % N % N % N % 
Lack of appetite 181 61         
 10 x 3 Gy   61 41.2 43 29.1 30 20.3 14 9.5 
 2 x 8 Gy   55 36.9 40 26.8 49 32.9 5 3.4 
Dyspnea 259 87         
 10 x 3 Gy   21 14.2 43 29.1 58 39.1 26 17.6 
 2 x 8 Gy   17 11.4 51 34.2 60 40.2 21 14.1 
Chest Pain 142 48         
 10 x 3 Gy   83 56.1 31 21.0 25 16.9 9 6.1 
 2 x 8 Gy   72 48.3 42 28.2 24 16.1 11 7.4 
Cough 249 84         
 10 x 3 Gy   24 16.2 74 50.0 46 31.1 4 2.7 
 2 x 8 Gy   24 16.1 72 48.3 48 32.2 5 3.4 
Hemoptysis 114 38         
 10 x 3 Gy   92 62.1 39 26.4 13 8.8 4 2.7 
 2 x 8 Gy   91 61.1 39 26.2 16 10.7 3 2.0 
Hoarseness 93 31         
 10 x 3 Gy   103 69.6 21 14.2 14 9.5 10 6.8 
 2 x 8 Gy   101 67.8 21 14.1 17 11.4 10 6.8 
Dysphagea 29 10         
 10 x 3 Gy   132 89.2 14 9.5 2 1.4   
 2 x 8 Gy   136 91.3 6 4.0 6 4.0 1 0.7 
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Most patients suffered from dyspnea (87%) and cough (84%), followed by lack of 
appetite (61%), chest pain (48%), hemoptysis (38%), hoarseness (31%), and 
dysphagia (10%). Distribution and intensity of symptoms were well balanced across 
both treatments groups (Table 3).  
The difference in the start of the treatment after random assignment between 10 x 3 
Gy and 2 x 8 Gy was less than 2 days. After random assignment, 35 patients did not 
receive the prescribed treatment scheme. In the 2 x 8-Gy arm, 14 patients did not 
finish their treatment. In the 10 x 3-Gy arm 18 patients received less than 10 fractions 
of 3.0 Gy, one patient had one additional fraction of 3.0 Gy, and two patients received 
16 Gy in two fractions.  
 
 
Figure 2: Changes in Total Symptom Score (with confidence interval) over time. Solid 
line: 10 x 3 Gy. Dotted line: 2 x 8 Gy. 
 
 
The overall results show that both treatments were equally effective, as they differ 
less than one point in average total symptom score. Symptom scores for both arms did 
not differ at start of the treatment, being 12.71 (95% CI, 10.28 to 15.14) and 12.87 
(95% CI, 10.35 to 15.39) for the 10 x 3-Gy and 2 x 8-Gy arms respectively (Fig 2). 
The average total symptom score over the initial 39 weeks was in the 10 x 3-Gy arm 
12.71 (95% CI, 12.28 to 13.12) and 13.07 (95% CI, 12.66 to 13.49) in the 2 x 8-Gy 
arm, with a difference of 0.37 (95% CI, -0.22 to 0.96; P = .22). 
Corrected for initial total symptom score and for time of follow up, the difference 
remained less than 1 point, with respectively 0.26 (95% CI, –0.23 to 0.75; P = .299) 
and 0.24 (95% CI, –0.30 to 0.78; P = .388). 
Analysis of each symptom showed some tendencies in response patterns during 
treatment (Fig 3). For cough (P = .84) and dyspnea (P = .84) no significant 
differences were seen. For the other symptoms, numbers were too small to compare 
these differences for each separate symptom and particularly for the changes in 
intensity per symptom between both treatment arms. All symptoms, except 
hemoptysis, initially intensified as the number of the patients suffering from that  
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Figure 3: Patterns of symptom response during treatment per treatment arm. Symptom 
score measures the experienced level of burden: white, not at all; gray, a 
little; dark gray, quite a bit; black = very much. 
 
 
particular symptom rose and/or the severity of the symptom increased as a result of 
acute toxicity. The incidence of dysphagia initially rose to 30 – 40% of the patients, 
and was finally hardly palliated. All other symptoms were eventually palliated in 
comparison to the pretreatment situation. 
An overview of the evolution of total symptom score pattern for both treatment arms 
over the initial 39 weeks is presented in Figure 2. In both arms, total symptom scores 
initially rose as a result of treatment-related side effects. This rise seems to be earlier 
and more intense in the 2 x 8-Gy arm reaching significance in week 1 to 2. Palliation 
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was reached in week 5 in the 2 x 8-Gy arm and in week 7 in the 10 x 3-Gy arm, as the 
average total symptom score was below the initial score. The palliative effect was 
longer in the 10 x 3-Gy arm, persisting until week 22, and was also less progressive in 
intensity than in the 2 x 8-Gy arm. This difference over time was significant (P < 
.001). 
No differences in severe (grade 3 to 5) toxicity between both arms influenced the 
different pattern of palliation. Five patients experienced severe acute toxicity of 
dyspnea, malaise, and/or nausea, four of whom were treated in the 10 x 3-Gy arm and 
one in the 2 x 8-Gy arm. No patient developed a myelopathy in our study. No 
significant differences in the usage and kind of comedication existed between both 
treatment arms to explain the observed differences.  
Reirradiation took place in eight patients (5%)  in the 10 x 3-Gy arm. One of these 
patients was even two times reirradiated. In the 2 x 8-Gy arm nine patients (6%) were 
retreated with irradiation. 
A subsequent treatment with chemotherapy after randomization was not registered. In 
a retrospective subgroup-analysis of a sample of 105 patients equally assigned to both 
treatment arms, four patients retrieved re-treatment with chemotherapy.  These four 
patients were all previously treated according the 10 x 3 Gy-arm.  
 
 
 
Figure 4: Kaplan Meier survival curve. Black line: 10 x 3 Gy. Grey 
line: 2 x 8 Gy. 
 
 
Somewhat unexpectedly, the survival analysis revealed a significantly better survival 
in the 10 x 3-Gy arm (P < .0299; Fig 4). The 1-year survival was 19.6% (95% CI, 
14.1 to 27.3%) in the 10 x 3-Gy arm (26 of 148 patients) and only 10.9 % (95% CI, 
6.9 to 17.3%) in the 2 x 8-Gy arm (15 of 149 patients). Even after 3 years, the survival 
rate in the 10 x 3-Gy arm was 5.6% (95% CI, 2.8 to 11.3) (four of 148) v 1.6% (95% 
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CI, 0.4 to 6.1) (two of 149) in the 2 x 8-Gy arm. This difference in survival existed 
from week 15 and further and varied between 4 and 11%. 
 
Discussion 
 
Our study comparing 10 x 3-Gy with 2 x 8-Gy palliative irradiation in NSCLC 
revealed a superiority of the former over the hypofractionation scheme. Thoracic 
symptom scores for both schemes were similar over the initial 39 weeks. However, 
the palliative effect differed significantly over time between treatment arms. In the 10 
x 3-Gy arm, the onset of the palliative effect occurred later and persisted longer. 
Furthermore, the 1-year survival was better in patients treated using the 10 x 3-Gy 
arm. 
We observed a reduction of symptoms in line with several other randomized studies, 
which found no differences in palliative effect using different fractionation schemes.6-
8,18-20 Only one report thus far showed a better palliative effect with 45 Gy in 18 
fractions in 3.5 weeks compared with 31.2 Gy in four fractions over 4 weeks. 21 
Our total symptom score gives no information on symptom relief per symptom, but is 
an indicator of the overall palliative effect. Symptom relief will vary depending the 
type, number, and intensity of the complaints. 4,22,23 An equal distribution for 
prognostic factors over both treatment arms is also important. Although in our study 
no stratification for all these factors was performed, all items were well balanced over 
both treatment arms. 
Bezjak et al8 proposed to restrict measurements of palliation only to the index 
symptom, because response of individual symptoms will be less than that of the index 
symptom. These larger changes in an individual patient will therefore not be seen at 
the group level when the average change was reported. As a result, analyzing the 
index symptom may be more sensitive to change at the expense of providing 
inadequate information about the overall palliative effect. 
Stephens et al22 proposed that palliation should not only measure reduction of 
complaints, but also stabilization and occurrence of new complaints due to tumor 
and/or treatment. Furthermore the duration of palliation should be stated. All these 
aspects are included in our scoring system of the palliative effect.  
We observed a significantly different pattern in palliation over a period of 39 weeks 
between the two treatment arms. The method for assessing palliation appears crucial. 
Hopwood et al24 showed that differences in missing information between studies can 
lead to incorrect conclusions, which may be a consequence of differing patterns of 
change in symptoms during treatment. The differences in the pattern of symptom 
reduction between both our treatment arms can support this finding. Measuring once 
or only a few times, or weekly as in our study, will produce differences in outcome. 
Therefore, comparing studies is difficult, as frequency and duration of measurements 
varies substantially.5 
Combining the sum of the palliative effect by symptom reduction and the symptoms 
induced by the treatment in our total symptom score can be responsible for visualizing 
these different effects in time and results in a more precise view on the overall effect 
of these particular treatments. 
Our results are consistent with those of Macbeth et al9, who also observed that 
hypofractionation resulted in a quicker reduction of complaints, whereas 
hyperfractionation resulted in a longer duration of palliation.  
Our data gave insufficient support to the assumption that the difference in pattern we 
found could occur because of differences in the radiobiological equivalent dose 
 86  
(BED).25,26 The 10 x 3-Gy arm was less toxic, and a steep and significant rise in total 
symptom scores was seen in the first weeks post-treatment after 2 x 8 Gy.  
The relation between tumor control and radiation dose with these palliative treatment 
schedules is uncertain. Notably, in this poor prognostic group, local tumor growth 
could be the major cause of complaints and possibly local tumor progression,and also 
the major cause of death. As follow-up in our study was based only on questionnaires, 
no data about objective tumor response were available. An earlier MRC study6 found 
no differences in radiological responses, using radiation doses comparable with that 
used in our study.  Even with higher doses, data about tumor control are conflicting. 
Sundstrøm et al20 presented no relation between tumor dose and local control on chest 
x-ray, whereas Nestle et al19 and Reinfuss et al27 found a tendency of better control 
with higher radiation doses.  
The observation of a survival gain in the 10 x 3-Gy arm in our study was the most 
surprising finding, and it must be interpreted with caution, as difference in survival 
were not detected in most other comparable studies4,6,7,18,19,20 and especially not in 
patients with poor general condition.6,8 The difference in survival seen in patients 
treated with a multiple fractionation scheme was only seen in those having a good 
performance score.8,9,27 In a subgroup analysis we also found that the advantage in 
survival in the 10 x 3 Gy-arm over the 2 x 8-Gy arm was statistically significant in 
patients with ECOG 0 to 1, but not in patients with ECOG 2 to 4. All patients with 
ECOG 0 to 1 had stage IV disease. Although there was a tendency, no significant 
difference in survival was seen in subgroup analysis between both treatment arms for 
stage IV. The fact that most patients had also a substantial weight loss could be 
responsible for this finding. The definition of a poor prognosis patient population is 
unclear and remains to be elucidated.  
From a statistical point of view, chance could be another explanation for finding a 
difference in survival between both treatment arms, although the level of significance 
that was detected is considered sufficient.28 Stephens29 has critical reviewed the risks 
of obtaining false positive results with sample sizes, and this factor cannot be fully 
excluded. As such, conformation of a survival advantage for the 10 x 3 Gy scheme 
will be necessary as it appears to be significant, and clinically relevant. 
Despite the prolongation in symptom relief and better survival, hardly any re-
treatment, including chemotherapy, was observed. This can be a result of our 
selection, as patients were at referral no (longer) candidates for chemotherapy. 
Secondly, the performance state will not automatically improve, despite a symptom 
response. And finally, only recently indications for PS ECOG 2 are formulated.10 
In patients with short expected survival 2 x 8 Gy can be the treatment of choice as 
most acute symptoms induced by toxicity can be treated or prevented with steroids 
and/or analgetics.30 However, based on the criteria of this study, we could not define 
this particular group of patients. Therefore, although the overall palliative effect is 
equal to that of 2 x 8 Gy, we still recommend 10 x 3 Gy because of a longer duration 
of the palliative response and a significant benefit in survival. 
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Summary 
 
Background: In poor-prognosis patients with non-small-cell lung cancer (NSCLC), 
radiotherapy can effectively palliate complaints. Controversy remains on whether 
short-course or more protracted schedules provide better value for money. 
Methods: A societal cost-utility analysis was conducted, alongside a Dutch multi-
center randomized trial with one-year follow-up, comparing radiotherapy in either a 
10×3 Gy or a 2×8 Gy schedule in 297 patients. Lifelong quality adjusted life years 
(QALYs) were estimated using the EuroQol questionnaire (EQ-5D). Lifelong societal 
costs were estimated using a model estimated from cost questionnaires filled out by a 
subset of patients. 
Results: QALYs were more favorable for the 10×3 Gy schedule than the 2×8 Gy 
schedule (20.0 versus 13.2 weeks, P = 0.04), which was mainly due to the difference 
in survival (38.1 versus 27.4 weeks, P = 0.03) as opposed to the difference in the 
average valuation of health (0.41 versus 0.37, P = 0.27). Radiotherapy (related) costs 
were estimated at $ 5236 versus $ 2512 (P < 0.001). The 39% difference in life 
expectancy rendered an estimated 30% difference in survival-related costs. The cost-
utility ratio was estimated at $ 40,900 per QALY. 
Conclusions: In our group of poor-prognosis NSCLC patients, the estimated cost-
utility ratio for the 10×3 Gy schedule was acceptable according to current economic 
standards. The additional costs for the protracted schedule were justified not by 
improved quality of life, but by longer survival.  
 
Keywords: cost-utility analysis; non-small-cell lung cancer; radiotherapy; palliation 
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Introduction 
 
In patients with non-small-cell lung cancer (NSCLC), palliative radiotherapy can 
effectively reduce chest pain and hemoptysis, and also dysphagia and dyspnea.1-3 
Combined-modality treatment for patients with stage III disease and chemotherapy for 
patients with stage IV disease have resulted in improved quality of life and survival.4 
However, patients are frequently too ill for these more intensive treatments.5 
Moreover, even after palliative chemotherapy, locoregional treatment may eventually 
be required to palliate locoregional complaints.  
Controversy remains on whether or not more protracted radiotherapy schedules 
provide better results than short-course.6 So far, none of the trials comparing different 
schedules have shown a difference in palliation.7– 10 On survival the results have been 
inconclusive: two Medical Research Counsel trials have shown no difference7,8, 
whereas two later trials by Macbeth and Bezjak9,10 did show a difference in especially 
patients with a good prognosis. So far, no economic evaluations on this subject have 
been published. 
To reach an evidence-based consensus on the preferred palliative schedule for patients 
with poor-prognosis NSCLC, a Dutch randomized trial was started in 1999.11 
Included patients were either stage IV patients or stage IIIA/B patients with weight 
loss or a poor performance score (Eastern Cooperative Oncology Group (ECOG) 
score ≥ 2).2 They were randomized to receive radiotherapy consisting of either ten 
fractions of 3 Gy (10×3 Gy) or two fractions of 8 Gy (2×8 Gy). The study showed no 
difference in average symptom control over the initial 9 months. However, there was 
a statistically significant difference in time pattern, suggesting prolonged palliation in 
the 10×3 Gy group with less worsening of symptoms than in the 2×8 Gy group. In 
addition, 1-year survival was significantly more favorable in the 10×3 Gy group 
(19.6% versus 10.9%). It was therefore concluded that, also for patients with poor-
prognosis NSCLC, the 10×3 Gy schedule was preferred over the 2×8 Gy schedule. 
However, in this conclusion the difference in costs between both treatments was not 
taken into account: the protracted 10×3 Gy schedule results in higher medical and 
patient costs and, also, the gain in survival leads to continued costs. As a result, 
controversy remained on whether the better effectiveness of the 10×3 Gy schedule 
justified the additional costs. 
Here we will present the full cost-utility analysis of our study. Effectiveness is 
measured by quality-adjusted life years (QALYs), which is the overall valuation of 
the lifelong health of the patients in the study. Effectiveness is compared to the total 
costs to society, including not only the medical costs of radiotherapy but also costs of 
other health care and costs incurred by the patients. Aim of the analysis is to show, 
from a societal perspective, which radiotherapy schedule provides better value for 
money. 
 
 
Methods 
 
From January 1999 until May 2002, a total of 303 NSCLC patients from 13 out of 21 
Dutch radiotherapy centers were included in the study. Table 1 shows the inclusion 
and exclusion criteria. Six stage III patients with ECOG scores 0 or 1 and no weight 
loss were later excluded because they did not satisfy the inclusion criteria. The 
remaining 297 patients were randomly assigned to schedules with either 10×3 Gy (in 
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four or five fractions per week, n = 148) or 2×8 Gy (one week apart, n = 149). 
Patients were followed for one year. Primary outcome measure of the study was a 
patient-assessed symptom score, measuring total burden on seven symptoms: loss of 
appetite, dyspnea, chest pain, cough, hemoptysis, hoarseness, and dysphagia (each 
rated on a four-point scale ranging from bothered not at all to bothered very much). 
 
* An Eastern Cooperative Oncology Group score of 2 denotes that the patient is ambulatory 
and capable of all self-care, unable to carry out any work activities, and up and about more 
than 50% of waking hours (www.ecog.org/general/perf_stat.html)  
† Weight loss was defined as a decrease of at least 5% in 3 months or at least 10% in 6 
months before inclusion. 
‡ Eligibility for chemotherapy was assessed by the treating pulmonologist, based on prior 
chemotherapy, weight loss and co-morbidity. 
 
At 5% significance level, a total of 268 patients were needed for the primary outcome 
measure to obtain a power of 90% for correctly concluding equivalent response.11 The 
study was approved by the Medical Ethics Committees of all participating institutions 
and random assignment took place after receiving informed consent of the patient.  
 
Assessment of quality adjusted life years 
 
In July 2002 the last systematic assessment of survival was performed. At that time 
269 (91%) patients had died. Until February 2004, 12 (4%) more patients were 
reported to have died. To obtain individual survival and QALY data for each patient, 
the remaining 16 (5%) patients were assumed to have died in February 2004, with 
survival ranging from 21 to 60 months. This underestimation of the survival time led 
to less favorable estimated results for the treatment schedule with better survival. 
During the one-year follow-up, starting before random assignment, patients filled out 
13 weekly and 21 biweekly mailed questionnaires containing questions on specific 
symptoms and on quality of life measured using the EuroQol classification system 
(EQ-5D). The EQ-5D assesses general health status, by five questions on mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression.12 From the EQ-5D 
classification system, the EQ-5D utility was calculated.13 This utility reflects the 
valuation by the general public of the reported health states, ranging from 1.00 
(optimal health), through 0.00 (as bad as death) to −0.594 (worse than death). In 
addition, patients directly evaluated their health on a 100 mm horizontal visual 
Table 1. Eligibility criteria for participation in the trial 
Inclusion criteria 
- cytologically or histologically confirmed NSCLC 
- either stage IV patients or stage IIIA/B patients with ECOG* score ≥ 2 or weight loss† 
- at least some self-reported burden due to the tumor on at least one of seven complaints: 
loss of appetite, dyspnea, chest pain, cough, hemoptysis, hoarseness, dysphagia 
- physically and mentally fit enough to participate in the study 
 
Exclusion criteria 
- stage IV patients with ECOG* score ≤ 2 that were still eligible for chemotherapy‡ 
- concurrent chemotherapy 
- prior radiotherapy to the chest 
- superior vena cava syndrome (SVCS) at presentation 
- other malignant diseases in the past 
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analogue scale (VAS), ranging from worst imaginable health to perfect health (0.0 to 
1.0). For each patient the quality adjusted life years (QALYs) were calculated as the 
lifelong area under the utility curve. Utility was discounted at 3% per year. Utility 
measurements were only available during the initial year. Moreover, especially 
shortly before their time of death, patients tended to stop returning their 
questionnaires. Of, on average, 17.3 possible lifetime EQ-5D measurements, 3.0 
(17%) were missing, of which 1.1 (6%) in the last month before dying. Because the 
values of the missing utility measurements are likely to be worse than the non-missing 
measurements, neglecting the missing data or carrying forward the last measurement 
would both lead to an overestimation of utilities. For that reason, the missing EQ-5D 
utilities were imputed, using a decreasing curve from the last available measurement 
(estimated from the data shown in Figure 2b using non-linear regression: imputed 
EQ-5D utility = constant × (1 + 50 / remaining lifetime) −1, with the constant fitted to 
the patient's last available EQ-5D utility, R2 = 0.23). This utility model provides 
results that are lower than carrying forward the last available utility measurement, but 
higher than linear descent. 
 
Assessment of costs 
 
For each patient, lifelong costs were estimated from a societal perspective. Estimated 
costs included the medical costs of radiotherapy, the non-medical costs of 
radiotherapy (time and travel costs incurred by the patients), other medical costs (like 
hospitalizations), health-related non-medical costs (like informal care) and survival-
related costs.14  
The medical costs of radiotherapy were estimated using a previously published 
department model15, in which costs of different types of staff, equipment, material, 
housing, and overhead were obtained from three radiotherapy institutions and 
combined to generate a typical Dutch radiotherapy department. To estimate the costs 
of different radiotherapy schedules, each cost item was assigned to either of three 
allocation bases: treatments (for cost items independent of the treatment schedule), 
fractions (for cost items proportional to the number of fractions given), or Gy (for cost 
items proportional to the dose delivered). This way, unit cost prices were estimated at 
$ 1898 per treatment, plus $ 109 per fraction, plus $ 9 per Gy, resulting in medical 
costs of $ 3260 and $ 2261 for the 10×3 Gy and the 2×8 Gy schedules, respectively. 
For divergent schedules and repeated radiotherapy, the actual schedules were used to 
estimate costs. Average reported time spent per fraction was 126 minutes and 68% of 
the patients reported a travel companion. Valued at $ 11 per hour16, average time costs 
per fraction were estimated at $ 38. Patients reported their means of transportation as 
car (42%), taxi (50%), ambulance (6%) or walking (3%). The average travel distance 
was 20 kilometers and average travel costs were estimated at $ 65 per fraction.  
Non-radiotherapy health care costs during the initial 12 weeks were estimated using 
six bi-weekly mailed cost questionnaires. For practical reasons and to limit the burden 
to the patients, these questionnaires were filled out by a subsample of the patients 
from three different radiotherapy institutes. Patients could refuse to participate 
without being excluded from the effectiveness study. Of 113 consecutive patients that 
were asked to fill out the cost questionnaires, 56 (50%) consented. Of, on average, 4.6 
possible lifetime cost questionnaires, 0.9 (19%) were missing, of which 0.4 (9%) in 
the last month before dying. In case of missing cost measurements, the previous 
available measurement was carried forward. In the three-page, mostly closed-format, 
cost questionnaires, patients reported consultations (GP, specialists, and paramedical 
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professionals), hospitalizations, purchased medication, home (nursing) care, paid 
domestic help, informal care, and out-of-pocket expenses (due to radiotherapy and 
otherwise).17 Most cost prices were obtained from Dutch standard prices that were 
designed to reflect societal costs and to standardize economic analyses.18,19 Medical 
costs of consultations varied from $ 10 per telephone GP consultation to $ 82 per 
neurologist consultation. Hospitalizations were valued at $ 545 per day for clinical 
admission, $ 218 per day for daycare, and $ 163 per day for nursing care. Reported 
health care costs include the patients' time and travel costs. Purchased medication was 
valued according to the Pharmacotherapeutic Compass20, plus $ 6 per non-drugstore 
purchase. Home nursing care and other home care were valued at $ 38 and $ 21 per 
hour, respectively. Other paid domestic care and informal care were both valued at 
$ 11 per hour.16 Out-of-pocket expenses were valued as reported by the patients.  
Lifelong non-radiotherapy health care costs for the entire sample were estimated using 
a regression model estimated from the data obtained from the cost questionnaires. 
Using linear multilevel analysis (MLwiN version 1.1), adjusting for repeated 
measures, significant predictors of total non-radiotherapy costs were selected 
(stepwise selection: enter 0.05, remove 0.10) from the following lifelong-available 
variables: time since randomization, time until death, age, gender, EQ-5D utility, and 
VAS utility. Also, two separate dummies for costs during the initial four weeks in 
both randomization groups were included, to capture the costs related to the initial 
radiotherapy.  
Because of the low labor participation among these patients, differences in 
productivity costs were assumed to be negligible.15 In a sensitivity analysis, 
consumption costs were included21, to the amount of $ 43 per day (average consumer 
expenditures for persons aged 65-74 years, excluding healthcare, insurance and 
pension, www.bls.gov/cex). 
Costs were discounted at 3%, updated to price level 2005 euros using the price index 
rate for the Dutch health care sector (www.cbs.nl) and converted to U.S. dollars using 
the July 2005 Dutch purchasing power parity index (€ 1 = $ 1.09, www.oecd.org). 
 
Analysis 
 
In the cost-utility analysis, the difference in lifelong QALYs was compared to the 
difference in lifelong societal costs. Whether a particular treatment is more cost-
effective than another depends on the willingness-to-pay (WTP) per QALY. The 
average net benefit (WTP × QALYs − Costs) in both randomization groups was 
compared, for a range of WTP values. Significantly rejecting equality of the net 
benefit demonstrates the superior cost-effectiveness of the more favorable schedule. 
The net benefit approach gets around the problems associated with uninterpretable 
negative cost-utility ratios. 
All outcome measures were estimated on an intention-to-treat basis. For all outcome 
measures, differences were tested using double-sided non-parametric bootstrapping22, 
with 1,000,000 replications and 0.05 significance threshold. Reported confidence 
intervals (CIs) are the corresponding symmetric 95% trimmed intervals. 
Bootstrapping explicitly compares the means in both groups without making 
distributional assumptions, thus allowing for skewed distributed costs.  
Statistical analysis only represents uncertainty due to the random selection of the 
patient population. Uncertainty due to modeling assumptions was analyzed using 
univariate sensitivity analyses on the assumed lifetime for patients with unknown date 
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of death (February 2004 versus five year after inclusion), the utility measure (EQ-5D 
versus VAS), and the included cost categories. 
 
Results 
 
* Symptom score ranging from 7 to 28, measuring total burden on seven symptoms (each 
rated on a  four-point scale ranging from bothered not at all to bothered very much). 
 
 
Table 2 shows the baseline characteristics of the 297 patients included in the study. 
Baseline characteristics of the subsample of 56 patients that filled out the cost 
questionnaires did not differ significantly from the rest of the sample (data not 
Table 2. Baseline patient characteristics 
  10×3 Gy 
(n = 148) 
 2×8 Gy 
(n = 149) 
 
Age (median, range) 69 (48 – 85) 69 (41 – 91) 
Sex (n, %) 
- male 
- female 
 
118 (80) 
30 (20) 
 
119 (80) 
30 (20) 
Total symptom score* (median, SD) 
EQ-5D utility (median, SD) 
VAS(median, SD) 
13 (2.4) 
0.62 (0.35) 
0.52 (0.27) 
13 (2.5) 
0.52 (0.35) 
0.59 (0.26) 
Tumor stage (n, %) 
- IIIA 
- IIIB 
- IV 
 
16 (11) 
56 (38) 
76 (51) 
 
24 (16) 
59 (40) 
66 (44) 
Eastern Cooperative Oncology Group score (n, %)
- score 0  
- score 1 
- score 2 
- score 3 
- score 4 
 
9  (6) 
45 (30) 
60 (41) 
33 (22) 
1 (1) 
 
5 (3) 
48 (32) 
44 (30) 
51 (34) 
1 (1) 
Substantial weight loss (n, %) 104 (70) 109 (73) 
Tumor type (n, %) 
- squamous cell carcinoma 
- adenocarcinoma 
- large cell carcinoma 
- other 
 
64 (43) 
37 (25) 
39 (26) 
8 (5) 
 
60 (40) 
27 (18) 
53 (36) 
9 (6) 
Months since diagnosis (median, range) 1 (0 – 88) 1 (0 – 99) 
Treatment indication (n, %) 
- primary lesion 
- recurrent lesion (no prior radiotherapy) 
 
142 (96) 
6 (4) 
 
147 (99) 
2 (1) 
Prior chemotherapy (n, %) 18 (12) 20 (13) 
Other treatment at start radiotherapy (n, %) 
- pain medication 
- antibiotics 
- other medication 
- supplemental oxygen  
80 (54) 
54 (36) 
5 (3) 
49 (33) 
9 (6) 
98 (66) 
67 (45) 
5 (3) 
58 (39) 
8 (5) 
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shown), except that it contained more stage IV patients (59% versus 48%, P = 0.05) 
and more patients with squamous cell carcinoma (57% versus 42%, P = 0.04). 
 
 
Quality adjusted life years 
 
In accordance with the poor prognosis of the patients, the survival time was known for 
95% of the patients. The solid lines in Figure 1 show the survival curves, assuming 
that the remaining 5% died in February 2004.  
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Figure 1. Survival, by randomization group 
 
The corresponding life expectancy was estimated at 38.1 weeks for the 10×3 Gy 
group and 27.4 weeks in the 2×8 Gy group (Table 3), with a statistically significant 
difference of 10.7 weeks (P = 0.03, CI 0.9 to 20.6 weeks). 
 
* The 5% missing survival times set at 5 years, instead of February 2004 
Table 3. Quality adjusted life expectancy, in weeks (averages and SD) 
 10×3 Gy 
(n = 148) 
2×8 Gy 
(n = 149) 
Difference 
(95% CI) 
P value 
Base-case analysis 
- Life expectancy 
- QALYs 
 
38.1 (49.3) 
20.0 (33.9) 
 
27.4 (35.7) 
13.2 (23.3) 
 
10.7 (0.9 to 20.6) 
6.8 (0.1 to 13.5) 
 
0.03 
0.05 
Sensitivity analyses 
- Life expectancy* 
- QALYs* 
- QALYs based on VAS 
 
44.4 (67.1) 
23.1 (44.1) 
21.6 (33.9) 
 
30.5 (47.9) 
15.0 (31.0) 
15.2 (24.6) 
 
13.9 (0.6 to 27.3) 
8.1 (-0.7 to 16.8) 
6.4 (-0.4 to 13.2) 
 
0.04 
0.07 
0.06 
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Figure 2a shows the valuation of health obtained from the EQ-5D, averaged over the 
measurements from those patients that were still alive. The utility improved during the 
initial months, but later on stabilized. 
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Figure 2a. EQ-5D utility, at time since randomization or time until death. 
 
Figure 2b shows the EQ-5D utility as a function of the remaining lifetime, instead of 
as a function of the time since randomization. Towards the end of life the EQ-5D 
utility markedly decreased, to values even below zero. In fact, 10% of all utility 
measurements were negative, indicating health states valued worse than death.  
  
0,0
0,2
0,4
0,6
0,8
1,0
013263952
Weeks until date of death
EQ
-5
D
 u
til
ity
10x3 Gy
2x8 Gy
Utility model
 
Figure 2b. EQ-5D utility as a function of the remaining lifetime. 
 
In line with Figure 2a, average utility over the remaining lifetime was somewhat more 
favorable in the 10×3 Gy group, but not statistically significantly so (0.41 versus 0.37, 
P = 0.27). Combined with the longer survival, quality adjusted life years were 
significantly more favorable in the 10×3 Gy group (20.0 versus 13.2 weeks, P = 0.05), 
with an estimated difference of 6.8 weeks (CI 0.1 to 13.5 weeks). 
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Costs of radiotherapy 
 
Average medical costs of the initial radiotherapy were estimated at $ 3120 for the 
10×3 Gy group and $ 2173 for the 2×8 Gy group (Table 4). The actual radiotherapy 
schedule differed from the randomization schedule for 35 patients (14% versus 10%, 
P = 0.28), mostly due to early treatment withdrawal.  
Apart from travel expenses, out-of-pocket costs (e.g. for menthol cream and 
additional telephone costs) were low. Time and travel costs made up 22% and 9% of 
the costs of the initial radiotherapy, respectively. Because a considerable part of the 
medical costs are independent of the schedule, time and travel costs even made up 
43% of the difference in costs. 
Repeated radiotherapy was equally frequent in both groups (5% versus 6%, P = 0.84), 
and the difference in costs of repeated radiotherapy was negligible ($ 150 versus 
$ 148, P = 0.98). The total radiotherapy costs were estimated at $ 4182 for the 
10×3 Gy group and $ 2512 for the 2×8 Gy group, with an estimated difference of 
$ 1670 (CI $ 1459 to $ 1881). 
 
 
 
Societal costs 
 
Health care utilization and costs, estimated from the cost questionnaires filled out by a 
subset of patients, showed no significant differences between both randomization 
groups (Table 5, P ≥ 0.16). Two-thirds of the estimated costs consisted of 
hospitalization costs.  
Although, over the initial 12-week period, the cost questionnaire did not show a 
difference between the randomization groups, the data did provide an opportunity to 
construct a model to estimate the difference in survival-related costs. Omitting 
statistically non-significant predictors (P ≥ 0.30), the model showed a relationship 
between costs and EQ-5D utility (P = 0.04) and increased costs during the initial four 
weeks in the 10×3 Gy group (P = 0.001), mainly due to hospitalizations. In the 
Table 4. Lifelong societal costs per patient (averages in $ and SD) 
 
 
10×3 Gy 
(n = 148) 
2×8 Gy 
(n = 149) 
Difference 
(95% CI) 
P value 
 
Initial radiotherapy 
- medical costs 
- time costs 
- travel costs 
- out-of-pocket costs 
Repeated radiotherapy 
Total radiotherapy costs 
 
 
 
3120 
308 
591 
14 
150 
4182 
 
 
2173 
63 
121 
6 
148 
2512 
 
 
947 
245 
470 
8 
2 
1670 
 
 
<0.001 
<0.001 
<0.001 
0.51 
0.98 
<0.001 
Non-radiotherapy costs 
- related to radiotherapy 
- related to survival 
Total non-radiotherapy costs 
 
 
1054 
11254 
12308 
 
0 
8651 
8651 
 
1054 
2602 
3656 
 
<0.001 
0.09 
0.02 
Total societal costs 16490 11164 5326 <0.001 
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2×8 Gy group, costs in the initial four weeks were not statistically significantly 
increased (P = 0.96, CI $-179 to $ 189). The model estimated the undiscounted 
weekly non-radiotherapy costs at $ 517, minus $ 395 times the EQ-5D utility, plus 
$ 276 during the initial four weeks in the 10×3 Gy group (χ2(2) = 14.7, Figure 3). 
After the initial four weeks, weekly non-radiotherapy costs according to this model 
vary from $ 122 for patients in perfect health (i.e. $ 517 – 1.0 × $ 395) to $ 752 for 
patients in worst possible health (i.e. $ 517 + 0.5940 × $ 395). 
 
 
 
 
 
Applying the estimated cost model to all patients, the inclusion of radiotherapy-
related costs, during the initial four weeks, increased the cost difference between both 
randomization groups by $ 1054 ($ 1054 versus $ 0, Table 4). Together with the costs 
of the initial and repeated radiotherapy, the radiotherapy (related) costs were 
estimated at $ 5236 versus $ 2512 (P < 0.001, difference $ 2724, CI $ 2501 to 
$ 2947). In addition, the 39% difference in survival led to a 30% difference in related 
non-radiotherapy costs (P = 0.09, difference $ 2602, CI $ −350 to $ 5555). Including 
both the radiotherapy (related) costs and the survival-related costs, the total difference 
in lifelong societal costs was estimated at $ 5326, in favor of the 2×8 Gy schedule 
(P < 0.001, CI $ 2330 to $ 8323). 
  
Table 5. Non-radiotherapy costs per patient during the first 12 weeks (averages in $) 
 10×3 Gy (n = 31) 2×8 Gy (n = 25)  
 Utilization Costs Utilization Costs P value 
 
General practitioners 
Lung specialist 
Radiotherapist 
Other specialists 
Paramedical professionals 
Hospitalization 
Analgesics 
Antibiotics 
Other medication 
 
 
3.4 
1.6 
1.2 
0.5 
1.0 
39% 
52% 
13% 
68% 
 
126 
164 
101 
50 
35 
2726 
76 
5 
143 
 
4.8 
2.5 
1.1 
0.8 
1.9 
16% 
56% 
4% 
48% 
 
142 
247 
94 
67 
71 
1157 
32 
1 
103 
 
0.72 
0.25 
0.83 
0.63 
0.48 
0.23 
0.16 
0.18 
0.53 
Home (nursing) care 
Paid domestic help 
Informal care 
Out-of-pocket expenses 
 
4.1 hr 
0.0 hr 
7.3 hr 
3% 
114 
0 
78 
1 
0.6 hr 
3.1 hr 
18 hr 
12% 
12 
33 
193 
11 
0.30 
0.22 
0.19 
0.44 
Total non-radiotherapy costs  3617  2162 0.30 
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Figure 3. Non-radiotherapy costs, by randomization group. 
 
Cost-utility analysis 
 
Compared to the 2×8 Gy schedule, the 10×3 Gy schedule provides significantly more 
QALYs, but at significantly higher costs. Aim of the cost-utility analysis is to show 
whether or not the additional costs of the 10×3 Gy schedule are justified by the 
additional QALYs, which depends on the relative value of QALYs and money: for 
high willingness-to-pay the 10×3 Gy schedule is preferred, whereas for low 
willingness-to-pay the 2×8 Gy schedule is preferred. The break-even point at which 
both are equally preferred is at willingness-to-pay equal to the cost-utility ratio of 
$ 40,900 per QALY. For willingness-to-pay below $ 19,400 per QALY and above 
$ 1,100,000 per QALY, the preference was statistically significantly in favor of the 
short- and the long-course schedule, respectively (P ≤ 0.05). 
 
 
Sensitivity analyses 
 
Sensitivity analyses were performed to explore the impact of various assumptions. 
The interrupted lines in Figure 1 show the survival curves, assuming that the 5% 
patients with unknown date of death survived for five years. These curves are almost 
identical to the Kaplan-Meier curves (11). Because survival was more favorable in the 
10×3 Gy group, also more patients in this group had unknown survival times (7% 
versus 3%, P = 0.12). Although this concerns only a small part of the patients, 
assuming longer survival times compared to the base-case analysis had a considerable 
impact on outcome: the difference in life expectancy between both groups increased 
from 10.7 to 13.9 weeks (CI 0.6 to 27.3 weeks) and the quality adjusted life 
expectancy increased from 6.8 to 8.1 weeks (CI –0.7 to 16.8). However, because also 
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the costs increased with life expectancy, the cost-utility ratio decreased by only 0.1%, 
to $ 40,800 per QALY.  
Using the patients' assessment of their health instead of society's assessment (VAS 
instead of EQ-5D) increased the estimated QALYs, but reduced their difference by 
6% (6.4 instead of 6.8 weeks, Table 3). Accordingly, the estimated cost-utility ratio 
increased by 6% to $ 43,300 per QALY. 
Non-radiotherapy costs were estimated using a cost model in which the increased 
costs related to the initial radiotherapy during the initial four weeks in the 2×8 Gy 
group were not statistically significant and were therefore excluded. Including these 
costs, despite the fact that they were not statistically significant, rendered a cost model 
in which the undiscounted weekly non-radiotherapy costs were estimated at $ 515, 
minus $ 393 times the EQ-5D utility, plus $ 276 and $ 5 during the initial four weeks 
in the 10×3 Gy group and the 2×8 Gy group, respectively. Using this model, the cost-
utility ratio would decrease by only 0.7% to $ 40,600 per QALY. 
All cost categories were in favor of the short-course radiotherapy, and, in contrast to 
the other sensitivity analyses, the extent to which the various cost categories were 
included in the analysis did have a considerable impact on the cost-utility ratio. 
Excluding survival-related costs reduced the cost-utility ratio from $ 40,900 to 
$ 20,900 per QALY. Instead, including consumption costs at $ 43 per day increased 
the cost differences by $ 3078 and the cost-utility ratio to $ 64,500 per QALY. 
Excluding all non-radiotherapy costs reduced the cost-utility ratio to $ 12,800 per 
QALY.  
 
 
Discussion 
 
In the palliative irradiation of poor-prognosis NSCLC patients, compared to the short-
course 2×8 Gy schedule, the long-course 10×3 Gy schedule has been shown to 
provide prolonged palliation and better survival.11 In the cost-utility analysis 
presented here, effectiveness was measured by quality-adjusted life expectancy, 
aiming to capture both length and quality of life. Similar to palliation, also the quality 
of life was valued better in the 10×3 Gy group, but non-significantly so. Combined 
with the significant 10.7 week difference in life expectancy, the significant difference 
in QALYs was estimated at 6.8 weeks. The difference in lifelong societal costs was 
estimated at $ 5326, of which 31% were radiotherapy costs, 20% were other 
radiotherapy-related costs during the initial four weeks and 49% were survival-related 
costs. The cost-utility ratio was estimated at $ 40,900 per QALY. Judged by the, often 
quoted, acceptability threshold of $ 50,000 per QALY23,24, the 10×3 Gy schedule 
therefore provides better value for money than the 2×8 Gy schedule. In the 
Netherlands this has confirmed the consensus that, indeed, the 10×3 Gy schedule 
should be the preferred standard treatment for poor-prognosis NSCLC patients. 
A number of remarks are in order concerning the economic preference for the long-
course radiotherapy schedule. Firstly, its interpretation should be that long-course 
radiotherapy need not be withheld because of costs, since the additional costs are 
acceptable. It should not be concluded that long-course radiotherapy should be 
imposed because of costs, if, for good reasons, a patient prefers the shorter schedule. 
On the contrary, long-course radiotherapy was estimated to increase costs by $ 5326. 
Secondly, in case of restricted radiotherapy capacity and pending the decision to 
increase that capacity, it may still be more efficient to use the limited capacity for 
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treatment of other patients with larger expected health gains. And, thirdly, treatment 
preference in settings other than that in our study can be influenced by differences in 
economic climate and treatment patterns. 
A matter of debate among health economists is to what extent future costs due to 
improved survival should be included in economic evaluations. In our base-case 
analysis we included both related and unrelated health care costs, because the QALY 
measure also included the health gain obtained from unrelated health care.14 Both 
practically and theoretically, it would have been impossible to identify and exclude 
unrelated effectiveness. Some argue that only related health care costs should be 
included, because otherwise it would be inconsistent to exclude other future costs of 
subsistence.25 In our analysis, this would have reduced the estimated cost-utility ratio 
from the base-case $ 40,900 per QALY to $ 20,900 per QALY, confirming the 
preference for the 10×3 Gy schedule. Others argue that not only all future health care 
costs should be included, but also future production and consumption costs.21 In 
general, this would favor treatment for the young, because their consumption is 
compensated by productivity. In our analysis, assuming a negligible difference in 
productivity, including consumption costs would have increased the cost-utility ratio 
to $ 64,500 per QALY for the 10×3 Gy schedule. This ratio should be judged by other 
than normal standards but does not seem unacceptably high. 
A second matter of debate among health economists is how health care costs are 
related to survival. Traditionally, health care models have described costs in relation 
to age. Recently it has been argued that costs are more related to the time until death, 
which would reduce the impact of ageing on costs.26,27 In our analysis we found that 
both age and time until death were not statistically significant predictors of cost. 
Instead, the EQ-5D utility measure was predictive, leading to increased costs towards 
death and a less than proportional relationship between survival time and costs. If the 
results in our terminally ill patient population are generalizable, then perhaps age is 
more predictive for chronic diseases, where quality of life is determined by disease 
progression, whereas time until death is more predictive in economic models for more 
acute conditions. 
 
Because both radiotherapy schedules provided roughly similar palliation, the 
conclusion of our economic evaluation strongly hinges on the survival gain. In our 
study the survival gain was statistically significant, but this has not been a consistent 
finding in other studies. In their Cochrane review of ten randomized trials6, Macbeth 
et al conclude that there is evidence for a modest survival gain after higher dose 
radiotherapy only in patients with better performance status. Kramer et al compared 
and discussed these results in detail.11 
Several remarks can be made concerning the validity of our research methods. 
Perhaps most importantly, because we had not anticipated the survival difference, 
long-term costs related to the difference in survival had to be estimated from cost data 
obtained in the initial 12 weeks. Although our model identified short-term costs 
related to the initial radiotherapy that should not be extrapolated and although during 
the initial 12 weeks already more than one-third of the patients had died, the cost 
model may still not have been representative for long-term health care costs 
associated with living and dying. Without gold standard we had no means to test the 
validity of the model. A second matter of concern is the used EQ-5D utility measure 
that is frequently used in economic evaluations from a societal perspective, but does 
not include quality of life domains that are specifically relevant in the valuation of 
end-of-life care.15,28 Unfortunately no valuation instrument exists that incorporates 
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such issues. Nevertheless, the distinct decrease of the EQ-5D utility towards the end 
of life demonstrates that the instrument is responsive to the changing health status of 
these patients and the results were very similar to results from other research in 
terminally ill cancer patients.15 These, and other, issues were addressed in the 
sensitivity analyses, which showed that they had very little influence on the estimated 
cost-utility ratio, thus suggesting that the obtained results are robust. 
 
In conclusion, the inclusion of survival-related costs in our economic evaluation led to 
a higher but still acceptable cost-utility ratio for the 10×3 Gy schedule. In our group 
of poor-prognosis NSCLC patients, the additional costs of the protracted schedule 
were justified not by improved quality of life, but by longer survival. 
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Chapter 1 
 
Palliative care is still an important and recurring issue in Non-Small-Cell lung cancer 
patients.1 Two of our studies were initiated in the nineties, but the results became 
available only recently, as accrual in these studies was relatively slow and less events 
in time occurred than expected upfront. However, despite changes in technical 
possibilities and in treatment strategies, the conclusions drawn and which we will 
discuss are still valid. 
 
Chapter 2 
 
Even nowadays, the majority of patients eventually will face complaints from tumour 
recurrence or metastases, as even after concommittant chemoradiation complete 
tumour response is seen in only 26% of the patients.2 In a prospective study, we 
retreated patients with external beam radiotherapy of 2 x 8 Gy. Those patients were 
primarely irradiated more than 6 months before and had complaints of an 
intrathoracical recurrence of a Non-Small-Cell Lung Carcinoma (NSCLC). We 
conclude, that this approach appears not only to be safe but is also effective in 
reducing complaints. Palliation persists more than 50% of the remaining life span in 
the majority of our patients.  
The effectiveness and safety of retreatment with external beam radiotherapy was also 
demonstrated in several other studies.3-9 The prediction of success and risks on 
toxicity of the treatment depends on the type of complaint and treatment scheme.3-9  
All these studies mention only the response rates, but none of them the duration of 
this palliative effect. In our opinion, the latter is an important issue in decision making 
if it is worthwhile or not offering this palliative treatment to patients. 
The schedule of 2 x 8 Gy in our study was chosen, because this was not only 
frequently used for recurrent NSCLC in brachytherapy settings10, but was also 
introduced as a safe and effective schedule for palliative treatment with external beam 
irradiation.11 Based on our recent findings (chapter 6) and other studies12-14, a 
multifractionated treatment scheme however appears to be more effective. Especially, 
for patients with a recurrence after primary irradiation, without metastasis and in a 
good general physical condition, Wu et al.8 showed that this approach has to be 
considered. Certainly, because we have overestimated the risk in exceeding normal 
tissue tolerances after retreatment, in the past.15-17 To decide on the appropriate 
schedule, life-expectancy and physical condition are important factors. An estimation 
of the life-expectancy can be made based on our study, as none of our patients lived 
longer than the interval between primary treatment and start of the retreatment, a 
finding also reported by Tada et al.9 Patients with Eastern Cooperative Oncology 
Group (ECOG) score 3 are no candidates for high dose reirradiation.9 Nevertheless, as 
numbers of patients are too small for randomized studies and the selection criteria 
vary in the different studies3-9,  the question which treatment scheme has to be 
preferred, will remain unanswered and has to be individualised. 
As chemotherapeutic regimens with better response rates and less toxicity became 
available, the role of reirradiation as palliative treatment became less important, but is 
still not negligible. 
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Chapter 3 
 
In the 1990's chemotherapy was also recognized as an effective modality for the 
treatment of patients with stage IIIA(N2) NSCLC. For long, primary radiotherapy in 
locally advanced Non-Small-Cell Lung Cancer was the only treatment option, but the 
results were unsatisfactory.18 During the National Dutch Consensus Meeting in 1997 a 
national survey showed that most pulmonologists regarded radiotherapy in stage III 
Non-Small-Cell lung cancer patients as a palliative treatment.19 This attitude was 
reflected by the substantial number (22%) of patients with stage IIIA NSCLC not 
referred for any therapy at all.20 Conversely, most of the radiation oncologists were 
convinced radiotherapy could still have a curative potential for these patients. At that 
time the term “radical radiotherapy” was introduced.19 The primary intention of this 
radiation treatment is to obtain persistent local tumour control, with a small chance of 
cure. After radiotherapy doses up to 60 Gy in 6 weeks, complete remissions were seen 
in about 12% 21 but the majority of patients developed distant metastases too.22 
Meanwhile, chemotherapy had proven to be effective, not only in combination with 
radiotherapy as senzitizer (EORTC study 08844)23 but also as induction 
chemotherapy before surgery (the Toronto phase II trial).24 The patients treated with 
these combined modalities not only had better tumour response rates, but also a gain 
in survival. It was therefore that the European Organization for the Research and 
Treatment of Cancer (EORTC) already launched study 08941 in 1994, a randomized 
phase III trial of surgery versus radiotherapy in patients with stage IIIA Non-Small 
Cell Lung Cancer (NSCLC) after a response to induction-chemotherapy. Selected 
patients with histological or cytological proven non-resectable stage IIIA(N2) NSCLC 
were given 3 cycles of platinum-based induction chemotherapy. Responding patients 
were then randomized between surgery, i.e. radical resection with lymph node 
dissection and optional postoperative radiotherapy, or thoracic radiotherapy, i.e. at 
least 40 Gy in 2 Gy daily fractions on the mediastinum with a boost up to at least 60 
Gy on the involved area. In order to observe an increase of 5-year overall survival 
from 15 (radiotherapy arm) to 25% (surgery arm), 292 events out of 358 randomized 
patients had to be observed. Secondary endpoints were progression free survival and 
toxicity.25  The main conclusion of this study is that no significant differences in 
overall survival nor progression free survival  in both treatment arms were seen. 
Consequently, radiotherapy after induction chemotherapy remained the standard 
treatment. Especially, in case of ‘no downstaging’ (ypN2) radiotherapy proved to be 
even superior to surgery.26 So, these patients with ypN2 disease are no longer 
candidates for surgical intervention. Also for those patients who had to undergo a 
pneumonectomy, one should always be very reluctant to perform surgery as mortality 
rates will increase.27-31 A further reason to prefer radiotherapy above surgery after 
induction chemotherapy is that the toxicity of surgery is probably underestimated as 
even after curative surgery in stage I and II NSCLC the quality of life is significantly 
impaired.32  A last reason to prefer radiotherapy above surgery after induction 
chemotherapy is that after surgery radicality was obtained in only 50% of the resected 
patients.27 Of those irradically resected, 40% received postoperative radiotherapy 
(PORT). PORT results in additional toxicity, whereas an influence on overall survival 
has not been proven and an influence on the disease free survival is debatable, 
according to the results of the PORT study.33,34 Regrettably, no data exist about QOL 
after randomisation between surgery and radiotherapy after induction chemotherapy.  
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A reason for the less favourable outcome of surgery in our study could be that surgery 
was less effective because of a suboptimal selection. The amount of tumourload in 
patients with upfront non-resectable stage IIIA(N2) disease varies substantially. This 
heterogeneity could be the reason of the low radical resection rate in our study even 
after a response to neoadjuvant treatment.35 With a better selection the number of 
radical resections could be increased. The subgroup of patients down-staged to 
ypN0/N1 disease, are considered good candidates for surgery by some authors. This 
preference for surgery for this subgroup is based on several phase II studies and two 
small phase-III studies.25 But this could not be confirmed in our study26 and the 
RTOG study.28-30 Esophageal ultrasound and endobroncheal ultrasound are techniques 
recently introduced for mediastinal staging.36 Presently the non-invasive PET/CT 
scans, changes in SUV's (standardized uptake values) from two serial PET/CT scans 
before and after three chemotherapy cycles or later, could allow prediction of 
histopathological response in the primary tumor and mediastinal lymph nodes and 
have prognostic value with a  sensitivity and specificity of 73% and 89% in prediction 
of ypN0 mediastinal lymph nodes.37 
As we performed no remediastinoscopy and these new techniques were not available 
at the start of our study, further studies are needed to elucidate selection criteria and to 
define the subgroups for which surgery still might play a role in the treatment of stage 
IIIA(N2) NSCLC. In these studies esophageal ultrasound (EUS),  endobroncheal 
ultrasound (EBUS), remediastinoscopy and/or PET/CT can be used to predict ypN0 
patients and these patients should then be randomised for surgical intervention or 
radiotherapy in combined modality treatments.36,37 
In case such a randomised study in downstaged IIIA(N2) NSCLC patients is 
considered, the radiotherapy treatment has to be revised too. More recent technical 
developments in planning systems and radiotherapy equipment make it possible to 
deliver higher treatment dosages. The prescribed tumour dose in our study, might be 
relatively low and could result in a lower local control. 
Sibley et al.38 reported high-dose conformal radiotherapy to result in a 2-year survival 
rate of 37% and a low morbidity rate. These results compare favorably with trials of 
chemoradiation or conventional radiotherapy. But local tumor progression still 
remains a problem in 64% of their patients. Socinsky et al.39 in a phase I study 
showed that dose escalation in combination with chemotherapy to 90 Gy was feasible. 
The one-year survival rate was 73%. Mean lung dose and V(20), the total volume of 
the lung receiving more than 20 Gy are the limiting factors in case of dose 
escalation.40 Bradley et al.40 showed that dose escalation to 83.8 Gy in fractions of 
2.15 Gy is safe for a V(20) < 25%, and to 77.4 Gy for a V(20) between 25 and 36% 
using three-dimensional conformal radiotherapy techniques. With a V20 >37% an 
excessive risk for the development of pneumonitis was seen. No concurrent 
chemotherapy was allowed in their study. Based on the results in sequential 
chemoradiotherapy, dose-intensification in stage IIIA NSCLC patients to 77.4 Gy 
could be considered in patients with a V(20) less than 36%. 
The results of the radiotherapy in our study could also be negatively influenced, 
because of the relatively long interval of 10 weeks (70 days) between the last 
induction chemotherapy course and the start of the thoracic radiotherapy. This could 
have had a detrimental effect on the final results. El Sharouni et al.41 showed that with 
a mean interval between end of chemotherapy and start of radiotherapy of 80.3 days 
(range 29 – 141 days), 41% of the tumours progressed before the start of the 
radiotherapy treatment. The estimated mean value of the tumour doubling time in 
their study was 46 days (range 8.3 – 171 days). O’Rourke et al.42 found that 21% of 
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their patients became incurable after a delay of 35 – 187 days. In our study the mean 
interval between last chemotherapy and start of the thoracic radiotherapy was 52 days 
(17 – 113 days). Only 5 patients (3%) were not treated after randomisation, because of 
tumour progression or clinical deterioration of the patient. However, no comparison 
between planning-CT scan and chemotherapy-evaluation-CT scan was done in our 
study. As long as the tumour stage according to the radiation oncologist remained 
IIIA, patients were still considered eligible for the study.  
Therefore, the number of patients with progression of the locoregional tumour after 
chemotherapy may be underestimated. 
Also a long overall treatment time could negatively influence the results of the 
radiotherapy. Continuous Hyperfractionated Accelerated Radiotherapy study 
(CHART) reduces the overall treatment time to 12 days, which resulted with a lower 
total dose in a survival rate comparable to that of induction chemotherapy followed by 
conventional radiotherapy.43 Bonner et al.44 showed a small advantage of HART 
(hyperfractionated accelerated radiotherapy) with twice-daily fractions till 60 Gy with 
or without chemotherapy compared with conventional radiotherapy till 60 Gy in 6 
weeks. However, the overall treatment time in the HART scheme was as long as in 
the conventional arm because of a interval of 2 weeks after 30 Gy reducing the 
potential benefit of the schedule. Belani et al.45 focused on shortening of the overall 
time in sequential chemoradiation. After two induction cycles of carboplatin-
paclitaxel chemotherapy patients were randomized between HART (hyperfractionated 
accelerated radiotherapy) tid 1.5 Gy till 57.0 Gy in 2.5 weeks and 64 Gy in 32 
fractions over 6.5 weeks. No significant difference between both treatment schemes 
could be detected although there was a trend in favour of the HART scheme. With 
HART 2- and 3 year survival rates were 44% and 34%, and 24% and 14% in the 
conventional arm. However, toxicity was more intense in the HART scheme. All 
these studies support the hypothesis that a further reduction in overall treatment time 
also of chemoradiotherapy and/or an intensification of the radiation dose also might 
improve the overall results. A way to obtain a shorter overall treatment time and to 
reduce the interval between chemotherapy and radiotherapy is to use these modalities 
concomitantly.  
In three recent studies46-48 with concurrent chemoradiation, all with different 
chemotherapeutic regimens and radiation schemes (see Table 1), results appeared 
superior to sequential chemoradiation treatment. Only Fournel et al.49  showed no 
significant difference between concurrent chemoradiation (Vineralbine/Cisplatin and 
conventional radiotherapy with a dose of 66 Gy in 6½ weeks) and sequential 
chemoradiation. The median survival after sequential chemoradiotherapy was 12–15 
months and 15–18 months after concurrent chemoradiotherapy. The acute toxicity 
however was substantially more severe in the concurrent arm. WHO grade III/IV 
leucopenia and thrombopenia occurs in sequential chemoradiotherapy in 5 –10 % of 
the patients and in concurrent chemoradiotherapy in 40–60 %. Acute oesophagitis 
occurred during sequential chemoradiation in 4% of the patients and during 
concurrent chemoradiation in 25–30 %. In a metaanalysis50, including stage I-II 
patients, concurrent chemoradiotherapy reduced the risk of death at two years with  
14% compared to sequential chemoradiotherapy, and  with 7% compared to 
radiotherapy alone at the expense of an increase in acute esophagitis. Therefore, 
Rowell et al.50 advises to be cautious in adopting concurrent chemoradiotherapy as the 
standard of care because of uncertainties about the true magnitude of benefit in  
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Abbreviations: N = number of patients; MVP = Mitomycin-Vindesine-cisplatin;  
VP = Vinblastine-cisplatin; EP = Etoposide-cisplatin; VrP = Vinorelbine-cisplatin;  
CT =  chemotherapeutic regimen; RT = radiotherapeutic regimen. 
 
comparison with sequential chemoradiotherapy. With short follow up and 
uncertainties about toxicity the optimal chemoradiotherapy regimen remains 
uncertain. 
 
The role of surgery after concurrent chemoradiation in resectable stage III NSCLC 
patients has been investigated in one randomized and one non-randomized study.30,51 
The necessity of adding surgery in this setting is also still an item for debate, as no 
significant differences in survival were seen, but the toxicity in the surgery arm is still 
too high. Subgroup analysis in the South-West Oncology Group (SWOG) study28,30 
revealed that patients who underwent a lobectomy have a better prognosis when 
adding surgery. However, the majority of patients in the RTOG study had no 3-D 
planning-CT and no stratification has been done for this type of surgery. So, also 
these data have to be interpreted with caution. 
 
Chapter 4  
 
The survival in both treatment arms of EORTC study 08941 could be less than 
expected, because of the use of less effective chemotherapy schemes at the start of the 
study. During the study new chemotherapeutic agents became available with higher 
response rates. The early suggestions of increased efficacy of the Gemcitabine and 
cisplatin combination prompted the EORTC Lung Cancer Cooperative Group to 
initiate a phase II trial to better define the toxicity and activity of this combination as 
an induction regimen for patients with stage IIIA NSCLC.52 This trial was the first of 
a series of phase II studies using new chemotherapy combinations within the setting of 
EORTC study 08941.  With this and other new chemotherapeutic agents the overall 
response rates increased and these regimens have been standard treatment since.53 
Nevertheless, the use of all these different induction chemotherapy schemes are of no 
Table 1. Sequential chemoradiation compared with concurrent chemoradiation 
Survival Toxicity Study N CT RT Schedule 
Median % (yr) Hematological Oesophageal 
Furuse46 314 MVP 56 Gy/5 ½ 
wks 
Sequential 
Concurrent 
13 
17 
9 (5) 
19 (5) 
76 
98 
 
Curran47  610 VP 
 
EP 
63 Gy/6wks 
63 Gy/6 wks 
69.2 Gy/bid 
Sequential 
Concurrent 
Concurrent 
14.6 
17 
15.2 
12 (4) 
21 (4) 
17 (4) 
 4 
25 
44 
Zatloukal48 102 VrP 60 Gy/6 wk Sequential 
Concurrent 
13 
20.4 
12 (2) 
42 (2) 
39.6 
64.7 
4.2 
17.6 
Fournel49 205 VrP 66 Gy/6 ½ 
wks 
Sequential 
 
 
Concurrent 
14.5 
 
 
16.3 
26 (2) 
19 (3) 
14 (4) 
39 (2) 
25 (3) 
21 (4) 
88 
(6 tox. death) 
 
75 
(10 tox. death) 
3 
 
 
32 
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influence on the final comparison between surgery and radiotherapy after induction 
chemotherapy, as they were equally divided over both treatment arms. 
 
Chapter 5  
 
During the EORTC 08941 study questions were raised about the quality of the data of 
the radiotherapy. A quality control was not not yet applied in the EORTC Lung 
Cancer Group at the start of EORTC study 08941 in 1994, and guidelines for writing 
protocols for clinical trials in radiotherapy were only published in 1995.54 At site 
visits halfway the study it was concluded, the radiotherapy treatment fields and set up 
appeared to be correct, but compliance to the protocol was subject to improvement. 
With the protocol amendment in 1999, the prescribed radiotherapy techniques 
fulfilled the criteria of modern radiotherapy and compliance improved. After the 
amendment no major protocol violations were seen. Overall, in the majority of 
patients treatment showed no or only minor protocol violations. Therefore, we are 
convinced that the quality of the radiotherapy treatment itself will hardly have any 
negative impact on the final results of the EORTC study. But our data support the use 
of strict radiotherapy specifications, dummy runs and quality control from the start of 
a large study and frequent quality assessments throughout to optimize the compliance. 
 
Conclusion chapters 3, 4 and 5 
 
The question whether there will be a subgroup of patients who might profit from 
surgery after induction chemoradiotherapy remains to be clarified. The higher toxicity 
of the combination treatments used today, have to be accepted as today these 
treatments are considered to be curative.55 Presently, radiotherapy after induction 
chemotherapy with second generation chemotherapy as Gemcitabine in combination 
with cisplatin is considered to be the standard daily practice for stage IIIA(N2) 
patients with a good performance score. 
 
Chapter 6 
 
For those patients who are no (longer) candidates for curative treatment or for 
palliative chemotherapy, palliative radiotherapy may be required. The balance 
between gain, in terms of a reduction of the complaints, and risks, in terms of the 
increase in toxicity, is the most essential aspect of palliative treatment. In 1999 a 
national multicenter randomized study compared the efficacy of  2 x 8 Gy versus our 
standard 10 x 3 Gy in patients with irresectable stage IIIA/B (with Eastern 
Cooperative Oncology Group score of 3 to 4 and/or substantial weight loss) and stage 
IV non-small-cell lung cancer. Two hundred ninety-seven patients were eligible and 
randomized to receive either 10 x 3 Gy or 2 x 8 Gy by external-beam irradiation. The 
primary endpoint was a patient-assessed score of treatment effect on seven thoracic 
symptoms. Study sample size was determined based upon an average total symptom 
score difference of more than one point over the initial 39 weeks post-treatment. The  
time course of symptom scores were also evaluated, and other secondary endpoints 
were toxicity and survival. We concluded, the 10 x 3-Gy radiotherapy schedule is 
preferred over the 2 x 8-Gy schedule for palliative treatment, as it results in a longer 
duration of the palliative response and improves survival. 
The assessment of palliation is not standardized. Therefore, interpretation of the 
results between different studies is difficult. Symptom relief can vary depending the 
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type, number, and intensity of the complaints.56-58 Therefore stratification and analysis 
by symptom can be useful. However, stratification for all factors will require large 
numbers of patients and create practical problems in running such trials. For this 
reason this is not implemented in our study. We introduced the patient-assessed total 
symptom score as a new method of how symptoms can be scored. This method has 
the disadvantage that it provides no information of symptom relief per symptom. 
Bezjak et al.12 proposed to restrict measurements of palliation only to the index 
symptom, being the most important complaint to initiate the treatment. The response 
of the index symptom will be stronger than that of other individual symptoms. These 
larger changes in an individual patient will therefore not be seen at the group level 
when the average change was reported. As a result, analyzing the index symptom may 
be more sensitive to change at the expense of providing inadequate information about 
the overall palliative effect. Our method has the advantage that it is a good indicator 
for the overall palliative effect.58 The sum of the score of 7 different symptoms was 
measured for each patient. We measured not only the reduction of complaints, but 
also stabilization and occurrence of new complaints due to tumor and/or treatment. 
Furthermore it was possible to report the duration of palliation for each separate 
treatment arm. Therefore the frequency in which symptoms are scored is also crucial. 
Hopwood et al.59 showed that differences in missing information between studies can 
lead to incorrect conclusions, which may be a consequence of different patterns of 
change in symptoms during treatment. The differences in the pattern of symptom 
reduction between both our treatment arms can support this finding. Measuring once 
or only a few times, or weekly during the first 12 weeks and 2-weekly in the 26 weeks 
thereafter as in our study, will produce differences in outcome. Therefore, comparing 
studies is also difficult because the frequency and duration of measurements varies 
substantially.60 
Most striking is the gain in survival for the more protracted treatment scheme in this 
poor prognostic patient group. This can be a matter of chance, although the level of 
significance that was detected is considered sufficient.61 What is missing is a 
comparison of the palliative effect obtained by radiotherapy and by chemotherapy. 
However, it is not very likely that such a study will ever be performed. 
 
Chapter 7 
 
This gain in survival and prolongation of the palliative effect is important for the 
individual patient, but the costs for society have to be acceptable too. In our cost-
effectivity study an estimated gain of 10.7 weeks in life expectancy and 6.8 weeks in 
QALYs in favour of 10 x 3 Gy is seen. These findings are comparable with the results 
of chemotherapy in palliative care for patients with PS 2. 62 The extra costs to be 
made for the multifractionated radiotherapy are not only acceptable from a socio-
economical perspective, but are also nearly half of the costs of those to be made by 
chemotherapy ($ 5236 vs $ 9450). 63 However, the estimation of costs is complex. 
The conclusion of our economic evaluation strongly hinges on the survival gain, but 
this has not been a consistent finding in other studies.60 In our analysis we corrected 
for differences in survival, survival at study closure and last available EuroQol 
measure, as neglecting the missing data would lead to bias and an underestimation of 
the costs. 
We included both related and unrelated health care costs in our base-case analysis, 
because the QALY measure also included the health gain obtained from unrelated 
health care. 64 Excluding unrelated health care costs 65, or including not only all future 
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health care costs, but also future production and consumption costs 66, would still 
support the preference for the 10×3 Gy schedule.  
In this study we found that both age and time until death were not statistically 
significant predictors of cost, while others argued, that costs are more related to the 
time until death, than to age. 67, 68 Instead, the EQ-5D utility measure was predictive, 
leading to increased costs towards death and a less than proportional relationship 
between survival time and costs. If the results in our terminally ill patient population 
are generalizable, then perhaps age is more predictive for chronic diseases, where 
quality of life is determined by disease progression, whereas time until death is more 
predictive in economic models for more acute conditions. 
Several remarks can be made concerning the validity of our research methods. 
Perhaps most importantly, because we had not anticipated the survival difference, 
long-term costs related to the difference in survival had to be estimated from cost data 
obtained in the initial 12 weeks. Although our model identified short-term costs 
related to the initial radiotherapy that should not be extrapolated and although during 
the initial 12 weeks already more than one-third of the patients had died, the cost 
model may still not have been representative for long-term health care costs 
associated with living and dying. Without gold standard we had no means to test the 
validity of the model. A second matter of concern is the used EQ-5D utility measure 
that is frequently used in economic evaluations from a societal perspective, but does 
not include quality of life domains that are specifically relevant in the valuation of 
end-of-life care.69, 70 Unfortunately no valuation instrument exists that incorporates 
such issues. Nevertheless, the distinct decrease of the EQ-5D utility towards the end 
of life demonstrates that the instrument is responsive to the changing health status of 
these patients and the results were very similar to results from other research in 
terminally ill cancer patients.69 These issues were addressed in the sensitivity 
analyses, which showed that they had very little influence on the estimated cost-utility 
ratio, thus suggesting that the obtained results are robust. 
 
In conclusion, because of the better treatment outcome in the 10 x 3-Gy arm and 
acceptable costs, 10 x 3 Gy has become the standard in palliative care in lung cancer 
in the Netherlands. For a subgroup of patients with minimal survival, 2 x 8 Gy could 
be an alternative. However, we were not able to elucidate the criteria for this subgroup 
of patients. 
 
Conclusions 
 
The best palliative treatment for each individual patient will be merely based on  
selection criteria. Many patients will not be fit enough to undergo combined treatment 
modalities, especially not in a concurrent setting. For future trials, the gain in survival 
will be as important, as will be the reduction of toxicity. Chemotherapy as single  
modality treatment will be an option for many patients. But even then, loco-regional 
tumour growth can give complaints and palliative irradiation will be indicated. The 
changes over time for the various indications evaluated in this thesis are summarized 
in the table 2. 
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In this thesis we demonstrated that combined modality of induction chemotherapy 
followed by radiotherapy has to be the standard treatment for patients ECOG 0–2 non-
resectable stage IIIA NSCLC. The role for surgery in this type of patients has still to 
be defined based on improved selection criteria and response measurements. Strict 
palliative care for this type of patients is no longer warranted. 
Based on our study using a total symptom score, we concluded that for those patients 
not fit enough to undergo chemotherapy with stage III-IV NSCLC and in a bad 
general condition, the multifractionated treatment scheme of 10 fractions of 3 Gy 4–5 
times a week remains the standard treatment in the Netherlands. Using the total 
symptom score, a significant different pattern in time between the hypofractionated 
and multifractionated treatment scheme could be shown. The duration of the palliative 
effect was in favour of the multifractionated scheme, as was the significant gain in 
survival and for quality-of-life corrected survival. This resulted in significantly higher 
costs in the multifractionated arm compared to the hypofractiated arm, but still within 
acceptable costs according to the Dutch standards.  
Table 2. 
Changing perspectives for patients 
in 
palliative care Non-Small-Cell Lung Cancer 
 Time period, treatment intention and - options 
 ≈1990 ≈1995 ≈2000 
Indication Palliative treatment Radical treatment Curative treatment 
Stage IIIA (pN2) 
Expectative, 
Palliative 
radiotherapy; 
Start of combined 
modality trials 
(with 2nd generation 
chemotherapeutics) 
Combined modality 
chemoradiotherapy: 
sequential 
Combined modality 
(with 3rd generation 
chemotherapeutics) 
chemoradiotherapy: 
Sequential, or concurrent 
Chemo(radiotherapy)-
surgery? 
 Palliative treatment Palliative treatment Palliative treatment 
Stage IIIB,IV with 
complaints of loco-
regional tumour 
(no candidate for 
chemotherapy)  
Best supportive care, 
Multifractionated or 
hypofractionated 
irradiation. 
Hypofractionated or 
multifractionated 
treatment schemes, 
Best supportive care. 
Multifractionated 
treatment schemes, 
 
Best supportive care. 
 Palliative treatment Palliative treatment Palliative treatment 
Recurrent tumour  
(after primary 
radiotherapy) 
Expectative, 
Repeat radiotherapy 
(seldom) 
Repeat radiotherapy 
(2x8 Gy), 
or chemotherapy 
Chemotherapy, or 
repeat radiotherapy with 
conventional planning 
(2 x 8 Gy) or 
in combination with 3-D 
planning 
(30 x 2 Gy) 
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For those patients, who develop a recurrent intrathoracical tumour after radical 
radiation treatment, we showed that repeat external beam treatment 2 x 8 Gy is a safe 
and effective palliative treatment. With the treatment equipment and planning-systems 
of today, higher dosages in repeat radiotherapy have to be considered. 
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Summary 
 
 
In the Introduction of this thesis the poor outlook for patients with a Non-Small-Cell 
Lung Cancer (NSCLC) is discussed. Most patients are only candidates for a palliative 
treatment approach. Treatment options are limited, because of former treatments, poor 
general condition of the patient, or tumour load and/or tumour stage.  
 
Despite former radiotherapy, repeated external beam irradiation is an option in case 
complaints are caused by tumor regrowth (chapter 2). Relief of hemoptysis and 
Superior Vena Cava Syndrome (SVCS) could be obtained in all evaluable cases. This 
treatment was less effective for coughing (67%) and dyspnea (35%). The overall 
median duration of these effects was 4 months. Although a relatively short time of 
palliation, it meant the complaints are precluded over more than 50% of the patients 
remaining lifespan. Acute toxicity is very mild. Complications were more frequent 
with 5 tumor related fatal hemoptysis (17%) and one death due to a broncho-
esophageal fistula (4%). Despite these findings, repeated external beam radiotherapy 
is effective as a palliative treatment for local complaints taking into account the poor 
prognosis and limited treatment options for this particular population. Nowadays, this 
treatment option is a part of our regular practice and is implemented in our treatment 
protocol. 
 
For patients in good general condition, chemotherapy gives further opportunities in 
palliative treatment. Patients with non-resectable stage IIIA(N2) were treated after a 
response on induction chemotherapy with radiotherapy or surgery (chapter 3). After 
induction chemotherapy, a reduction in distant metastasis was expected and therefore 
locoregional control became a major issue. For stage I and II, surgery is the standard 
above radiotherapy based on historical data. For stage III, radiotherapy was the 
standard in the Netherlands. It was expected, that surgery after a response to induction 
chemotherapy showed a decrease of locoregional failure and a better chance of 
survival compared to radiotherapy. However, this could not be supported by the 
findings in our study, as no differences in overall, nor progression free survival were 
found. An underlying cause could be the inhomogeneity of tumor load in stage 
IIIA(N2) NSCLC patients, as well as the lack of adequate restaging procedures. After 
surgery only 50% of the resections proved to be radical and 40% of the irradically 
resected patients were referred for postoperative radiotherapy. Therefore, in stage 
IIIA(N2) radiotherapy after induction chemotherapy has become the standard 
treatment in the Netherlands. 
 
Search for new treatment combinations led to the use of Gemcytabin® and Cisplatin as 
induction chemotherapy in patients with stage IIIA(N2) NSCLC with a high response 
rate of 70.2% (chapter 4). The toxicity was acceptable and mainly hematological. 
Because of the better response rate compared to former chemotherapy regimens and 
acceptable toxicity, the Gemcitabine®-Cisplatin regimen has since become common 
practice in combination treatments in the region of the Comprehensive Cancer Centre 
East. This gain in effectiveness could explain the better overall survival for the 
patients in our study. However, the kind of chemotherapy scheme will be of no 
influence on the comparison between surgery and radiotherapy after induction 
chemotherapy as these schemes were equally divided over both treatment arms. 
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Quality assurance of radiotherapy descriptions at start of EORTC study 08941 was 
not performed. In 1999 radiotherapy data were tightened for: time interval between 
last chemotherapy course and start of thoracic radiotherapy, the use of a 3-D planning 
CT, dose and fractionation scheme to the primary tumour, the involved - and 
uninvolved mediastinum, and duration of radiotherapy. A significant improvement of 
all quality parameters was noted, except for the interval between last chemotherapy 
course and start of thoracic radiotherapy, which decreased slightly. The latter reflects 
logistic problems rather than poor compliance (chapter 5). For future trials, the 
EORTC guidelines for writing protocols for clinical trials for radiotherapy of the 
EORTC Radiotherapy Group have to be used. Control of protocol prescriptions by 
dummy runs will enhance protocol compliance.  The relatively low total tumour dose, 
and the allowed interval of 10 weeks after last induction chemotherapy course, could 
cause a decrease in overall survival or progression free survival. 
 
Patients, who are no candidates for any chemotherapeutic regimen, can be referred for 
palliative radiotherapy. Many of these patients will have a poor general condition.  
Because of the relatively shortage of radiotherapy facilities, it was assumed for this 
particular group of patients that no differences would be found between 10 x 3 Gy and 
2 x 8 Gy for palliation as for prognosis (chapter 6). Both treatment arms were equally 
effective, as the average total symptom score over the initial 39 weeks did not differ. 
However, the pattern of these scores over time differed significantly. Palliation in the 
10 x 3-Gy arm was more prolonged (until week 22) with less worsening symptoms 
than in the 2 x 8-Gy arm. 
Survival in the 10 x 3 Gy-arm was significantly better than in the 2 x 8 Gy-arm with a  
1-year survival of 19.6% versus 10.9%. 
 
Life Expectance (LE) and for Quality of Life corrected survival (QALE) differed 
significantly in advantage of the 10 x 3 Gy-scheme (chapter 7). Despite the fact that 
costs for the 10 x 3-Gy arm were significantly higher, they were still acceptable 
according to the Dutch Standard. In the Netherlands for patients with NSCLC in poor 
general condition, and not eligible for chemotherapy, 10 x 3 Gy has become the 
standard. For the poor prognostic group with minimal survival, no standard care has 
yet determined. 
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Samenvatting 
 
In de Inleiding van dit proefschrift wordt de slechte prognose belicht van patiënten 
met een niet-kleincellige vorm van longkanker. De meeste patiënten komen slechts 
voor palliatieve (op klachtengerichte, en niet op levensverlenging beogende) 
behandeling in aanmerking. De behandelingsmogelijkheden zijn beperkt, hetzij door 
reeds gegeven behandelingen, hetzij door de slechte algemene conditie van de patiënt, 
hetzij door de uitbreiding van de kanker zelf. 
 
Ondanks eerdere bestralingsbehandeling, is herbestraling te overwegen in geval dat 
een hernieuwde groei van het gezwel gepaard gaat met klachten (hoofdstuk 2). 
Klachten als bloed ophoesten (hemoptoë) en het vena cava superior syndroom 
(VCSS), te herkennen door stuwing van de vaten in hals en gelaat, ontstaan door druk 
op de lichaamsader in de borstholte door het gezwel zelf en/of door uitzaaiingen in de 
lymfklieren, konden in de meeste gevallen goed worden bestreden. Deze behandeling 
had minder succes bij de bestrijding van hoestklachten (67%) en kortademigheid 
ofwel dyspnoe (35%). De mediane duur van klachtenvermindering was 4 maanden. 
Hoewel deze duur relatief kort is, betekent dit toch dat hernieuwde klachten konden 
worden voorkomen gedurende meer dan 50% van de resterende levensduur van de 
patiënten. De acute bijwerkingen waren mild. Complicaties traden op in de vorm van 
5 fatale bloedingen (17%), in combinatie met hernieuwde uitgroei van het 
kankergezwel, en 1 patient overleed ten gevolge van een fistel, die tussen de luchtpijp 
en de slokdarm ontstond (4%) zonder dat sprake was van hernieuwde groei van het 
kankergezwel. Ondanks deze bevindingen beschouwen we herbestraling als een 
effectieve en veilige behandeling voor locale klachten ten gevolge van een 
hernieuwde groei van het kankergezwel, gelet op de slechte prognose en de beperkte 
behandelingsmogelijkheden voor deze patiëntengroep. Deze behandelmogelijkheid 
maakt tegenwoordig vast onderdeel uit van onze behandelingsrichtlijn. 
 
Chemotherapie geeft extra mogelijkheden voor patiënten in een goede algemene 
conditie. Indien de tumor kleiner is geworden na behandeling met chemotherapie 
(inductiechemotherapie genoemd) bij patiënten met een stadium IIIA(N2) niet-
kleincellige longkanker (dwz alleen aan dezelfde zijde als waar de tumor is gelegen in 
de borstholte zijn ook uitzaaiingen in de lymfklieren aanwezig) werd aansluitend 
geloot tussen óf een chirurgische, óf een bestralingsbehandeling (hoofdstuk 3). Door 
de inductiechemotherapie zouden microscopisch kleine (niet met verder onderzoek 
zichtbare) uitzaaiingen elders in het lichaam mogelijk alsnog kunnen worden 
bestreden. Omdat de patiënt dan minder kans heeft om te overlijden aan uitzaaiingen, 
is het van des te meer belang dat het gezwel en de lymfklieruitzaaiingen blijvend 
worden uitgeroeid. Voor kleine tumoren zonder of met beperkte lymfklieruitzaaiingen 
(stadium I en II) vormt chirurgie de standaardbehandeling en vindt radiotherapie 
alleen plaats als chirurgie niet mogelijk of niet gewenst is. Voor stadium III was 
radiotherapie de standaardbehandeling in Nederland. Deze opties zijn hoofdzakelijk 
gebaseerd op historische gegevens en niet gestaafd met gerandomiseerd (via loting 
bepaald) onderzoek. Wij verwachtten met ons onderzoek aan te tonen dat een 
chirurgische behandeling vergeleken met een bestralingsbehandeling, na een 
tumorverkleining ten gevolge van de inductiechemotherapie, een grotere kans op het 
definitief uitroeien van de longkanker zou geven en daardoor ook de kans op 
overleving zou doen toenemen. 
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Ons onderzoek wees echter anders uit, omdat geen verschil in hernieuwde uitgroei 
van de longkanker, noch verlenging van de ziektevrije periode konden worden 
aangetoond. Omdat de hoeveelheid en uitbreiding van de kanker in dit stadium enorm 
kan verschillen, zou dit één van de redenen kunnen zijn dat we geen verschil hebben 
gevonden. Ook het ontbreken van goede herstadiëring (het preciezer in kaart brengen 
van de tumorreactie na inductiechemotherapie) kan daarbij een rol hebben gespeeld. 
Na chirurgie bleek slechts bij 50% van de patiënten het gezwel volledig verwijderd te 
kunnen worden. Tevens onderging 40% van deze geopereerde patiënten alsnog een 
bestraling. Bovendien overleden 8% van de patiënten bij wie de gehele long moest 
worden verwijderd in aansluiting op de operatie. Op basis van deze gegevens lijkt 
bestraling aansluitend aan inductiechemotherapie bij patiënten met stadium IIIA, niet-
kleincellig type, longkanker nog steeds de beste behandeloptie. 
 
Onderzoek naar nieuwe geneesmiddelen leidde tot het gebruik van Gemcytabine® en 
Cisplatinum voor inductiechemotherapie behandeling bij patiënten met stadium IIIA, 
niet-kleincellig type, longkanker (hoofdstuk 4). Een verkleining van het gezwel in 
70% van de behandelde patiënten was nog niet eerder waargenomen. De bijwerkingen 
waren acceptabel en beperkten zich hoofdzakelijk tot een verandering in het 
bloedbeeld. Sindsdien wordt deze combinatie standaard gebruikt in onze IKO 
(Integraal Kankercentrum Oost-Nederland) regio. Deze verbeterde effectiviteit zou 
kunnen leiden tot een betere overleving van de patiënten in onze studie. Omdat deze 
behandeling gelijkelijk over beide behandelingsmogelijkheden (chirurgie en 
bestraling) is verdeeld, zal dit geen effect hebben op het aantonen van een eventueel 
verschil tussen de effectiviteit van deze beide behandelingen. 
 
Kwaliteitscontroles op de bestralingsuitvoering en –voorschriften werden bij de start 
in 1994 van EORTC studie 08941 nog niet standaard uitgevoerd. In 1999 werden de 
bestralingsvoorschriften verscherpt voor: het tijdinterval tussen de laatste 
chemotherapiebehandeling en de start van de bestraling op de borstholte, het gebruik 
van 3-dimensionale (3-D) planning systemen, doserings- en fractioneringsschema 
zowel op de longtumor zelf, als de aangedane en niet-aangedane lymfklierregio’s in 
de borstholte, en de totale duur van de bestralingsbehandeling. Een duidelijke 
verbetering van alle kwaliteitskenmerken werd bereikt met uitzondering van de 
beperking van het tijdinterval tussen chemotherapie en start van de 
bestralingsbehandeling. Dit laatste was eerder te wijten aan logistieke problemen dan 
aan het niet willen voldoen aan de studievoorschriften (hoofdstuk 5). Bij toekomstige 
studies zullen de richtlijnen van de EORTC voor het schrijven van protocollen ten 
behoeve van klinische studies nauwgezet worden gevolgd. Het opvolgen van deze 
voorschriften wordt gecontroleerd door allereerst een beoordeling van een 
proefbehandeling (dummy run). Dit zal de betrouwbaarheid van de resultaten ten 
goede komen. De relatief lage dosis toegepast op het longgezwel en het toestaan van 
een interval van 10 weken tussen het einde van de inductiechemotherapie en start van 
de bestraling, zouden een afname van de overlevingskansen en de ziektevrije periode 
kunnen hebben bewerkstelligd. 
 
Indien patiënten geen chemotherapeutische behandeling kunnen ondergaan, kunnen 
zij worden verwezen voor een palliatieve bestralingsbehandeling. De meeste van deze 
patiënten zullen een slechte algemene conditie hebben. Omdat er een tekort aan 
bestralingscapaciteit aanwezig was, meenden wij dat voor deze specifieke groep 
patiënten een behandeling met 2 hoge bestralingsfracties (2x8Gy) net zo goed zou zijn 
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als 10 relatief lage bestralingsfracties(10x3 Gy), zowel voor de klachtenbestrijding 
(palliatie) als voor de levensverwachting (hoofdstuk 6). 
Beide behandelingsmogelijkheden bleken inderdaad even effectief in het doen 
afnemen van de klachten, aangezien de door ons gebruikte totale symptoomscore 
gemiddeld over 39 weken geen verschil gaf te zien. Opvallend was echter wel, dat de 
afname in de 10x3 Gy behandeling beduidend langer aanhield (tot week 22) en de 
toename van de symptomen na aanvang van de behandeling beperkter bleef. Ook de 
kans om 1 jaar te overleven in de 10x3 Gy arm (19,6%) was beduidend langer dan in 
de 2x8 Gy arm (10,9%). 
 
De levensverwachting (LE) en de voor kwaliteit van leven gecorrigeerde overleving 
(QALE) verschilden beduidend in het voordeel van de 10x3 Gy behandeling 
(hoofdstuk 7). Ondanks de beduidend hogere kosten van de 10x3Gy behandeling, 
bleven deze acceptabel gemeten naar de in Nederland geldende normen. 
Voor Nederland geldt nu dat de 10x3 Gy behandeling de standaardbehandeling dient 
te zijn. De selectiecriteria voor patiënten in een zeer slechte conditie en minimale 
overlevingskansen, die eventueel toch met 2x8 Gy behandeld zouden kunnen worden, 
kunnen we op basis van onze studie niet aangeven. 
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Ik had een droom: onderzoek te doen naar het verbeteren van de kansen voor 
patiënten met longkanker en daarop te promoveren. Daartoe moesten echter eerst de 
nodige voorbereidingen worden getroffen en nog een lange reis worden afgelegd. Een 
reis, waarvoor ik dank verschuldigd ben aan allen, die mijn pad kruisten/volgden op 
deze reis, en zonder wie ik deze reis niet had kunnen volbrengen. 
Mijn reis begon in 1987 toen Albertine van Dijck en Jan Werre mij verzochten vanuit 
het hoge Noorden in het ARTI te komen werken en daarbij onderzoek op te zetten. 
Het eerste reisdoel was daarbij nog bescheiden gericht op de regio zelf. Omdat 
patiënten bij wie eerdere radiotherapie was toegepast en die een recidief ontwikkelden 
geen behandelopties meer hadden, werd in samenwerking met de longartsen in de 
regio de studie voor herbestraling opgestart. We hadden echter grootsere, Europese, 
aspiraties. Daartoe werd samenwerking gezocht met de EORTC longkanker 
werkgroep. Op een gedenkwaardig weekend in 1990 toog ik tesamen met Eric 
Ullmann, met een nauwelijks te beteugelen enthousiasme, en Peter de Bruyn, nuchter 
en zakelijk, naar Parijs voor onze eerste kennismaking met dit gezelschap. Onze 
eerste vingeroefeningen met het opzetten van studies nam daarmee een aanvang, en 
bleek een lange hobbelige weg te zijn. Later ontmoette ik in Praag Jan van Meerbeeck 
en Paul van Schil, welke voor mij nadien belangrijke medereizigers op deze lange reis 
werden. Het was echter met Ted Splinter met wie ik, samen als missionarissen op 
zendingswerk, niet naar het donkere Afrika, maar in 1994 naar het Hollandse Breda 
toog. Daar hebben we onze Nederlandse collega longartsen en radiotherapeuten in een 
achteraf zaaltje moeten overtuigen van het feit, dat de behandeling voor het stadium 
IIIA longkanker intensiever moest gebeuren, een revolte toentertijd. Gelukkig was 
onze reisbrochure bij aanvang al dusdanig overtuigend, dat het lukte landelijk 
voldoende longartsen en radiotherapeuten aan te monsteren, zodat het schip koers kon 
kiezen. De data invoer van alle patiënten die inscheepten werd voor mij verricht door 
de datamanagers van het IKO (Jeannine Akkermans en Linda Mol). Hand- en 
spandiensten werden verricht door alle administratieve medewerkers, laboranten en 
collega radiotherapeuten op het ARTI, zodat ik de mogelijkheid had aan mijn 
reisverslag te werken. Het ordenen en bewerken van alle documenten was daarbij in 
goede handen bij Carla van Cingel en Esther van Nuland. 
Een groot probleem moest echter nog worden opgelost: Om ons schip zo goed 
mogelijk te laten varen, moest nog de meest geschikte samenstelling van de brandstof 
(chemotherapie) worden achterhaald. De toenmalige mengsels hadden slechts een 
rendement van hooguit 40%. Na verschillende mengsels te hebben getest in EORTC 
verband, bracht onze samenwerking met Nico van Zandwijk en Egbert Smit 
uiteindelijk het juiste mengsel aan het licht en kon dit rendement worden opgevoerd 
naar 70%. Deze chemotherapie wordt sindsdien in onze regio als standaard gebruikt. 
In de regio werd ik ook gesteund door de longartsen in Rijnstate (Alysis), een veilige 
thuishaven. Maar ik kon ook volop vertrouwen in onze drukke buitenpost Harderwijk 
op de longartsen Dolf Hendriks en Steven Gans en de chirurgen Ronald Beck en 
Wilfried Lackin. Helaas moest Ted om persoonlijke redenen het schip tussentijds 
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konden bereiken. 
In 1998 ontmoette ik Jan-Willem Leer, met wie ik samen het plan smeedde om de 
reisverslagen te bundelen tot een volwaardig reisdocument. Daartoe was het 
noodzakelijk dat ik nog een reis zou ondernemen, waarbij ik zou onderzoeken of 
patiënten in een slechte conditie met longkanker, beter af waren met een langere 
reisduur op een langzaam oplopend pad, dan wel via de binnenbocht met een korte 
steile weg omhoog. Dat de patiënten beter af waren met een rustige reis kon worden 
achterhaald door de nimmer aflatende inzet van Mirjam Scholten. Steeds wist zij de 
afzonderlijke wandelaars weer te traceren en hun persoonlijke reisbevindingen te 
ontfutselen, een huzarenstukje! Dat geldt ook voor onze rekenmeesters uit Leiden, 
Hans van Houwelingen, Wilbert van den Hout, en Ronald Geskus. Zij moesten een 
boel rekenwerk verrichten, en kwamen daarbij tot de conclusie dat dit lange reisje 
zeker meer kost dan het korte reisje, maar dan heb je ook wat, of niet? 
 
Deze lange reis kende ook zijn eigen prijs. Mijn vaste reisgenote gedurende vele 
jaren, Mieke, heeft in het zicht van de haven, besloten haar bestemming te wijzigen en 
is haar eigen koers gaan varen. Zonder haar jarenlange inzet voor ons gezin was het 
mij niet mogelijk geweest deze reis zo ver te volbrengen, en ik wil haar daar toch ook 
voor danken. Door de steun van mijn kinderen (Stijn, Cindy, en Brenda), mijn ouders, 
buren en vrienden, lukte het mij toch deze zware reis alsnog tot een goed einde te 
brengen. Mijn beste vriend René Verheyen in het verre Amsterdam wil ik daarbij 
zeker niet vergeten. In de woelige wateren heeft hij menige reddingsboei 
toegeworpen. Daarnaast  was hij een trouw lezer van mijn reisverslagen, waarbij hij 
geregeld een glimlach niet kon onderdrukken bij het lezen van mijn “Engelse” 
teksten. 
De conditie werd op peil gehouden met steun van mijn tennismaten, welke alle wel en 
wee rond het publiceren van de reisverslagen gezellig bij de borrel na het zoveelste 
partijtje tennis, moesten verdragen. Deze last zal vanavond echter vast en zeker 
gecompenseerd worden! 
Bijzonder moedig zijn mijn vrienden Joost Verbunt en Hans Jansen, die het zelfs 
aandurfden mij hier vandaag te seconderen op deze allerlaatste stap. Deze stap wil ik 
echter niet zetten zonder ook degenen te danken die, ondanks hun slechte 
vooruitzichten, trouw onze spreekuren bleven bezoeken en belangeloos hun bijdrage 
leverden: onze patiënten. Voor hen betekent het goed ten einde brengen van deze reis 
het bewijs dat hun inzet niet tevergeefs is geweest en dat we weer een kleine stap in 
de goede richting hebben gezet. 
 
Dit stuk van mijn reis zit erop. Een deel van mijn droom is uitgekomen, waarvoor 
nogmaals dank aan allen die mij daarbij hebben geholpen. De realiteit laat echter zien 
dat we nog steeds een lange weg hebben te gaan, voordat longkanker kan worden 
genezen. “Hora est!”: Het is nu tijd om even te rusten en te slapen, op zoek naar 
nieuwe dromen. 
 
         Gijs Kramer 
Post Scriptum 
 
Gijs is helaas nooit meer toegekomen aan nieuwe dromen. Toch heb ik besloten zijn 
oorspronkelijk dankwoord in zijn geheel te handhaven. 
         Jan Willem Leer 
